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ABSTRACT 
 
TITLE OF THE ABSTRACT:  ‘An observational trial to study the role of 
Thromboelastography in comparison with conventional coagulation testing in assessing the 
disease severity among adult patients with snake envenomation at a tertiary care centre 
hospital in Southern India.’ 
DEPARTMENT:   General Medicine 
NAME OF THE CANDIDATE: Dr.Perla Harsha Teja 
DEGREE AND SUBJECT:  M.D. Branch I General Medicine  
NAME OF THE GUIDE:  Dr Samuel George Hansdak 
 
Objectives: To compare Thromboelastography with conventional coagulation tests in 
patients presenting with snake envenomation.To analyse the demographic, clinical and 
laboratory profiles; to identify the predictors of severe envenomation. 
Methods: In this prospective observational cohort study with internal comparison, patients 
with snake envenomation presenting to CMC Hospital, Vellore between January 2013 and 
June 2014 fulfilling inclusion criteria were divided into low and high severity groups. 
Demographic, clinical and laboratory parameters were collected and analysed. We compared 
the two groups with respect to thromboelastography and conventional coagulation tests in 
identifying severe envenomation and clinical evidence of coagulopathy at admission. 
Correlation of thromboelastography with factors casuing coagulopathy and the risk factors 
that would predict severe envenomation were also analysed. Statistical analysis was done 
using STATA 13 software. 
Results: A total of 72 patients were included: 32 with mild envenomation and 40 with severe 
envenomation. Sensitivities of thromboelastography (TEG), whole blood clotting time 
(WBCT), prothrombin time (PT) in identification of severe envenomation were 92%, 56% 
and 64%. Sensitivities of TEG, WBCT andPT in identification of clinical coagulopathy were 
81.3%, 59.4% and 65.6%. The predictive value for a milder course when TEG was normal 
was 88.95% compared to WBCT and PT (56%, 62.5%). TEG was also highly sensitive in 
identification of thrombocytopenia (94.7%, p value: 0.0001). None of the risk factors 
analysed were found to be statistically significant on multivariate analysis in predicting 
severe envenomation. 
Conclusion: In patients with an acquired cause of coagulopathy such as snake envenomation, 
thromboelastography as a single test could prove to be a significant advance in the better and 
early identification of severe envenomation and coagulopathy.  
Keywords: Snake bite, Envenomation, Thromboelastography, Coagulopathy. 
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INTRODUCTION 
 
Snake envenomation is a common medical emergency that is seen 
predominantly in rural areas. Snake envenomation often leads to significant mortality 
and morbidity if adequate supportive and treatment measures are not initiated early. 
Hence snake envenomation’s and the resultant deaths are a major and important 
public health problem in the rural tropics. This is particularly due the fact that health 
services in these areas are not only poorly accessible but are often suboptimal, and, in 
some instances, have a scarcity of antivenom, which is the only specific treatment. 
India not only has the highest number of envenoming’s annually but also has the 
highest mortality rate annually with an estimated 11,000 deaths occurring every year 
according to current estimates.(1) 
Traditionally snake envenoming is still managed using routine tests like 20 
min whole blood clotting time (WBCT) and prothrombin time, which form the basis 
for administration of Anti Snake Venom (ASV) to the patients. Therefore it is 
important to accurately know the coagulation status of the patients at admission for 
effective administration of ASV. Thromboelastography (TEG) is a relatively new 
technique that assesses the dynamic coagulation status of the blood. Management 
algorithms based on Thromboelastography for conditions like liver transplantation, 
massive trauma and cardiac surgery have been shown to decrease both transfusion 
requirements and intraoperative blood loss. The purpose of the study is to describe the 
clinico-epidemiological profile of patients with snake bite, role of 
thromboelastography as a predictor of snake envenoming and to assess the clinical 
severity in patients with snake envenoming. Hence it can be assessed in future for 
better management of patients with snake envenomation. 
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Vellore district and its nearby areas are heavily infested with venomous 
snakes, and the victims are mostly healthy young individuals mostly belonging to the 
lower socio-economic strata, most of them bread winners of the family. 
This is a prospective observational cohort study done on patients presenting 
with newly diagnosed snake envenomation to Christian Medical College and Hospital 
(CMCH), Vellore. All patients fulfilling the inclusion criteria were assessed by a 
clinical research form at admission to casualty in CMCH. Routine blood 
investigations were done as per protocol and blood samples for Thromboelastography 
were collected along with the routine investigations. The patients were followed up 
till discharge or death to assess the final outcome. Further analysis of TEG parameters 
against various coagulation parameters was studied and analysed.  
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AIMS AND OBJECTIVES 
 
Aim: 
 
The primary aim of the study was to study the role of Thromboelastography 
(TEG) in assessing the disease severity among adult patients with snake 
envenomation in a tertiary level teaching hospital in South India. 
 
Objectives: 
 
The objectives of the study were: 
1. To prospectively study the demographic characteristics, details of clinical and 
laboratory parameters among adult patients admitted with snake envenomation 
to a tertiary care center, Christian Medical College and Hospital, Vellore. 
 
2. To study in detail the demographic, clinical and laboratory risk factors 
predicting high disease severity in patients with snake envenomation. 
 
3. To compare Thromboelastography with conventional coagulation assays (20 
minute whole blood clotting time, Prothrombin time, activated partial 
thromboplastin time) in assessing the disease severity in patients with snake 
envenoming. 
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REVIEW OF LITERATURE 
 
The complex inter-relationship between Man and Snake is filled with 
ignorance and prejudice. In this scientific era, we should learn to respect the 
creatures by studying them. 
Ramona and Desmond Morris: Men and Snakes (1965). 
 
Snake bite is an important neglected tropical health disease which has a high 
socio -economic impact on the community especially in the rural areas. It can be 
classified as an important occupational hazard in many parts of the world, especially 
in countries with predominant rural population working in the fields such as India. In 
developed countries such as America and Europe there is higher frequency of snake 
bites amongst the people who are in the habit of keeping snakes as their pets, many of 
the times it being unlawful. In developing countries snake bites which are dangerous 
occur mainly especially among rural population who are active as various agricultural 
workers, daily wage labourers, cattle and goat herders and rarely fisherman. Other 
significant population group affected are the people of certain tribes such as Irula in 
South India who act the traditional and native snake charmers.(2) 
 
HISTORY OF SNAKE BITE: 
 
Snakes have always evoked a feeling of awe and curiosity. Their apparent 
renewal of life with casting of skin and the power of some of them to inflict suffering 
and death have given them a supernatural aura which made them worthy of worship 
by some ethnic groups. Knowledge regarding snakes and the effects of envenomation 
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dates back to centuries. Even primitive men knew that snakes can cause diseases. 
There are wonderful tales of famous snakes like “Vasuki” and “Thakshaka” of Indian 
mythology. In one Homeric epic, the wound of Philoctetes was said to be caused by 
snakebite. The snake sacred to Asclepius, the Greek god, lives in clefts of earth and 
can heal wounds and ulcers by licking them. In ancient Egypt magical religious 
treatment was given by snakebite.  
The earliest scientifically documented reference to Indian snakes available 
might be credited to Dr. Patrick Russell. He was responsible for distinguishing many 
venomous snakes from non-venomous ones. He had written about and investigated 
many snakes. His work was extensive particularly on viper it was thus named Viper 
Russelli, appropriately named after him.(2)Sir J. D. Fayrer (1873) carried out detailed 
investigation on the physiology of venom of Indian snakes and wrote a book titled 
“Thantoophidia of India” in 1874. Col. Frank Walls (1908) strived hard to add our 
knowledge of the habits and distribution of snakes in his work entitled “The 
Poisonous Terrestrial Snakes of our British Indian Dominions and How to recognize 
them”. It was Col. Gharpurey (1935), medical man turned ophiologist, who first 
attempted to dispel the ignorance and superstition woven around the Indian snakes, 
both venomous and non-venomous. He wrote book called “Snakes of India” in semi 
technical knowledge. 
The most important landmark in the treatment of snake envenomation was the 
development of anti-snake venom which was prepared by Calmette. Monovalent 
antivenom was first developed against Russell’s viper in India. Later came the 
polyvalent antivenom from the central research institute, Kasauli. The Later 
developments were supportive measures like dialysis and blood component therapy. 
Latest trends are rapid immunodiagnostics and administration of specific monovalent 
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anti-venom, development of antivenin against locally seen snakes and development of 
vaccine. 
 
PROBLEM OF SNAKE BITE: 
 
The actual true worldwide burden of snake bite is not well known and documented 
because of high level of under reporting and serious misreporting.  
 
Worldwide burden of snake bite with emphasis on South East Asia: 
 
Swaroop and Grab in 1954 were the first to assess the global incidence and 
mortality of snake bites.(3) Their study published in the bulletin of the World 
Health Organization estimated 500,000 envenomings and 30,000 – 40,000 deaths 
per year (data from China, USSR and central European countries was unavailable 
at that time). As they lacked relevant information, these figures by Swaroop and 
Grab are certainly an underestimation of the true burden of the problem.  
The second assessment by Chippaux JP et al again published in the 
bulletin of the World Health Organization (WHO) in 1998, reported that there are 
about 5 million snakebites worldwide each year, leading to 125,000 deaths.(4) 
This study was more reliable as it was based on a greater number of publications. 
Still many information gaps remained in the study, one of the main question being 
how much were the local studies representative of the wider epidemiological 
situation.(4)According to Chippaux, Myanmar had the highest number of deaths 
secondary to snake bite among all the Asian countries. The majority of the bites 
involved the Russell’s viper, which constituted about 70% of the total bites. 
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According to this study, in India the data regarding incidence and mortality are 
fragmentary because less than 40% of snake bite patients attend hospitals for 
medical care rather first consults traditional practitioners or quacks and only 
subsequently resort to modern medicine. Most of the data regarding the 
epidemiology of snake bite are very unreliable due to the poor condition of 
the reporting systems in place in developing countries. Moreover, the 
mortality and morbidity secondary to snake bite are a gross underestimation 
as most of the bites (approximately 80% of all documented cases) occur 
among non-urban/rural population.(4) 
Kasturiratne et al conducted a study in 2007 which was based on the WHO 
database. The study concluded that at least 4,21,000 snake envenomation’s and  
20,000 deaths occur from snake bites globally every year.(1)The primary data was 
obtained by the researchers by three ways namely searching for snake bite 
publications, extraction of country-specific mortality data from databases 
maintained by United Nations organizations, and identification of grey literature 
by discussion with key informants. This study also warns that the actual figures 
might be as high as 94,000 deaths and 18,41,000 envenomation's globally every 
year. That study also concluded that approximately one case of snake 
envenomation occurs for every four cases of snake bite. Based on aforementioned 
fact, they predicted that the worldwide incidence could  be anywhere from 1.2 
million to 5.5 million every year. South Asia was estimated to have the highest 
number of cases of envenomation's (approx. 1,21,000). This number was closely 
followed by South East Asia region (1,11,000) and Eastern Sub-Saharan African 
region (43,000) yearly. The study concluded that with 81,000 envenoming’s and 
11,000 deaths annually India to have highest number of envenoming’s in the 
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world. Among the Asian countries, Sri Lanka (30,000 bites per year), Vietnam 
(30,000 bites per year) and Nepal (20,000 bites per year) were the other countries 
apart from India to have a very high incidence of envenoming’s.(1) 
A postal survey conducted in 21 of the 65 administrative districts of 
Bangladesh estimated an annual incidence of 4.3 per 100,000 population and a 
case fatality of 20%.(5) 
A recent review article by Alirol et al in 2010 again stresses the fact that 
South Asian region was the hot spot for snake bites and India being the country 
with the maximum burden.(6) 
 
Indian scenario – Snake bite in India: 
 
Haiti et al in 1992 conducted an epidemiological survey of snake bites among 
26 villages of Burdwan district, West Bengal and showed an annual incidence of 0.16 
per cent per year and mortality rate of 0.016 per cent per year.(7) They also showed 
that the number of bites were maximum at the onset of monsoon period in the months 
of July and August. They also showed that the majority of the patients went to the 
traditional healers or consulted them prior to coming to the hospital.(7) 
Kulkarni ML & Anees S (1994)(8)conducted eight years prospective study 
on Pediatric victims up to 18 years of age in a teaching hospital from 1985 to 1992 in 
Karnataka. Males were predominant over females with male to female ratio of 2:1. 
Most of the victims 40.4% belonged to 11-15 yrs. Maximum (33%) bites occurred 
between October to December followed by 31.4% between April to June. Majority 
90% of victims were from rural area and 79.9% bites were on the lower limbs. 58.6% 
victims had hemotoxic envenomation and 12.5% cases had neurotoxic envenomation. 
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Mortality recorded was5.2%.(8) 
Lal P et al. (2001)(9)carried out a seven years retrospective descriptive study 
to know the Socio-demographic profile of snake bite cases admitted to JIPMER 
Hospital, Pondicherry from 1990 to1996. A proportional increase in incidence of 
snake bite was observed from 2.9/1000 admissions in 1990 to 5.2/1000 admissions in 
1996.Adults of 15-60 yrs age group accounted 81.8% of cases and male to female 
ratio was 2.1:1. Majority(68%) were rural males and 93.8% of cases were agricultural 
workers/ labourers. 40% of bites occurred during rainy season. Mean duration of 
hospital stay was 2 days. Majority85% were relieved or cured and 13.5% mortality 
was recorded.(9) 
Bawaskar H S (2002)(10)conducted a three years prospective study of snake 
bitecases admitted to Bawaskar Hospital and Research Centre, Mahad , Raigad, 
Maharashtrafrom January 1998 to January 2001. Most 29.7% of victims were less 
than 20 yrs followed by 25.3% belonged to 21-30 yrs age group. Most 65.9% of bite 
occurred during monsoon season. Of the 91 cases, 46 (50.5%) were envenomated of 
which 43.5% showed haemotoxic symptoms and 56.5% showed neuroparalysis. 
Mortality of 10.9% was recorded and all were due to neurotoxic envenomation.(10) 
Chauhan S et al (2005) (11)conducted a five years retrospective study with 
aim of studying pre-hospital treatment received by snake bite victims admitted to 
PGIMER Hospital, Chandigarh from January 1997 to December 2001. First aid was 
given in 70.8%of cases prior to hospitalization, of which 41.4% received first aid 
from Quacks. 12.7% of victims directly went to PGIMER Hospital. ASV was given in 
41.4%, tourniquet in22.86%, Incision and drainage in 20%, Tetanus toxoid in 7.14% 
and local remedies in5.7% of cases. 43.2% victims needed mechanical ventilation and 
6.95 days was the average duration of Hospital stay.(11) 
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Brunda G& Sasidhar RB (2007)(12)conducted a five years retrospective 
study from 1999 to 2003 in University College of Science, Osmania University, 
Hyderabad. They observed that majority of the cases 71% belonged to 21 to 50yrs age 
group. Males76% were predominant over females with male to female ratio of 3:1. 
Most of the bites50% were recorded in rainy season during June to September.(12) 
Bawaskar H S et al. (2008)(13)conducted one year prospective study of 
snake bite victims admitted to five hospital of five different districts of rural 
Maharashtra. 26.9%victims belonged to 21-30 yrs age group followed by 19.2% 
victims in 11-20 yrs age group. 48.4% of bites occurred between June to October. 
60.4% victims had bites on lower limbs. Maximum 90 (49.5%) bites occurred 
between 6 AM to 6 PM and 75% of bites that occurred during this time period were 
by viper species and all the 45 cases that occurred between 12.01 AM to 6AM were 
due to elapid species. 71.9% of victims had fang marks with oozing of blood at the 
site of bite. Bite by big four species was estimated to be 30.2% by Saw-scaled viper, 
20.8% by Russell’s viper, 26.3% by Krait and 22.7%by Cobra.(13) 
Suchithra N et al. (2008)(14)carried out a prospective study of snake bite 
cases admitted to Kottayam Medical College, Kerala for a period of one and half year 
from May 2005 to December 2006. Of the 586 cases, 34% cases had envenomation; 
58% of victims were males and 52% belonged to 31-50 yrs age group. 93% of bites 
occurred outdoor and in 34.5% of venomous bites the snakes were identified. 93.5% 
had local signs of envenomation. Morality of 3% was recorded. Capillary leak 
syndrome, respiratory paralysis and intracerebral bleeding were risk factors for 
mortality.(14) 
Alirol E et al. (2010)(6)observed that 90% and 98% of snake bite victims 
were given tourniquet application as first aid in Nepal and Bangladesh respectively. 
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28% and20% of victims were given incision in and around bite site as first aid in 
Bangladesh and North East India respectively. 
Inamdar et al in 2010 conducted an 10 year retrospective study in 
Maharashtra which showed a case fatality rate of 5.4% with higher incidence of 
mortality among women and neurotoxic bite.(15) 
Mohapatra B et al (2011)(16) analyzed the million death survey conducted in 
India which was nationally representative study with 1,23,000 deaths from 6,671 
randomly selected areas in 2001-03.Snake bite was found to be more common among 
rural population with male predominance. Maximum victims belonged to 15-29 years 
age group and the bite was more common during monsoon season.0.47% of mortality 
was assigned to snake bite.(16) 
Ahmed SM et al (2012) (17) conducted a prospective study on 113 patients 
and reported male preponderance of 69.4%, mean lag time (time elapsed between bite 
and first dose of anti-snake venom) of 5.3 ± 1.4 hours and the mean anti-snake venom 
dose of 12.3 ± 2.4 vials. They also showed a positive correlation between lag time and 
total dose of anti-snake venom. The overall mortality was 5.1%.(17) 
 
Data from Tamil Nadu: 
 
Though Tamilnadu has been documented to be among the 13 states with high 
burden of snake bite with a proportional mortality of 5.3 per 1000 population by 
Mohapatra et al in analysis of the million death study in 2011, there is a severe 
paucity of reporting of snake bites from Tamil Nadu.(16) 
 Vaiyapuri S et al (18) in 2013 conducted a survey among the rural population 
of Tamilnadu and suggested that the snakebite incidence is higher than previously 
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reported at 3.9% of those surveyed. Mortality corresponded to 0.45% of the 
population. They also showed that snake bite caused profound socioeconomic impact 
on the survivors in terms of cost of treatment. The consequences are severe on long 
term effects on health, including affecting the ability to do regular work.(18) 
These figures stated above clearly point out the fact that the incidences of 
snake bite that are estimated by the various hospital based studies are just the tip of 
problem. The actual incidence, mortality and morbidity may be much more than the 
estimated values stated above. 
 
DISTRIBUTION OF VENOMOUS SNAKES IN INDIA 
 
More than 2800 species of snakes are recognized in the world over, but only 
375 of these have front fangs that make them capable of injecting venom during bite. 
The venomous snakes belong to 5 families. The snakes belonging to the Colubridae 
family snakes dominates all others types of snakes in numbers, size and distribution.   
Earlier studies and books reported that India had about 242 species of different 
snakes distributed all over the country of which 57 species are of the poisonous 
type.(19) Currently according to the recent publications India has a total of around 
276 snake species in the country.  62 species are poisonous, 42 are mildly-poisonous 
and 172 are non-poisonous. Among the 62 poisonous species, 20 belong to the sea 
snake variety and 42 are land dwellers. 38 out of the 42 types of land snakes are 
distributed in a very small limited geographical areas.(20)The remaining four species 
are known for the vast majority of snake bites across the country and the ensuing 
complications and death. Commonly called as the ‘big four’ they are the - Indian 
Cobra (Naja naja), Common Krait(Bungarus coerulus), Russell’s viper(Vipera 
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russeli) and Saw Scaled Viper(Echis carinatus). They predominantly belong to the 
families of Elapidae, Colubridae, and Viperidae. Local effects and bleeding are the 
usual manifestations of the bites of Viperidae, Colubridae and Crotalidae. 
Neurological symptoms, particularly paralysis are the predominant manifestation of 
Elapidae group of species whereas paralysis and myolyis are the predominant mode of 
injury by Hydrophidae.(21) 
One of the widely accepted concepts in Indian snake venom discussions and 
research is the notion of the so called ‘‘Big 4 Snakes of Medical Importance,’’ which 
includes the Russell’s viper (Daboia russelii), the saw scaled viper (Echis carinatus), 
the Indian or spectacled cobra (Naja naja), and the common krait (Bungarus 
caeruleus). These 4 snakes have been believed to cause the vast majority, if not all, 
fatalities due to snakebite. Among these four snake species, no particular species is 
more dangerous, and any of the four bites is considered dangerous than the other. Few 
reasons for them being called the ‘big four’ include: 
 Indian Cobra- One of the most wide spread in distribution. As it occurs in 
areas with high density of human settlements, particularly attracted by rats it 
has higher chance of human interaction and confrontation than the other 
species. 
 Common Krait- Is included because of its potent venom and many a times 
the patient does not realise he has been bitten. Fang marks are difficult to find 
and sudden onset neurological paralysis is common. 
 Russell’s viper – Causes severe coagulation abnormality associated with 
severe local reactions and bleeding and can lead to compartment syndrome. 
Endemic areas are characterised by high frequency of bites. 
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 Saw Scaled Viper–Has a specific venom component called Ecarin which can 
lead to life threatening envenomation causing death secondary to bleeding.(20) 
 
Some species of Indian snakes such as the King cobra (Ophiophagus hannah) 
are recognised to be capable of causing severe and lethal envenoming. But 
comparatively the fatalities attributed to this and other dangerously toxic species of 
snakes are relatively negligible owing to the fact not only that these species of snakes 
are rare in distribution as well as there is very minimal number of bites and contact 
with human population due to these rare dangerous species of snakes. 
 
WHO in 1981 developed and published a methodology to identify the snakes 
that are of medical significance. The proposed WHO classification was: (22) 
 Class I— Snake species which commonly cause serious disability or 
death. 
 Class II— Snake species which are uncommon causes of bites but are 
capable of causing serious effects once envenomation has occurred.   
 Class III— Snake species which are known to commonly cause bites but 
incidence of serious effects due to envenomation is very uncommon. 
 
This methodology may be considerably more valuable than the ‘‘big 4 ’’ 
concept, particularly in view of the fact that reliable epidemiological data regarding 
snake bite and envenomation are not readily available in India. The contribution made 
by each particular species of snake to the overall morbidity and mortality figures 
isunknown.In view of the above facts, a validated methodology such as the definition 
given by the World Health Organization, which can provide the ability to assess 
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medical significance of the snake bite without particular reliance on specific numbers 
alone, is a much more useful tool for medical professionals and doctors practising in 
the community.  
 
The Snakes of Medical importance in India that are listed by the World Health 
Organization are as follows:(22,23) 
 Class I 
o Cobra 
o Russell’s Viper 
o Saw-Scaled Viper 
 Class II 
o Krait 
o King Cobra  
o Hump nosed pit viper 
o Mountain pit viper. 
 Class III 
o White Lipped Pit Viper and other non-venomous species  
 
There are about 104 species of snakes in South India of which only 37 are 
poisonous. The poisonous snakes commonly seen in Tamilnadu are Russell’s Viper 
(Vipera russelli or Vipera duboi), saw scaled or carpet viper (Echis carinatus), cobra 
(Naja naja), Indian krait (Bungarus caeruleus) and sea snakes. 
Very often the hunting habitat of these four snakes may overlap. But each one 
has its own special microhabitat and food preferences which lead to few regions 
having a higher incidence of a particular snake type. One example is a recent study 
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conducted in South India which reported a significant number of cases of snake 
envenomation among plantation workers in Kerala due to bites by the Malabar pit 
viper and Hump nosed pit viper. These two snake species are emerging as medically 
important species and unfortunately ASV (anti-snake venom, antivenom, antivenin) 
for these species is not available in India.(6)Hence, it’s essential to study the other 
venomous species which are medically important rather than focusing on the big four 
species. 
 
 
 
 
 
 
 
Figure 1:  The Russell’s viper 
(Vipera russelli or Vipera duboi) 
Figure 2:  Saw Scaled Viper or 
Carpet Viper (Echis Carinatus) 
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PHARMACOLOGY OF SNAKE VENOM 
 
Snake venom is toxic saliva secreted by modified parotid glands which are 
located in the snake’s mouth, below and behind the eye. The purpose of venom is two 
folds. Firstly to immobilize or kill the prey before it is swallowed and secondly, to aid 
digestion by breaking down the prey’s tissues. Often, when the snake bites it prey, the 
enzymes present in its venom start breaking down the prey’s tissues even before the 
prey is dead or swallowed.(8) For snakes, venom is not a weapon of mass destruction 
nor is targeted at human race. 
Figure 4: The common krait 
(Bungarus caeruleus) 
Figure 3: The Indian or 
spectacled cobra (Naja naja) 
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Venom is a clear, amber colored fluid when fresh. It is most complex of all 
poisons and contains more than 20 different components. The venom mainly consists 
of proteins which include variety of enzymes, non-enzymatic polypeptide toxins and 
non-toxic proteins. Other than proteins, the venom also consists of carbohydrates, 
metals, lipids, free amino acids, nucleotides and biogenic amines. Of the components, 
the more lethal and deleterious fractions are peptides and proteins of low molecular 
weight (6000 to 30,000). The polypeptide toxins (non-enzymatic proteins) are 
categorized into neurotoxins and hemorrhagens. 
Neurotoxins: 
 
The neurotoxins are most abundantly found in elapid (Cobra, Krait) and 
hydrophid (sea snakes) venom. They are also present in lesser quantities in some 
vipers such as Russell’s viper of South India and Srilanka. Neurotoxins act either 
at pre-synaptic or post-synaptic levels. The Krait venom acts pre-synaptically on 
the nerve terminals. It causes initial release of acetylcholine but then damages the 
nerve terminal and prevents further release. It is for this reason that Krait 
envenomation victims do not respond to Anticholinesterase therapy and often take 
longer time to recover than Cobra envenomation victims.(10,12) Cobra venom 
acts post-synaptically by competing with acetylcholine for receptors at 
neuromuscular junction and leads to curare like paralysis. The earliest sign of 
neurotoxic paralysis is ptosis followed by external ophthalmoplegia. Paralysis 
involves the proximal muscles first and then the distal muscles and recovery 
occurs in the reverse order. The internal ophthalmoplegia is attributed to 
autonomic dysfunction. 
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Hemotoxins: 
 
Hemorrhagins (Zinc metalloproteinases) damage the endothelial lining 
of blood vessel walls causing spontaneous systemic haemorrhage. The 
enzymatic components of venom consists of enzymes such as Phospholipases, 
Hyaluronidase, Hydrolases, Procoagulant enzymes, Acetylcholinesterase. The 
pathophysiological manifestations of these enzymes are clearly evident in case 
of viper venom. Procoagulant enzymes present in Russell’s viper which 
stimulate the blood clotting cascade are: 
a. RVV-X—A glycoprotein activates factor X by calcium dependent 
reaction, factor IX and protein C 
b) RVV-V— An arginine ester hydrolase activates factor V. 
Saw scaled viper venom contains a Zinc metalloprotein i.e. ecarin which 
activates prothrombin. The procoagulant enzymes activate clotting cascade and result 
in formation of fibrin in the blood stream. Most of this is immediately broken down 
by the body’s own fibrinolytic system. Eventually, within 30 minutes of the bite, the 
levels of clottingfactors become so depleted (consumption coagulopathy) that the 
blood will no more clot. Deciding the potency of the venom is problematic. It is 
obviously not possible to determine this by experiments on humans. Experiments 
conducted on mice by Ernest and Zug indicate venom of Hook nosed sea snake and 
Russell’s viper are more potent. But when we consider the land snakes, these do not 
confirm to the general experience in this two snakes. Whitaker and Captain while 
dealing with Common Krait, describe it as producing “the most potent venom of all 
our land snakes”. Going by findings elsewhere also, this observation has to be 
expected as correct. One of the curious feature of venom is that its composition not 
only differs from species to species, but differs even among individuals of the same 
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species inhabiting different geographical areas and even among the individuals of 
same litter. Thus, ASV needs to be prepared from species prevalent in the particular 
region.(6,20,24)Potency of the venom differs depending on various factors such as 
age and health of the individual snake. New-born and very young snakes have more 
potent venom than adults. This is Nature’s way of compensating for lesser quantity in 
the new born and the very young. There may be seasonal variation in the quantum and 
potency of the venom. Venom produced soon after hibernation is very potent whereas 
that produced during moulting phase is less toxic. Male snakes produce more venom 
than female snakes.(25) 
 
 
CLINICAL FEATURES OF SNAKE 
ENVENOMATION(26–28) 
 
The symptom with which the patient presents depends upon the composition 
of the venom. Depending upon the species, the following symptoms may be seen. 
Local symptoms 
 
o Puncture marks of the fangs. 
o Pain 
o Oozing from the bite wound. 
o Swelling 
o Discoloration 
o Necrosis. 
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Systemic symptoms 
 
The symptoms may vary in different individuals and with different species of 
snake but it can be classified into neurotoxic, haemotoxic and myotoxic based on 
predominant symptoms. 
 
 General - nausea, vomiting, malaise, abdominal pain, weakness, drowsiness, 
prostration. 
 Cardiovascular system - dizziness, faintness, shock, hypotension, cardiac 
arrythmias, pulmonary oedema. 
 Hemostatic disturbances - Bleeding from bite site, I.V.lines and old partly 
healed wounds. Spontaneous bleeding from gums, epistaxis, bleeding into tears, 
hemoptysis, hematemesis, rectal bleeding or melaena, hematuria, bleeding per 
vaginum, bleeding into skin, mucosa, intracranial hemorrhage (meningism from 
subarachnoid hemorrhage, lateralizing signs and/ or coma from intracerebral 
bleed). These symptoms are seen in viper envenomation. 
 Neurological symptoms such as drowsiness, paraesthesiae, taste and smell 
abnormalities, ptosis, ophthalmoplegia (external and internal), facial muscle 
paralysis, aphonia, difficulty in deglutition, respiratory and generalized flaccid 
paralysis are seen in elapid snakes and also in Russell’s viper bite found in South 
India and Srilanka. 
 Myotoxic symptoms such as skeletal muscle breakdown (rabdomyolysis) are seen 
in Sea snakes. It is characterized by generalized pain, stiffness and tenderness 
ofmuscles, trismus, myoglobinuria, hyperkalemia, cardiac arrest, acute renal 
failure. 
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 Renal system is often involved in Russell’s viper bites, Sea snake bites andcauses 
loin pain, hematuria, hemoglobinuria, myoglobinuria, oliguria/anuria, uraemia 
(acidotic breathing, hiccups, nausea, pleuritic chest pain). Saw scaled viper is not 
known to cause renal failure unlike Russell’s viper. 
 Gastro intestinal system - Acute abdomen in Krait bite is due to 
neuromyositis(13)and in Viper bite due to gastro intestinal and/or retro peritoneal 
bleeding. 
 Ophthalmic – Ptosis is the earliest sign indicative of neurotoxiciy followed by 
ocular muscle palsy. Hemorrhages into conjunctiva, anterior chamber, vitreous 
orretina, lid edema, conjunctival chemosis, retinal and optic nerve oedema, optic 
neuritis, optic atrophy and rarely cortical blindness can be seen.(29–31) 
 Endocrine (Acute pituitary/ adrenal insufficiency) system – It is often reported 
with Russell’s viper envenomation. It has two phases -Acute phase is 
characterized by shock, hypoglycaemia and Chronic phase (months to years after 
bite) manifests with weakness, loss of secondary sexual characters, amenorrhoea 
(Sheehan’s syndrome), testicular atrophy, hypothyroidism.(32,33) Sometimes, 
patients with neurotoxic envenomation may present with brainstem death like 
signs such as areflexia, dilated & non reacting pupils and no spontaneous 
respiratory efforts. Confirmatory tests for brainstem death like Electro cerebral 
silence on EEG for at least 30 minutes and absence of blood flow in 4 vessels 
cerebral angiography should be done. Prolonged ventilator support may revive the 
patient (in case the patient is not brain dead).(34–38) 
 Other complications which can occur in snake bite patients are - Acute pulmonary 
oedema(39), extensive necrosis requiring amputation of the limb, chronic ulceration, 
osteomyelitis with malignant transformation and neurological sequelae. 
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MANAGEMENT OF SNAKE BITE 
 
World Health Organisation (WHO/SEARO) has published guidelines that are 
specific for the South East Asia region countries such as India for the clinical 
management of snake envenomation’s. These guidelines were published in the 
supplementary issue of the South East Asian Journal of Tropical Medicine and Public 
Health.(26,28)WHO/SEARO guidelines are currently universally followed. The 
following management is as per the WHO guidelines:  
 
First aid (20,26,40) 
 
First aid is the procedure to be carried out immediately or very soon after the 
bite before the patient is taken to a hospital or dispensary.  The most important thing 
in first aid is ‘Do No Harm’ to the victim than anything else. WHO established a 
Snakebite Treatment Group in 2004 to tackle the problem of snake bite in the world. 
The primary objective of the group was to identify problem areas in terms of snake 
bite so that the current high level of snake bite mortality that could be reduced.In July 
2006 India convened a National Snake Bite Conference and developed national 
protocols for first aid after snake bite and treatment following envenomation.  
The first aid that was recommended by the committee is based on the 
pneumonic: 
 “Do it R.I.G.H.T”. 
 
R = Reassurance of the patient. This is very essential as a majority if the bites are 
from non-venomous species and less than half of the bites from venomous species 
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actually envenomate. Just fear is capable of psychological shock causing death so 
reassurance is important. 
 
I = Immobilization of the limb affected similar to stabilisation of a fractured limb. 
Children can be carried to the hospital.  It is very essential to immobilize the patient 
also(masterly immobility). Do not apply any pressure in form of tight compressions 
or tourniquets that blocks the blood supply. If a vehicle is not available for 
transportation, victim can be carried on a stretcher, basket or a light bedstead 
(charpoy) to comply with masterly immobility. Immobilization reduces the venom 
absorption and circulation. 
 
G.H = Get to Hospital Immediately or as early as possible. Traditional remedies have 
been shown to have no benefit in treating snakebite. 
 
T =Tell the doctor, about the incident and signs and symptoms the victim manifests 
with. 
Unfortunately, most of the popular, traditional, affordable and locally 
available first aid methods such as tourniquets, incision and drainage, wound washing, 
stone application, electrical therapy, cryotherapy, pressure immobilization method, 
squeezing of the wound and sucking/suctioning are proved to be useless or even 
dangerous and precious time is lost in applying them and cause further delay in 
approaching to the health care centres. The only benefit of these methods are, they can 
give reassurance to the anxious victim and reduce the psychosomatic effects and may 
act as placebo in non-venomous snakebites. But these methods are not medically 
helpful and are not to be practiced. 
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Caution: Never attempt at killing the snake as it is mere waste of time and 
leads to other victims. If killed, carry it very carefully to the hospital for identification 
by the doctor. Care should be taken while handling even the dead snake as even the 
severed head can bite and this reflex is present up to one hour after death of the snake. 
Every case of snake bite should be taken to doctor. The victim must be admitted and 
observed for at least 24hours for signs and symptoms and treated accordingly. Even in 
known cases of non-venomous snake bite, victim should be taken to doctor for 
administration of Tetanus toxoid. 
 
Precautions against snakebite(20) 
 
‘Prevention is always better than cure’ 
Snake bites can be prevented by simply learning the type of snake inhabiting 
in respective regions and learning their behaviour and habitat. 
a. Carry a torch while walking in the dark and ‘mind the step’. 
b. Clothing covering the legs such as full pants and protective foot ware such as shoes or 
gum boots act as barrier and minimize the venom injected. 
c. In snake infested areas, make sure that snakes don’t refuge in shoes, pockets of coats, 
trousers before they are worn. 
d. Tea, coffee plantation workers should be vigilant while working as bushes are 
favourite habitat of Pit vipers. 
e. In areas where Common Krait occurs, sleeping on the floor should be avoided. 
f. Never provoke a snake. Generally, snakes avoid confrontation with human beings. 
Learn to recognize the warning sign given by the snake before it strikes such as 
stopping of flickering of tongue, hissing (Russell’s viper), hood raising (Cobra), 
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coiling of body into ‘S’ shape (Saw-scaled viper), vibration of tail (Bamboo pit viper). 
Further provocation of snake on displaying warning sign leads to bite and 
envenomation. 
g. If the snake is likely to strike, keep yourself at a safe distance. When a snake is poised 
to strike, it strikes with tremendous speed. 
h. Moulting snakes have foul temper and are very aggressive. 
i. Younger snakes are more easily irritable and quicker to strike than an adult. New born 
of venomous species have fully operational fangs and enough venom to cause severe 
envenomation in humans. 
j. Do not indulge in bravado while handling or dealing with venomous snakes. Even a 
momentary carelessness even by an experienced and careful person can prove to be a 
terrible mistake. 
k. If a snake has bitten any person, neither he nor anyone else should remain at the site 
as the snake keeps lurking around in the vicinity due to its peculiar mode of hunting 
its prey at leisure 
l. Do not venture out alone into terrains where snakes are likely to be found. Go atleast 
in pairs. Both the companions should be well informed about snakes as they can take 
care of each other during emergency. 
 
Anti-snake venom (ASV, antivenin, anti-venom) (25) 
 
Anti-snake venom is an immunoglobulin that is purified from the serum of a 
horse or sheep which have been immunized with the venom of one or more snake 
species. Enzyme refined F(ab)2 fragment of IgG type is what is usually used. In 1887, 
Henry Sewell laid the foundations of antivenin therapy by his experiments conducted 
42 
 
in the University of Michigan, USA, on various snake venoms. Albert Calmette, a 
student of Louis Pasteur (founder-Director of Pasteur Institute in Saigon, Vietnam) 
followed up the research done in US and discovered ASV in 1891. The first antivenin 
became commercially available in 1927 in USA. 
 
ASV in India 
ASV can be of monovalent (specific to venom of single species) or 
polyvalent type (specific to venom more than one species). In India, only polyvalent 
ASV is available. It’s effective against only the ‘Big four’ species. ASV is 
ineffective against other species like Hump nosed pit viper and others. One ml of 
polyvalent ASV can neutralize 0.6 mg of Cobra and Russell’s viper venom and 0.45 
mg of Krait and Saw-scaled viper venom. One vial of ASV (10 ml) can neutralize 
6mg of Russell’s viper and Cobra venom. In India, ASV is manufactured in public 
sector by Haffkine Biopharmaceuticals Ltd, Mumbai; Bharat Serums and Vaccines 
Ltd, Mumbai; King Institute, Chennai. M/s.Vins Bio-products Ltd, Hyderabad; Serum 
Institute, Pune and Biological ‘E’ Ltd, Hyderabad in private sector also produce ASV. 
In an Indian study, it has been found that the Specific venom neutralizing property of 
ASV depends upon the geographical origin of the snakes used for procuring venom 
for immunization. It was observed that the dose of ASV required to treat victims at 
Pondicherry was double the dose required for victims at Maharashtra. The ASV used 
for treatment was obtained from Pune and Mumbai respectively where the Saw scaled 
viper venom is procured from the snakes caught in Western Maharashtra. The 
effectiveness of ASV produced in India is also questionable against venom of 
Sochurek’s Saw scaled viper found in Rajasthan. Thus, it is advised to prepare 
ASV from venom procured from snakes from same geographical areas. ASV is 
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scarce and costly. The lyophilized venom supplied to institutions for manufacturing 
ASV is costly. The Irula Snake Catchers’ Industrial Cooperative Society, Vadnemeli, 
Tamil Nadu, is a major supplier of lyophilized snake venom and chargesRs.10,000 
per gram of cobra and Russell’s viper venom and Rs. 30,000 to 80,000 per gram of 
Saw scaled viper and Common Krait venom. Hence, ASV is very valuable and should 
be used judiciously. 
 
Administration of ASV (26) 
Administration of ASV to any patient with history of snake bite without any 
signs and symptoms of envenomation should be strongly discouraged as the patient is 
unnecessarily exposed to ASV which has risk of life threatening reactions an 
sensitization apart from ASV being scarce. 
Indications(26,28) 
ASV should be administered only if and when the patient has proven signs of 
either systemic or local envenomation. Only unbound venom present in the blood 
stream or tissue fluid is neutralized by ASV. 
Systemic envenomation 
a) Evidence of Hemostatic abnormalities: spontaneous systemic bleeding 
(clinical), coagulopathy (20 minute WBCT or other laboratory) or 
thrombocytopenia. 
b) Evidence of Neurotoxic envenomation: ptosis, external ophthalmoplegia, 
muscle paralysis, inability to lift the head etc. 
c) Evidence of Cardiovascular abnormalities: hypotension, shock, cardiac 
arrhythmia, abnormal ECG. 
d) Acute renal failure: oliguria/anuria, increased blood Creatinine/ Urea. 
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e) Persistent and severe vomiting or abdominal pain. 
Local envenomation 
a. Local swelling involving more than half of the bitten limb (in the absence 
of a tourniquet) or severe swelling of the digits (toes and finger). 
b. Rapid extension of the swelling within few hours of bite (beyond ankle or 
wrist when bite on hands or feet). 
c. Development of an enlarged tender lymph node draining the bitten limb. 
 
Anti-Venom Reactions: 
 
There are predominantly three types of reactions: 
1. Early(anaphylactic) reactions 
2. Pyrogenic reactions 
3. Late (serum sickness-type) reactions. 
 
The incidence of early and late reactions can be decreased by pre-treatment with 
antihistamines, corticosteroids and subcutaneous adrenaline. Early antivenin 
reactions cannot be predicted by the usual hypersensitivity tests as they are not the 
typical IgE-mediated reactions to equine serum proteins. Complement is activated by 
the antivenins in vitro. The complement activation along with immune complex 
formation in vivo leads to the clinically similar reactions that this hypersensitivity is 
associated with. Aggregates of Ig G probably activate the complement system. The 
hypersensitivity reactions may start as early as 10 min. They can be delayed till within 
10 minutes to as late as 180 minutes. The prominent features are itching, fever, cough, 
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nausea, tachycardia, palpitations. The reported incidence of antivenin hypersensitivity 
can vary from 3% to 54%.(41) 
Literature from the WHO states that ASV hypersensitivity reactions increase with 
the dose of ASV used. They also state that these reactions decrease with the use of 
refined ASV is used. But this may not hold good due to various reports by recent 
studies.(41)Patients must be observed carefully for at least three hours post ASV 
administration in order not to miss the mild reactions and thereby prevent wrong 
attribution of deaths to envenoming itself.  Though 40% of the patients having early 
reactions may show features of severe reactions such as systemic anaphylaxis with 
bronchospasm, angioedema and rarely hypotension, deaths are usually rare in this 
group. Early reactions can be readily treated by subcutaneous adrenaline given at a 
dose of 0.5 to 1ml of 0.1 % solution (1:1000, 1 mg/ml)in adults. Antihistamines 
(e.g.chlorpheniramine maleate and others) should be given by intravenous route to 
neutralize the effects of anaphylaxis caused by histamine release. 
Pyrogenic reactions occur as a result of contamination of the ASV and the 
diluting fluid by endotoxin like substances. They are characterised by high grade 
fever developing 1-2 hours post treatment. The presenting features are usually rigors, 
warm extremities suggesting vasodilatation and a later hypotension caused by fall in 
blood pressure. Febrile seizures may occur in predisposed children. Emergent cooling 
measures must be undertaken immediately. 
Late (serum sickness-type) reactions develop 1 to 12 days (mean 7 days) after 
treatment with antivenin therapy. These reactions may be dose related and the 
incidence and speed of develop of these reactions is higher with higher the dose of 
ASV administered. The main clinical features include low grade fever, itching, 
arthralgia, mainly of the temporo-mandibular joint, lymph node enlargement, 
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periarticular swellings with effusions, mononeuritis multiplex, mild albuminuria and 
rarely encephalopathy. These reactions respond to antihistamines such as 
chlorpheniramine in mild cases. More severe cases of late reactions may require 
corticosteroids usually given over a course of five days. 
 
 
COMPLICATIONS OF SNAKE BITE 
 
1)  Hypotension 
Very scanty information exists in literature regarding this aspect of snake 
envenomation. The incidence of hypotension in various studies ranges from 10- 26 
percent with a study from Medical College in Kottayam, Kerala showing the 
incidence as 22 % where as a study from Jammu medical college showing an 
incidence of 10%. A series of 46 cases of fatal snake envenomation from Thailand 
showed that 26% of the mortality was due to uncorrected hypotension. Worldwide the 
snake species causing hypotension commonly are the Burmese Russell’s viper, Vipera 
palestini and the North American rattle snake.  
Snake causing hypotension in pregnancy can be caused by exaggerated supine 
hypotension syndrome or by antepartum haemorrhage causing intrauterine 
death.(42,43) Hypovolemia becomes an important contributing factor for both early 
and late onset hypotension. The causes include excessive sweating due to kinin 
system activation or the venom itself, vomiting and diarrhea. Fluid restriction 
practiced by the local traditional healers also contributes to hypovolemia. Other 
important cause is the generalized increase in capillary permeability seen post 
envenomation. This causes a sort of capillary leak syndrome that is observed 
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especially secondary to viperine bites and patients additionally develop both 
conjunctival and facial oedema. Loss of plasma secondary to a severe local reaction at 
the injured area could be another cause of hypovolemia.(44,45) Internal and external 
bleeding can cause hypovolemia which can be due to various factors such as 
coagulation failure caused by Disseminated intravascular coagulation, platelet 
function and number abnormalities, and also the venom toxins such as  haemorrhagins 
which produce endothelial damage causing  seepage of red cells across the capillary 
walls. Venom also causes release of histamine and serotonin which only further 
aggravate the vasodilation leading to more hypotension. SIRS and DIC by themselves 
can produce hypotension and shock by vasodilation. Other rare causes include 
myocardial dysfunction causing low ejection fraction, acute pituitary failure or 
adrenal haemorrhage. Antivenin therapy can also cause early onset hypotension as a 
complication 
 
2)   Respiratory failure:(46–48) 
Severe cases of Elapid poisoning mainly affect the muscles of eyes, throat, 
tongue and chest wall causing opthalmoplegia and paradoxical respiration ultimately 
leading to respiratory failure. These toxins act both pre-synaptic as well as 
postsynaptically. The respiratory failure is mainly type II causing both hypoxia and 
hypercapnia secondary to CO2 retention. The severity of respiratory failure is related 
to the dose, potency, site of venom entering the body and timely medical support with 
Anti snake venom. 
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3)  Renal failure: 
The causes of renal failure include hypovolemia that occurs due to various 
factors described above such as disseminated intravascular haemolysis, direct venom 
induced toxicity causing papillary necrosis and rarely anti-snake venom induced acute 
interstitial nephritis. ASV administration early in the course of treatment has been 
associated with decreased incidence of ARF. ASV does not provide complete 
protection against this complication.  A study done by Merchant et al in 1989 in 29 
cases of snake bite with renal failure showed renal histology of tubular necrosis in 
35%, cortical necrosis in 24% tubular degeneration in 17% and glomerular changes in 
17%.(49) The significant glomerular changes seen were ballooning of glomerular 
capillaries in 59%, splitting of glomerular basement membrane in 40.7%, swelling of 
endothelial cells in 29.6% and focal proliferation of mesangial cells in 17%.(49) 
Development of oliguria within 24 hours of snake bite and cortical necrosis were 
associated with higher mortality.(49) A significant factor involved in the pathogenesis 
of viper bite-induced glomerular disease may be mesangiolysis that has been shown 
experimentally.(50)Haemorrhagic Glomerulonephritis is very rare.(49–51) 
 
4)  Gangrene: 
Local necrosis which when neglected can result in complication of gangrene. Wound 
need to be frequently examined for evidence of necrosis and gangrene. Early signs 
include formation of blisters, blackening or blanching, loss of sensation over the 
affected area and a characteristic smell of tissue necrosis. As the risk of secondary 
bacterial infection is very high, spontaneous sloughing of the necrotic tissue should 
not be allowed. The dead tissue must be removed under spinal or local anaesthesia 
with aseptic precautions as soon as possible. 
49 
 
THE PROBLEM AND IMPORTANCE OF 
COAGULOPATHY IN SNAKE BITE 
 
Snake venom is a combination of cytotoxins, hemotoxins, neurotoxins and 
myotoxins. Earlier, the venom of a particular snake was considered to be one kind 
only, either hemotoxic or neurotoxic, and this erroneous belief still persists in many 
parts of the world where updated literature is hard to access.(52)Snake venom is a 
complex mixture consisting of many active agents. Most of these agents have multiple 
effects and very few components, if any, may have a single ‘pure’ effect. 
“Procoagulant” as well as “anticoagulant” venom components have been identified in 
in vitro test systems. “Procoagulant” snake venom components may cause in vivo 
massive intravascular coagulation leading to circulatory arrest and rapid death.  
Smaller doses of procoagulant venom components applied to large organisms as in the 
case of snake-bite accidents in humans, may cause a consumption coagulopathy with 
localized or generalized bleeding.(53) Further workers like R.M. Kini et al have 
shown several snake venom constituents especially enzymes such as phospholipase 
A2, proteinases, nucleotidases or L-amino acid oxidase interfere in platelet 
aggregation whereas some venom factors induce platelet agglutination.(54) 
A case series of snake bites conducted among children in Australia showed that all the 
children with clinical signs of envenomation demonstrated coagulopathic laboratory 
features when assessed by prothrombin time (PT), activated partial thromboplastin 
time (APTT), fibrinogen levels and fibrinogen degradation products (FDP)s. This 
observation was made in all cases, independent of the species of snake causing the 
bite.(55)  Hence it indicates that even snake bites which have been classically referred 
to as classically neurotoxic in earlier days have some amount of coagulation 
dysfunction associated.   
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Thereby the study concluded that assessment of derangement in  
coagulopathy could provide not only a highly sensitive, specific testing but also 
an reliable indicator of envenomation.(55) In a 5 year retrospective analysis by 
Chew et al found that even snake bites due to Elapidae family such as Cobra which 
are classically referred as ‘purely’ neurotoxic there were several cases of 
hemotoxicity also occurring concurrently.(56) 
 
Haematological alterations 
 
 Haemoglobin: Fall in haemoglobin can be due to various causes such as loss 
of blood into the affected limb, seepage of red cells secondary to increased 
capillary permeability and hemolysis secondary to the venom itself. 
 
Disseminated Intravascular Coagulation (DIC) 
 
DIC is a dangerous complication which can be very fatal if unrecognised. 
Viper bites are especially known to lead to the occurrence of DIC. The underlying 
pathophysiologic process is characterised by extensive and diffuse intra vascular 
activation of clotting cascade leading to depletion of coagulation factors. This 
overutilization of clotting factors and platelet causes an acquired haemostatic defect in 
the clotting process. The whole process gets triggered by the snake venom which 
leads to simultaneous activation of several steps in the coagulation process. Hageman 
factor (Factor XII) is directly activated by the venom components. The toxins also 
induce accelerated tissue factor expression on the endothelial cell surface. Cell surface 
activation with the tissue factor then further accelerates the other reactions. Micro 
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thrombi and emboli are deposited throughout the micro vascular network as a result of 
this extremely potent thrombogenic stimulus. The early thrombogenic phase is later 
followed by a phase involving consumption of procoagulant factors and secondary 
fibrinolysis. Continued formation of fibrin followed by fibrinolysis leads to 
haemorrhage caused by depletion of coagulation factors, platelets and anti-
haemostatic effect of fibrin degradation products. DIC may be acute or sub-acute 
usually. Rarely it may be chronic. Snake bite is one of the important causes of 
consumptive coagulopathy.(57)The severity of clinical presentation depends on the 
stage of the DIC. Severe cases can have extensive bleeding from the mucous 
membranes and sites of breach in skin continuity. Venepuncture and catheter insertion 
sites may present with continuous ooze. Rarely features include development of 
acrocyanosis and pre-gangrenous changes in the digits due to thrombosis. Similar 
changes can be seen in the genital area and nose. These areas are characterised by 
markedly reduced blood flow secondary to thrombosis and vasospasm. Patient can 
have MODS (multi organ dysfunction syndrome) due to extensive ischemia caused by 
micro vascular thrombosis. Thrombotic process affecting the large vessels can cause 
venous as well as arterial thrombosis leading to various manifestations such as deep 
venous thrombosis which can reversible as well as ischaemic stroke.(58–60) 
Thrombocytopenia can occur with rattlesnake poisoning.(61) 
Early recognition of DIC followed by prompt institution of appropriate 
therapy coupled with intense laboratory monitoring help in reducing mortality due to 
DIC. Low platelet count along with fragmented RBS’s called as schistocytes 
constitute the predominant laboratory manifestations. These are formed due to 
trapping and damage of red cells in the fibrin thrombi. Prothrombin time, Activated 
Partial Thromboplastin time and Thrombin time are prolonged. Secondary fibrinolysis 
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leads to low fibrinogen levels and elevated levels of fibrin degradation products 
(FDPs). Such very low fibrinogen levels can be associated with internal bleeding like 
intracranial or intra-abdominal bleeds.(62) 
 
Venom induced consumption coagulopathy 
 
Concept of venom induced consumption coagulopathy (VICC) being different 
from disseminated intravascular coagulation (DIC)(63) 
Isbister et al have been the proponents of the concept of venom induced 
consumption coagulopathy (VICC).(63) They say that VICC has many times been 
likened to DIC because of the elevated D-dimer, prolonged PT and low fibrinogen but 
it does not have other important features that are associated with DIC, such as 
systemic micro thrombi. Also VICC time course differs by rapid onset and resolution. 
The mechanism of initiation of coagulation activation may be different. The problem 
of the overlapping clinical syndromes of thrombotic microangiopathy and VICC in 
snake envenoming could be the most likely reason for researchers developing the 
mistaken idea that snake envenomation causes DIC.(63) 
 
LABORATORY INVESTIGATIONS 
 
Routine investigations 
 
 Leucocytosis is commonly present with neutrophil predominance.  
 Anaemia follows the initial haemoconcentration resulting from extravasations of 
plasma.   
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 Thrombocytopenia is common after bite by Russell’s viper and can be venom 
induced or secondary to DIC. Bites by Saw scaled viper also cause low platelet 
levels universally. 
 Prolonged whole blood clotting time usually indicates low fibrinogen levels. 
Other sensitive methods to diagnose defibrination are assay for FDP’s and 
fibrinogen level testing. 
 Rapid rise in creatinine phospho kinase, associated with hyperkalemia and 
elevated myoglobin is diagnostic of rhabdomyolysis.  
 Black or brown coloured urine on urinalysis is suggestive of intra vascular 
haemolysis causing myoglobinuria.  
 Electrocardiographic abnormalities include bradycardia, ST-T changes, first or 
second degree heart blocks. Tall T waves can be seen due to hyperkalaemia. 
 Pituitary and renal failure are known to occur. This may cause changes in the 
hormonal profile of the patient. 
 
CLOTTINGTIME: 
 
Clotting time will be prolonged in most cases of moderate to severe 
envenomation. 20 minute whole blood clotting time is a simple and sensitive bedside 
test of systemic envenomation. 
CLOT OBSERVATION TEST: 
 
This is a very simple test that assesses the status of blood coagulation. 3-5 ml of 
freshly drawn venous blood is kept in a clean glass tube 20 minutes and left 
undisturbed. After 20 minutes the tube is tipped to see whether the blood has clotted. 
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If the blood remains unclotted even after 20 minutes, then it is a sure sign of 
envenomation.(64,65) 
CLOT RETRACTION TEST: 
 
This test is done similar to the above test but is observed for a longer period. 5 ml 
of venous blood is taken in a completely dry test tube which is kept slanting. 
Periodical examination of the tube is conducted. Not only must the venous blood 
sample clot in less than 20 minutes but also the clot must retract in 2-6 hours. Straw 
coloured serum must be separately seen. Envenomed patients have defective or 
prolonged abnormal clot retraction times.(66) 
PROTHROMBIN TIME: 
 
Fibrin production by means of the extrinsic and common pathways requires factor 
VII, tissue thromboplastin, factor X, factor V, prothrombin and fibrinogen. Both the 
pathways are measured by prothrombin time. The assay involves plasma re -
calcification in the presence of excess tissue factor. Unlike activated partial 
thromboplastin time this test does not require contact activation. It bypasses the 
intrinsic pathway and the factors involved. Platelet numbers do not affect the test 
because tissue thromboplastins in the sample contain phospholipids that act as platelet 
substitutes. Of the five coagulation factors measured by the plasma PT (fibrinogen, 
prothrombin, factors V, VII, X), three factors namely prothrombin, factor VII and X 
are vitamin k-dependent and can be affected by coumarin like drugs. As a result, the 
plasma PT is most widely used for controlling dose of oral anticoagulant therapy. The 
plasma PT usually is prolonged when the plasma levels of any of the requisite factors 
are lower than 10% of normal. It is more sensitive to deficiencies of factors VII and X 
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than deficiency of fibrinogen and prothrombin. Multiple modified techniques and 
various thromboplastins have been developed to increase the utility of the PT in the 
control of coumarin based anti-coagulant therapy. 
The expression of the PT as a percentage of normal is not recommended. This is 
because the dilution curves used to arrive at this figure may be misleading and often 
have little quantitative meaning. Use of the standardised International normalized 
Ratio (INR) in monitoring oral anticoagulation therapy is recommended. The plasma 
PT performed with bovine thromboplastin or with Thrombotest reagent is abnormal in 
individuals affected with certain genetic variants of factor IX deficiency. 
 The Russell’s viper venom initiates coagulation by the direct activation of factor 
X   and does not require factor VII due to the presence of an enzyme. Therefore “One 
Stage Prothrombin Time” performed with this venom (called the Stypven time) can 
reliably distinguish between deficiency of factor X and factor VII.  
 
ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) 
 
The Activated Partial Thromboplastin Time is a simplest test of the intrinsic 
pathway and common pathways of coagulation cascade. The test involves 
recalcification of a mixture of plasma and phospholipid platelet substitute, leading to 
formation of fibrin at a normal rate. This can happen only if the clotting factors 
involved in the intrinsic pathway namely prekallikren, HMW kininogen, and factors 
VIII,IX, X, XII and  factors in the common pathway i.e. factors V, X, prothrombin 
and fibrinogen are present in normal amounts. Various kinds of platelet substitutes 
may be used, such as brain chloroform extract, crude cephalin fractions as well as 
soybean phosphatides (inosithin). In the APTT test, in order to make the test 
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unaffected by the number of platelets remaining in the plasma such platelet substitutes 
are provided in excess. These platelet substitutes which are only partial 
thromboplastins, are incapable of activating the extrinsic pathway by themselves, 
which requires additional complete tissue thromboplastin. Thus, the Partial 
Thromboplastin Time can bypass the extrinsic pathway and is unaffected by factor 
VII. Other uses of the assay include detection of factor deficiency, screening for the 
lupus anticoagulant, and to monitor anticoagulation for patients on heparin. 
The Partial Thromboplastin time is more sensitive to deficiencies of factor IX 
and VIII than to deficiencies of factor XII and XI or factors involved in the common 
cascade. But with most of the techniques used, the test is abnormal if plasma level of 
any of the essential factors is less than 15 – 30 % of the normal. The assay thus can 
indicate some mild coagulation factor deficiency disorders. However, this ability of 
the assay to detect mild coagulation factor deficiency is reagent dependent. Certain 
reagents may not detect factor deficiency even as low as 5 – 10%. Like all other one 
stage tests, the PTT value may be shortened by high levels of a single factor, most 
common factor being factor VIII. Thus in summary, a short PTT could signify any of 
the various hypercoagulable states, but very high levels of any of the factors involved 
in the intrinsic pathway or the common pathway may mask deficiencies of other 
factors. 
Originally, contact activation used to be provided by the glass tube. Lately the 
addition of other activators, such as Ellagic acid or particulate silicates (Celite or 
kaolin) is shown to provide more optimal and standardized contact activation, and 
thus represents a significant improvement over the original test which was non 
activated. Currently the activated PTT (APTT) is routinely used assay to evaluate 
intrinsic coagulation pathway. The APTT of prekallikren (Fletcher factor) deficient 
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plasma is abnormal when it is done by standard methods using particulate activators 
(Celite or kaolin). This abnormality can be minimized or abolished by methods like 
protracted contact activation for 15 minutes, as compared with 2-3 minutes used in the 
standard technique. The APTT may be normal in prekallikrein deficiency patients 
when ellagic acid (soluble activator) is used. 
 
THROMBOELASTOGRAPHY (TEG/ROTEM): 
 
 Thromboelastography was originally described in 1948 by Dr Hellmut Hartet 
at the University of Heidelberg.(67) Thromboelastography monitors coagulation 
cascade as a whole dynamic process unlike traditional tests which reveal isolated 
information at various points in the process of clotting.(68)TEG is a dynamic study of 
process of coagulation, which mechanically studies the process of fibrin formation as 
well as platelet aggregation followed by fibrinolysis.(68) 
 Difference between TEG and ROTEM: They are in fact two analogous 
systems that are commercially available;  
o ROTEM -TemInternational GmbH, Munich, Germany 
o TEG- Hemoscope Corporation, Niles,IL. 
 
Both use the same technique described by Hartert with slightly different nomenclature 
and technical differences. The primary hardware difference between the systems is 
that TEG operates by moving a cup in a limited are (±4°450every 5s) filled with 
sample that engages a pin/wire transduction system as clot formation occurs whereas 
the ROTEM has an immobile cup where in the pin/wire transduction system slowly 
oscillates(±4°450every 6s).(69) 
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Measurement technology: 
 
The TEG measures the viscoelastic properties of blood in vitro. Blood sample 
(typically 0.36 ml) is placed into a cuvette (cup) which is rotated gently through 4º 
45´ (cycle time 6/min) to imitate sluggish venous flow and activation of coagulation. 
Various patterns of changes that occur in the forces of shear-elasticity based on the 
type of blood sample taken can be documented on a graph. These patterns help us to 
determine of the kinetics of clot formation, clot growth, strength and stability of the 
clot that is formed. Analysis of the stability and strength of the clot formed provide 
information regarding the ability of the clot to perform the work of haemostasis. The 
kinetics of clot formation determines the adequacy of various quantitative factors that 
are available for clot formation which can be measured. Therefore TEG can measure 
various aspects of haemostasis such as the life of a clot in vitro, time taken to 
formation of the initial clot, evaluation of a developing clot in its acceleration and 
strengthening phases as well as study the phenomenon of clot retraction and clot lysis. 
            A small venous blood sample (0.36ml) after activation is placed in a 
prewarmed cuvette. A piston suspended form above is then lowered into the well 
containing the blood sample. This piston rotates in a 4.5 degree arc backwards and 
forwards where as in ROTEM the piston is static and the well rotates. Earliest formed 
fibre strands interact with the activated platelets and attach themselves between the 
suspended piston and the surface of the cuvette. The movement arising out of the clot 
formation in the cuvette is transmitted onto the suspended piston. When a "weak" clot 
forms it can stretch more and can therefore delay the arc movement of the piston. 
Therefore a clot that is weak will be expressed as a narrow graph on 
thromboelastography. On the other hand if a strong clot is formed, it will be able to 
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move the piston proportional to the movement of the well, thereby creating a thick 
graph on thromboelastography. 
 
 
 Figure 6: A typical TEG tracing showing the parameters of measurement 
The strength of the clot represented over time on a graph shows a characteristic cigar 
shaped figure. 
Figure 5: Schematic illustration 
of the instrumentation utilized in 
Thromboelastography 
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Parameters of Measurement: 
There are mainly five parameters of measurement. They measure different stages of 
clot development and are as follows: 
 R time:This is the period of time from initiation of the test to the time of initial 
fibrin formation. 
 K time:This is a period of time from beginning of clot formation to time taken for 
the amplitude of TEG graph to reach 20 mm, and it represents the dynamics of 
clot formation. 
 Alpha angle: This is an angle formed between the line in the middle of 
thromboelastogram and the line tangential to the developing "body" of the 
thombelastogram. This angle represents the rate of acceleration or kinetics of 
fibrin cross-linking and build up. 
 MA–refers to maximum amplitude of the clot formed. It reflects the strength of a 
clot and is dependent on number and function of platelets and their interaction 
with fibrin. 
 MA60: This value measures the rate of amplitude reduction at 60 min. after the 
MA has been achieved and it represents the stability of the clot. 
Clinical interpretation of different stages of coagulation by 
thromboelastography testing: 
 
 Clot formation: 
o Clotting factors— r, k times 
 Clot kinetics: 
o Clotting factors—r, k times 
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o Platelets—MA 
EXAMPLES OF QUALITATIVE TEG TRACES FOR INTERPRETATION: 
 
Figure 7: Figure showing various TEG traces for interpretation in specific conditions 
leading to defects in coagulation. 
 Clot strength/stability: 
o Platelets—MA 
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o Fibrinogen— MA 
 Clot resolution: 
o Fibrinolysis—LY30/60; EPL A30/60 
Table 1:  Correlation between TEG and ROTEM parameters: 
TEG Parameters  ROTEM Parameters 
R time Clotting Time (CT) 
K time Clot Formation Time (CFT) 
Alpha angle Alpha angle 
Maximal Amplitude (MA) Maximal Clot Firmness (MCF) 
 
The usefulness of thromboelastography has been sufficiently documented in 
general surgery(70), cardiac surgery(71–73), urology(74), in obstetric patients(75–
77), and in liver transplantation(78,79). Probably this is the only test currently that can 
measure all the steps of clotting in a dynamic way till eventual lysis of the clot or clot 
retraction occurs. Newer machines are very cost-effective, and this has been 
demonstrated in several studies.  
As far we know, this test namely thromboelastography (TEG/ROTEM) 
has not been studied as an index of envenomation in patients presenting with 
snake bite in India. On searching PUBMED and INDMED databases there are 
noprior studies assessing role of TEG either as predictor of disease severity or 
for evaluation of coagulopathy in snake bite cases in adults in India. 
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JUSTIFICATION/RATIONALE FOR THE STUDY 
 
Based on the above observations(52–57,61–66,80) we have postulated that 
any significant envenomation after a snake bite by any species of snake with have a 
measurable effect on the clotting process. Inspite of the effect being subclinical at 
times, this alteration of clotting cascade can be detected by a test of coagulation which 
does dynamic assessment of the coagulation status such as Thromboelastography 
(TEG/ROTEM) than the conventional assays regularly used (WBCT/PT/APTT).  
This postulate contradicts the conventional wisdom like certain snake venom, 
particularly venoms causing only neurotoxicity clinically have a single pure action. It 
is also well established that ischaemic reperfusion injury following tourniquet use 
itself may be responsible for disturbances of coagulation and considerable toxicity, 
circulatory instability and metabolic derangement.  
Therefore we plan to look at a newer and sensitive test of hemostasis namely 
thromboelastography to serve as an indicator for identifying envenomation and also as 
a predictor of severe disease status.  
Hadley et al in 1999 have studied TEG among 51 children admitted with 
snake bite to hospital in Durban, South Africa. They have shown that a normal 
thromboelastogram could provide assurance that snake envenomation or reperfusion 
injury secondary to tourniquet has not affected the coagulation status and hence 
clinically the syndrome is less likely to be severe in nature.(81) The study also 
concluded that the negative predictive value of TEG, i.e. a normal graph had a better 
prediction of a milder clinical course when it was  compared to other traditional 
64 
 
assays such as prothrombin time and INR.(81) So therefore even though TEG cannot 
identify the cause of the abnormality, it is understood that it is very good at 
identifying the abnormalities of clotting process.  
Summarising, the proposed study aims to see that in developing countries 
such as India where there is almost nil availability of specific and rapid venom 
detection kits for widespread use after a common problem such as snake bite, if 
any of the tests of coagulopathy including newer tests such as 
thromboelastography can be useful as predictors of clinical outcome. 
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MATERIALS AND METHODS 
 
SETTING: 
 
The study was conducted among the patients presenting to the Emergency department 
and Department of General Medicine of Christian Medical College Vellore Hospital 
with features of snake envenomation. 
Christian Medical College Vellore is a tertiary level hospital providing health 
services to the population of Vellore city in the state of Tamil Nadu. It is 2500 bedded 
hospital with a daily outpatient attendance of more than 6,500 patients every day. 
Around 80 – 100 snake envenomation’s are seen every year in the Emergency 
Department of the hospital. This study was conducted in the department of 
Emergency Medicine, General Medicine and Clinical Pathology for a period of 18 
months.  
Sequentially encountered patients with snake envenomation were recruited 
after taking written informed consent and were followed up till discharge with a 
clinical research form.  Every patient was subjected to a 20 min whole blood clotting 
time (20min WBCT) test at admission. Additional two citrated samples of 3 ml whole 
blood were taken at admission and 6 hours later from the patient along with the 
routine blood samples. 
The acute management of patients was provided by the Department of 
Accident and Emergency. Later the patients were admitted to the medical wards or 
ICU depending on the severity where they were followed up till discharge. The 
patients are mostly from the lower and middle socio-economic strata and are mostly 
from Tamil Nadu and Andhra Pradesh. 
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DETAILS OF STUDY DESIGN: 
 
 Study type:  Analytical study 
 Study design: Prospective observational Cohort study with nested case control 
design. It involved observation and obtaining data from adult patients with snake 
envenomation and follow up of this cohort of patients till discharge. The cohort 
was divided into patients with mild to moderate envenomation and severe 
envenomation according to snake bite severity score by Dart et al and comparison 
of various factors was made to predict severe envenomation 
 Type of comparison group: Internal comparison 
 Duration of the study: The study was conducted between November 2012 and 
August 2014 on a prospective basis. The recruitment phase spanned over an 18 
month period from January 2013 to June 2014. The total period of study 
including analysis and write was 21 months. 
 
PATIENTS: 
 
Study population: All patients admitted to Christian Medical College Hospital 
Vellore during the period January 2013 to June 2014, with history of snake bite 
having noticed the offending snake and patient with doubtful history of snake bite but 
with definite acute onset of symptoms and signs of local systematic envenomation 
without any other causes for the same. We included those who consented to 
participate after careful exclusion criteria. 
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 Patients were recruited principally under 2 clinical categories: 
1. Patients with mild/moderate severity of snake envenomation 
2. Patients with high severity of snake envenomation. 
Sources of information: 
1. Study participants interview 
2. Hospital records examination 
3. Laboratory testing results. 
 
Inclusion criteria: 
 
1. Age more than 15 years 
2. Newly presenting to the emergency department with alleged history of 
snake bite with features of snake envenomation like local bite site reaction, 
hemotoxicity or neurotoxicity.  
Exclusion criteria: 
 
1. Age less than or equal to 15 years. 
2. Pregnant women 
3. Patients with known haematological disorders or malignancies that 
may affect the coagulation pathway. 
4. Patients on known anticoagulant or antiplatelet medications. 
5. Patients with known history of chronic liver disease.  
6. Patient refusing to give consent to be part of the study.  
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Outcome measures: 
 
Primary outcome: Sensitivity and Specificity of Thromboelastography in 
assessing disease severity in patients with snake envenomation. 
Secondary outcomes: 
 
1. To determine the severity of snake envenomation based on Snake bite severity 
score. 
2. To determine the demographic, clinical and laboratory risk factors predicting 
high disease severity in patients with snake envenomation. 
3. Sensitivity and Specificity of Thromboelastography in assessing coagulopathy 
in patients with  snake envenomation 
4. To assess the role of TEG in identification of platelet abnormalities. 
5. To assess the role of Thromboelastography in identification of low fibrinogen 
levels 
 
PROTOCOL IMPLEMENTATION 
 
Step 1 Recruitment: 
 
All patients who fulfilled the inclusion criteria were recruited by the principal 
investigator after obtaining a written consent (annexure 1). Details on demography, time of 
bite, environment setting, clinical deficits, presentation to hospital, risk factors, imaging 
findings, investigations, course of hospital stay and treatment taken were obtained and 
recorded in the clinical research form (annexure 2). Each patient underwent the severity 
estimation of snake envenomation by the Snake Bite Severity Score by Dart et al which was 
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administered to the patients by the principle investigator at the time of recruitment. Patients 
recruited were categorized according to the severity type of snake envenomation (Mild to 
moderate envenomation: score <8, Severe envenomation: score>=8) based on the score 
obtained by the above mentioned scoring system.  The researcher did not interfere with the 
management or the investigations that were ordered for each patient during their entire 
hospital stay.  
 
Step 2: Data collection 
 
A history and physical examination was done for all recruited patients at the time of 
enrolment. The following data were collected in data extraction forms for all recruited 
patients. (Annexure 2) 
1. Baseline demographics – age, sex, place of residence, date of admission, time 
of admission and mode of transport. 
2. Details of onset of symptom and presentation: Time of snake bite, time of first 
medical contact after the snake bite, time of presentation to CMC after the 
snake bite, details of first aid including the type of first aid received and 
details of Anti Snake Venom received. 
3. Details of Snake Envenomation:  
a. Site of the snake bite 
b. Features of local envenomation including presence of cellulitis, local 
pain, necrotising fasciitis, compartment syndrome and local bleeding 
c. Features of hemotoxicity including bleeding gums, epistaxis, 
hematemesis, haematuria, intra-abdominal/intracranial bleed and 
details of blood transfusions. 
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d. Features of neurotoxicity including ptosis, opthalmoplegia causing 
diplopia, cranial nerve palsies, breathing difficulty with paradoxical 
respiration requiring ventilation. 
e. Features of nephrotoxicity including rise of creatinine, requirement of 
dialysis. 
f. Features of rhabdomyolysis including rise of creatinine phosphokinase.  
 
4. Assessment of risk factors : 
1. Timing of bite 
2. Environment in which snake bite occurred. 
3. Usage of footwear. 
 
5. Scoring Systems: 
Clinical severity of the snake envenomation was assessed by Snake bite 
severity score by Dart et al. The Snakebite Severity Score (SSS) is a validated 
and objective scale to assess severity of envenomation including six body 
categories: local wound, pulmonary, cardiovascular, gastrointestinal, 
hematologic, and nervous system effects. The total score ranges from 0-20. 
The score correlated with physician assessment at initial patient presentation (r 
= 0.63,Z = 6.52, P < 0.000001). 
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Ref :  Dart RC, Hurlbut KM, Garcia R, Boren J. Validation of a severity score for the 
assessment  of  crotalid snakebite.(82) 
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6. Quantitative variables: 
F1: Clinical parameters: 
1. Blood pressure 
2. Heart rate/rhythm abnormalities 
3. Respiratory rate 
4. GCS score 
5. Pallor and Icterus 
F2: Laboratory parameters: 
1. Glucose levels (by glucometer) 
2. Temperature (by thermometer) 
3. Oxygen saturation (by pulse oximetry) 
4. Complete blood count including platelet count (by automated coulter counter) 
5. Serum electrolytes (by automated chemistry analyser using ion selective 
electrodes) 
6. Prothrombin time with International Normalised Ratio [PT with INR] (by 
automated coulter counter) 
7. Activated Partial Thromboplastin Time [APTT] (by automated coulter counter) 
8. Thromboelastography(TEG) / Rotational Thromboelastometry(ROTEM) 
9. Serum Fibrinogen Level 
10. Liver Function Tests (by automated chemiluminiscence assay) 
11. Serum Creatinine (by automated chemistry analyser using calorimetric method) 
12. Serum Lactate Dehydrogenase (by chemiluminiscence assay) 
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13. TEG/ROTEM: sample was obtained at admission and if normal was repeated 6 
hours later. (Kindly refer to standard operating procedures (SOP) attached in 
appendix 3a). 
 
7. Normal Values 
a) Normal TEG(ROTEM) parameters 
             CT(Clotting Time): 324 – 565 (seconds),  
             CFT(Clot Formation Time) 112 – 224(seconds), 
             Alpha Angle: 50 – 68 (degree),   
  MCF(Maximum Clot Firmness) : 55 – 66 (mm) 
b) Prothrombin time is considered prolonged if INR > 1.2 
c) Whole blood clotting time > 20 min is considered prolonged. 
d) Activated partial thromboplastin time is considered prolonged if > 34 sec 
 
8. Definitions: 
SNAKE BITE DEFINITION: (any of the following) 
1. Patient presenting with history of snake bite with  
a. snake seen by patient or bystanders or 
b. snake brought along with the patient to the hospital 
c. Circumstantial evidence of snakebites, having noticed the snake but could 
not be identified. 
d. By identification of the snake from the photographs 
e. By the description given by the patient about the snake's length, thickness, 
colour, head etc 
f. By the development of signs and symptoms of local or systematic 
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envenomation 
g. Patients with fang marks-Two puncture wounds were taken as due to 
poisonous snake and inverted 'U' shaped or multiple teeth marks were 
taken as non-poisonous 
2. Unknown bite with characteristic clinical envenomation responding to Anti Snake 
Venom therapy. 
 
DEFINING ENVENOMATION TERMS: 
1. Non-venomous bite : 
a. No signs of envenomation after a period of 24 hour observation in the hospital 
emergency department. 
2. Local envenomation: ( any of the following ) 
a. Local swelling  in the absence of a tourniquet 
b. Enlarged tender lymph node draining the bitten limb 
c. Cellulitis, Necrosis, Blistering 
d. Necrotising fasciitis 
e. Compartment syndrome –absent pulses. 
3. Haemotoxicity: 
a. Characteristic hemorrhagic manifestations (either local or systemic bleed)  or 
b. Whole blood clotting time › 20 minutes or 
c. Deranged PT/PTT 
4. Neurotoxicity- (any of the below) 
a. Ptosis or Opthalmoplegia 
b. Limb muscle weakness grade 4 or less 
c. Respiratory paralysis-paradoxical breathing / Type 2 respiratory failure 
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d. Respiratory failure requiring need for intubation 
5. Definition of Renal failure – KDIGO 2012 guidelines : (any of the below) 
a. Increase in serum creatinine by ≥0.3 mg/dL (≥26.5 micromol/L) within 48 hours 
b. Increase in serum creatinine by ≥1.5 times baseline, which is known or presumed 
to have occurred within the prior seven days 
c. Urine volume <0.5 mL/kg/h for six hours 
6. Definition of Rhabdomyolysis: Creatinine phosphokinase levels > 195 U/L. 
 
Step 3 Follow Up 
 
All patients of snakebite were carefully monitored during hospital stay till discharge 
to find out development of any further complications or new symptoms and signs. 
Each patient was followed up till discharge and details such as ASV requirement, 
Clinical course (improved or deceased), development of complications, and 
requirement of blood products, dialysis, ventilation or any surgical procedure for 
compartment syndrome were assessed. 
 
MEASURES TO REDUCE POTENTIAL BIAS 
 
As this was an observational study only, the patient management was not be 
influenced by the study. Recall bias was the other bias that was anticipated to occur during 
the collection of the exposure variables (with respect to past history). All attempts were 
taken to minimize this bias by trying to procure evidence in the form documentation, 
wherever possible, for the history given by the participants. Other possible sources of bias 
include: 
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a) Method of blood collection. 
b) Bias during performing the laboratory tests. 
c) Assessment of disease severity with questionnaire. 
 
SAMPLE SIZE CALCULATION: 
 
A detailed scientific literature review was done in the Pubmed and Indmed 
databases to identify studies done to determine the role of thromboelastography (TEG) 
in patients with snake envenomation. Hadley et al in 1999 have shown in 51 children 
admitted with snake bite to hospital in Durban, South Africa that normal TEG provides 
assurance that envenomation or reperfusion has not affected the clotting cascade and 
therefore the clinical syndrome is unlikely to be severe. They also showed that normal 
TEG has a better predictive value for a benign clinical course as compared to traditional 
clotting assays such as INR.(81) 
Therefore the sample size was calculated based on the following assumptions. 
The sensitivity of TEG in assessing disease severity was expected to be 95% and 
specificity was expected to be 45%.(68) Different levels of precision were assessed 
and at a precision of ±5 and ±15 for sensitivity and specificity respectively, a total 
sample size of 76 was calculated. 
 
Sensitivity  Precision  Sample size 
95 2 200 
95 4 118 
95 5 76 
77 
 
Specificity  Precision  Sample Size 
45 5 395 
45 10 100 
45 15 44 
 
 
STATISTICAL ANALYSIS: 
 
The data collected was entered with Microsoft Office EXCEL software following which 
statistical analyses were performed using STATA (DATA analysis and statistical 
software) version 13.00 for Windows 97 and above. Continuous variables were 
summarized as mean with standard deviation or median with maximum and minimum 
values of the ranges. The categorical variables were summarized as numbers and 
percentages. Pie charts and bar graphs were used to plot single variables. The chi – 
square test was used for comparison of categorical variables. Odds ratios (OR) and 
confidence intervals (CI) were calculated and a ‘p’ value less than .05 was considered 
statistically significant. All reported p values are two sided.Diagnostic accuracy 
measures with 95% CI (Sensitivity, Specificity, Positive predictive value and Negative 
predictive value) were calculated for 20 minute whole blood clotting time, Prothrombin 
time, activated partial thromboplastin time and Thromboelastography. Logistic 
regression methods were used to assess factors associated with poor clinical response. 
All analysis were done using the STATA software version 13.0 (STATACORP, 
TEXAS) and Microsoft EXCEL for data entry. 
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RESULTS 
 
The study was carried out in the Emergency department and the Medical wards of Christian 
Medical College Hospital, Vellore between January 2013 and June 2014. 
Figure 8: STROBE Figure–Flow of patients into the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total number of patients presenting to 
CMC Vellore with alleged history of snake 
bite over a period of 18 months.  N = 124                                                          
ASSESSED FOR ELIGIBILITY         N 
= 93 
TOTAL NUMBER OF PATIENTS 
RECRUITED IN THE STUDY                                            
N = 72 
1. No of patients with one of the coagulation 
tests not being done at admission itself                                                     
N = 18 
2. Patient presented >24 hours after snake 
bite. N = 7 
NUMBER OF PATIENTS FOR ANALYSIS: 
1. Socio-demographic and clinical outcome analysis 
(including patients with one of the coagulation 
studies not done )       N = 72 
 
2. Number of patients with complete coagulation 
data available for analysis                 N = 47 
NOT ASSESSED FOR ELIGIBILITY 
1. Missed invitation to participate(case not 
informed for recruitment  at admission)     
N= 22 
2. Refused consent.                  N= 9 
EXCLUDED   N = 21 
1. Ineligible for study (dry bites/ cases with 
Severity score =0)               N = 14 
2. Patients on : 
a. Antiplatelets        N = 3 
b. Anticoagulant      N =1 
3. Pregnancy                            N = 2 
4. Chronic Liver Disease         N=1 
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A total of 124 patients with newly diagnosed case of snake envenomation, above the 
age of 15 presented to the emergency department. 22 patients missed invitation to 
participate at admission and 9 patients refused consent to take part in the study. Hence 
the remaining 93 patients were assessed for eligibility. 21 patients were further 
excluded due to various reasons after assessing for eligibility ( 14 patients had dry 
bites, 3 were on antiplatelet medication, 1 patients was on anticoagulation, 2 patients 
were pregnant, 1 patient had history of chronic liver disease). Of the remaining 72 
patients, all of the patients data was included in the descriptive analysis while only 
those for whom the complete data for coagulation testing was available (i.e. 47 
patients) were included in the final statistical analysis. 
 
The Results are presented under the following headings: 
1. Analysis of baseline demographic, clinical and laboratory characteristics. 
2. Analysis of predictors of severe envenomation. 
3. Comparison and analysis of thromboelastography with other coagulation tests. 
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Analysis of Demographic, Clinical and Laboratory characteristics 
 
 DEMOGRAPHIC DETAILS 
 
Total number of patients:  72 
Gender distribution of the patients:  
There were a total of 53 males (74 %) and 19 females (26 %).The male to female ratio 
was 2.78.The gender distribution is shown below. 
 
Figure 9: Pie chart showing distribution of patients with snake envenomation based on 
gender. 
 
Age distribution:   
The mean age of the study population was 40.78 ± 13.5 years. The oldest patient was 81 years 
old while the youngest was 16 years old. The patients recruited were divided into 4 age groups: 
1] <20 years of age 
2] 21 to 40 years 
MALE, 53, 74% 
FEMALE, 19, 
26% 
Gender Distribution 
MALE
FEMALE
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3] 41 to 60 years 
 4] >65 years of age. 
 
 
Figure 10: Bar graph showing distribution of patients by age and gender 
Males: Snake bites were more common among males and a similar trend was present in all the 
age groups of <20, 21 – 40, 41 – 60, >60 years of age. While 73.6% of all the patients were 
males, the maximum number of males with snake envenomation belonged to the age group of 
41 – 60(23) closely followed by age group of 21 – 40(22). 
Females: Equal numbers of females with snake envenomation were present in the age groups 
of 21 – 40 and 41 – 60 years which also had the highest number of bites. There was only one 
case below the age of 20 and no patients in this category above the age of 60 years. 
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Baseline characteristics: 
Table 2: Baseline demographic characteristics of patients at admission. 
Characteristic of Patients 
(N=72) 
Frequency 
N (%) 
Mean Age 40.78±13.53 years 
Male gender 53 (74) 
Co- Morbidities 
Diabetes Mellitus 
Hypertension 
Smoking 
Alchohol 
Coronary Artery Disease 
 
5 (6.9) 
4 (5.5) 
8 (11.1) 
4 (5.5) 
1 (1.3) 
First medical contact  in hours                
(Bite to needle time) 
2.61 ± 2.01 hours 
Duration of Hospital Stay 6.53 ± 4.65 days 
 
 The incidence of co morbidities as expected was less as the predominant 
population was between and 21-60 years old and were among the strong workforce 
group. 
The mean bite to needle time for first medical contact was 2.6 hours with a standard 
deviation of +/- 2 hours. The minimum time was 0.25 hours (15 min) by a patient who 
sustained a bite nearby a hospital. The maximum time for first medical contact was 9 
hours by a patient who resided in a tribal area over the hills with no primary hospital 
nearby. 
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The mean duration of hospital stay was 6.5 day with standard deviation of 4.6 days. 
The maximum duration of stay was 24 days and minimum duration was 2 days. 
Occupation: 
The distribution of various occupations among the patients is as follows: 
 
Figure 11: Pie chart showing distribution of patients based on occupation. 
 
The predominant occupation among the study population comprised of farm labourers 
(34%) and farmers (29%) who together made up more than 60 % of the population. 
Most of the females with snake envenomation were housewives (84%, 16/19) who also 
helped in the farm during the harvest periods. 
 
Region of residence:  
Overall 71% [N =51] of study patients were residents of Tamilnadu. The remaining 29% were 
from Chittoor district in neighbouring state of Andhra Pradesh.  
The distribution based on residence is shown below: 
21, 29% 
24, 34% 
16, 22% 
3, 4% 8, 11% 
Occupation 
FARMER
LABOURER
HOUSEWIFE
OFFICE WORK
STUDENT
85 
 
 
Figure 12: Pie chart showing distribution of patients based on their area of residence 
Time of bite: 
The maximum number of snake bites occurred in the early morning hours (23 bites) or in the 
evening hours (22 bites). 
 
Figure 13: Bar diagram showing the distribution of patients with respect timing of the 
day during which they sustained the snake bite. 
51, 71% 
21, 29% 
Region of Residence 
TAMIL NADU
ANDHRA PRADESH
 23, 32% 
10,14% 
22,30% 
17,23% 
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Time elapsed since presentation to the hospital: 
57% (N=41) of the patients presented within 6 hours of sustaining the snake bite to 
the hospital, 10 patients presented between 6 to 12 hours after the bite, 14 patients 
presented within 12 – 24 hours after the bite. 7 patients had presented after 24 hours 
of the snake bite.     
 
Figure 14: Bar diagram showing the distribution of patients with respect to time 
elapsed since the bite to presentation to the hospital  
 
Mode of transport: 
The predominant mode of transport was the ambulance provided by the government 
(108 services) which were utilized by 21 patients. 20 patients came by autorickshaw, 
16 used four wheelers like cars, 10 used motorcycles and five patients were brought 
by foot. 
41, 57% 
10,13% 
14,19.5% 
7, 9.5%  
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Figure 15: Bar diagram showing the distribution of patients with snake bite describing 
the mode of transport utilized by them to come to the hospital. 
Snake brought with the patient: 
The snake was killed and brought along with the patient in 15% of the patient 
population (11 patients). 
 
Figure 16: Pie chart showing the number of patients with the snake brought along. 
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Snake Identification:The type of snake species was identified in about 42% (N=30) 
of the patient population. The remaining 58% (N=42) were not able to identify the 
snake bite. 
 
Figure 17: Distribution of patients based on the ability to identify the type of snake 
species causing the bite. 
 As stated earlier only 11 patients had killed and brought the snake along with 
them which we were able to identify. 19 more patients could identify the snake or 
provide the description of the size, shape, colour, pattern of head and scales based on 
which assumed the species of snake.   
Type of snake species:  
Majority of the patients (58%, N=42) could not identify the snake species that 
had bitten them. Among the identified species the most common species was 
Russell’s viper (31%, N=22) followed by krait (5%). There were 2 cases each of 
documented Saw scaled viper and Indian cobra. 
YES, 30, 42% 
NO, 42, 58% 
Snake Identified 
YES NO
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Figure 18: Distribution of patients according to the species of snake that they had 
been bitten with. 
 Environmental Setting: 
 
Figure 19: Distribution of patients according to the environmental setting during the 
time of bite.  
 
42, 58% 
22, 31% 
2, 3% 
2, 3% 
4, 5% 
Type of snake species  
Unknown
Russel's viper
Saw scaled viper
Indian cobra
Krait
58, 81% 
14, 19% 
Environmental Setting 
OUTDOOR/FIELDS
INDOOR/HOUSE
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CLINICAL PARAMETERS: 
 
Baseline Clinical Parameters: 
Table 3: Details of clinical parameters (categorical variables) at admission 
Clinical features Percent  Number of patients (n =72) 
Pain at the bite site  90.28% 65 
Local swelling  87.50% 63 
Fang mark  78% 56 
Cellulitis 73.6% 53 
Tachypnoea (RR>20/min) 69.44% 50 
Neurotoxicity 66.67% 48 
Local bleeding 63.89% 46 
Ptosis/Opthalmoplegia 54.16% 39 
Renal failure 51.39% 37 
Vomitng  48.61% 35 
Tachycardia(HR>100/min) 36.11% 26 
Systemic bleed 34.72% 25 
Paradoxical respiration 18.05% 13 
Necrotising fasciitis 13.89% 10 
Compartment syndrome 8.33% 6 
 
 The most clinical feature was pain at the bite sit which was present in 90.28% 
of the patients followed by local swelling which was seen in 87.5% of the population. 
 
91 
 
Table 4:  Details of clinical parameters (continuous variables) at admission: 
Variable n Mean S.D. Median IQR 
ASV vials received outside 72 6.39 6.25 6 1.5-8 
ASV vials received in the hospital 72 11.25 5.98 10 7.5-14 
Total ASV vials received 72 17.61 7.71 16 14-20 
Heart rate 72 99.57 24.43 97 82-112 
Systolic blood pressure 72 115.64 23.34 110 100-125 
Diastolic blood pressure 72 73.22 14.04 70 60-80 
Saturation (Spo2) at admission 72 94.06 8.45 96 93-98 
 
 
Figure 20: Distribution of patients according to the different clinical syndromes of 
snake envenomation 
7, 10% 
13, 18% 
3, 4% 
6, 8% 
13, 18% 
30, 42% 
Types of Envenomation 
Local swelling  only
Haemotoxicity with / without local
swelling
Neurotoxicity only
Neurotoxicity with Local swelling
Haemotoxicity + Neurotoxicity
with / without local swelling
Haemotoxicity + Neurotoxicity
+renal failure  with / without local
swelling
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Fang Mark: 
 
Figure 21: Distribution of patients with respect to presence of fang mark. 
Site of Snake Bite: 
 
Figure 22: Distribution of patients with respect to the site of snake bite. 
Left lower limb with 42% was the most common site of bite among the 
patients followed by right lower limb with 38%. We had one patient with a snake bite 
over the anterior abdominal wall which happened when he was sleeping the fields. 
Yes, 56, 78% 
No, 16, 22% 
Prescence of Fang Mark 
Yes
No
Right Upper 
Limb, 8, 11% 
Left Upper Limb, 
6, 8% 
Right Lower 
Limb, 27, 38% 
Left Lower Limb, 
30, 42% 
Trunk, 1, 1% 
SITE OF SNAKE BITE 
Right Upper Limb
Left Upper Limb
Right Lower Limb
Left Lower Limb
Trunk
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Coagulopathy: 
 
Figure 23: Chart showing the percentage of patients with systemic bleeding among 
the patients with snake bite. 
 
Figure 24: Distribution of various types of systemic bleeding among the patients with 
systemic bleeding in patient with snake bite.  
Present , 25, 
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Systemic bleeding 
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Bleeding Gums, 6, 
17% 
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Gross Hematuria, 
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Hemetemesis, 7, 
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IV site ooze, 2, 6% 
Intracranial bleed, 
2, 6% 
Intrabdominal 
bleed, 1, 3% 
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Intracranial bleed
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Neurotoxicity: 
 
Figure 25: Chart showing the percentage of patients with neurotoxicity among the 
patients with snake bite. 
 
Figure 26: Distribution of types of neurotoxicity among the patients with snake bite.  
 Predominant neurotoxic features comprised of ophthalmic manifestation 
which comprised of almost 84% (ptosis was seen in 47% and diplopia in 37%).  
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48, 67% 
Absent, 24, 
33% 
Neurotoxicity 
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Diplopia, 30, 
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LABORATORY PARAMETERS: 
Baseline laboratory parameters: 
Table 5:  Details of laboratory parameters at admission 
Variable n Mean S.D. Median IQR 
Hemoglobin 72 12.75 2.64 13.15 11.3-14.5 
Total Count 71 18050 9791 17500 10120-22000 
Platelets 71 169459 106492 175000 74000-253000 
Total Bilirubin 45 2.83 3.44 1.6 0.7 - 3.5 
Albumin 45 3.64 0.66 3.6 3.1 - 4.2 
AST 46 130.37 216.39 56.5 29 – 134 
ALT 46 30.41 31.62 19.5 12 – 36 
RBS 67 169.57 87.93 146 120 – 190 
CPK 57 3236.6 5984.68 913 275 – 3427 
LDH 28 1825 1330 1459 759 – 2546 
Creatinine 72 27.69 18.32 25.5 11 – 43.5 
Urea 67 61.63 55.34 36 26 – 88 
Sodium 70 137.74 4.99 139 134 – 141 
Potassium 70 12.47 5.98 12 8 – 17 
Fibrinogen 17 299 190 320 127 – 446.7 
Prothrombin time 72 22.65 20.94 14.75 11.95 - 23.5 
INR 72 2.01 1.71 1.40 1.10 – 2.15 
APTT 72 40.43 36.06 28.25 25 – 35.3 
 
 
, 
 
RBS: Random Blood Sugar, AST: aspartate aminotransferase, ALT: Alanine 
aminotransferase, CPK: creatinine phosphokinase, LDH: Lactate dehydrogenase, 
INR: International Normalized Ratio, APTT: Actiated Partial Thromboplastin Time 
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ROTEM PARAMETERS 
Variable n Mean S.D. Median IQR 
ROTEM_CT 46 775.63 929.42 399 283 – 860 
ROTEM_CFT 41 19.15 11.75 19 9 – 29 
ROTEM_A 40 46.35 21.98 46.5 31.5 – 67 
ROTEM_MCF 44 42.55 18.62 44 34 - 58 
ROTEM_ML 33 9.52 5.56 10 4 - 15 
 
 
TEG PARAMETERS 
Variable n Mean S.D. Median IQR 
TEG_R Time 25 7.53 7.88 3 1 - 14 
TEG_K Time 25 10.08 6.30 10 5 - 15 
TEG_Angle 25 36.05 21.44 35 23.6 - 55.6 
TEG_MA 25 42.02 20.17 44.70 34.8 - 56.3 
TEG_Ly30 25 0.04 0.13 0 0 – 0 
 
 
 
 
 
ROTEM: Rotational Thromboelastometry, TEG: Thromboelastography,CT: Clotting Time, 
CFT: Clot formation time, A: alpha angle, MCF: maximal clot firmness, ML: Maximal lysis, 
MA: maximal amplitude, Ly30: Lysis at 30 seconds. 
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TREATMENT VARIABLES: 
First Aid: 68% (49 patients) received first aid prior to coming to the hospital. 
 
Figure 27: Pie chart showing the distribution of patient with respect to first aid 
received prior to admission. 
 
Figure 28: Pie chart showing the distribution of the different types of first aid received 
prior to admission. 
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23, 32% 
First Aid 
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Anti-Snake Venom: 78% of the patient population (56 patients) received ASV at a 
local centre prior to coming to our hospital. 22% (16) did not receive any ASV prior 
to admission.  
 
Figure 29: Distribution of patients based on ASV received prior to hospitalization. 
Incidence of ASV hypersensitivity:  
 
Figure 30: Chart showing the incidence of ASV hypersensitivity among the patients 
with snake bite. 
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No, 16, 22% 
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Type of ASV hypersensitivity: 
 
Figure 31: Chart showing the distribution of type of ASV hypersensitivity among 
patients with Snake Bite who had hypersensitivity to ASV. 
Antibiotic Usage: 87.5% (N=63) of the patients received antibiotics during the 
treatment. The various types of antibiotics used is describes below. 
 
Figure 32: Pie chart showing the distribution of patients with respect to the type of 
antibiotic used. 
Severe, 4, 25% 
Mild, 12, 75% 
Type of ASV Hypersensitivity 
Severe
Mild
46, 73% 
2, 3% 
4, 7% 
9, 14% 
2, 3% 
Type of Antibiotic Used 
Amoxicillin Clavulanate
Benzyl Penicillin
Cloxacillin
Piperacillin Tazobactam
Meropenem
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Table 6: Treatment details during the admission period 
Treatment received  Percentage (%) N ( total =72) 
ASV use 100 72 
Antibiotic Use 87.5 63 
Mechanical ventilation 18 13 
Dialysis 19.44 14 
Blood transfusion 16.67 12 
Surgical intervention such 
as fasciotomy/debridement 
6.94 5 
 
 
Mortality: 
Table 7: Distribution of cases based on final outcome at discharge 
OUTCOME N (72) % 
Alive 68 94.5 
Dead 3 4.17 
Discharge against medical advice  1 1.37 
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Analysis of Risk factors of Severe envenomation. 
 
Out of the 72 patients that were analysed  
 40 patients (55.5%) had snake bite severity score of ≥ 8 points suggestive 
of severe snake envenomation clinically at the time of admission. 
 32 patients (44.5%) had a score of ≤ 7 and were classified as cases of 
mild envenomation. 
Demographic Predictors: 
Table 8: Univariate analysis –Demographic risk factors for the development of severe 
envenomation following snake bite. 
Variables Mild 
envenomation 
(N=32) n(%) 
Severe 
envenomation 
(N=40)n(%) 
Odds 
Ratio 
95 % 
Confidence 
Interval 
P-
value 
Sex 
Male gender(n=53) 
Female gender (n=19) 
 
30 (75) 
10 (25) 
 
23(71.8) 
9(28.2) 
 
 
0.85 
 
 
0.29 – 2.43 
 
 
0.765 
Address 
Tamilnadu(n=51) 
AndhraPradesh(n=21) 
 
24 (60) 
16 (40) 
 
27(84.4) 
5(15.7) 
 
 
3.6 
 
 
1.14 – 11.3 
 
 
0.028* 
Snake Identified 17 (42.5) 13(40.7) 0.92 0.36 – 2.37 0.873 
Snake brought with 
patient 
4 (10) 7(21.9) 2.52 0.66 – 9.53 0.173 
First Aid 26 (65) 23 (71.9) 1.37 0.50 – 3.77 0.535 
Tourniquet 25 (62.5) 19 (59.4) 0.87 0.34 – 2.27 0.787 
Local Herbs 7 (17.5) 5 (15.6) 0.87 0.24 – 3.06 0.832 
Native treatment use 2 (5) 4 (12.5) 2.71 0.46 – 15.87 0.268 
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On analysis of various demographic characteristics associated with patients 
presenting with snake bite, the predictors were “region of residence”, with patients 
presenting from Tamil Nadu having a significant chance of developing severe 
envenomation with an Odds ratio of 3.6 (p value = 0.028) than patients presenting 
from Andhra Pradesh. Factors such as sex, identification of the snake, first aid, usage 
of tourniquet and native medication were not significantly associated with severe 
envenomation. 
 
Clinical Predictors: 
Table 9: Univariate analysis – Clinical risk factors for the development of severe 
envenomation following snake bite.  
Variables 
Mild 
envenomatio
n 
(N=32)n(%) 
Severe 
envenomation 
(N=40) n(%) 
Odds 
Ratio 
95 % 
Confidence 
Interval 
P-value 
Fang Mark  33 (82.5) 23 (71.9) 0.54  0.17 – 1.66 0.285 
Prior ASV 30 (75)  26 (81.25) 1.44  0.46 – 4.51 0.527 
ASV 
Hypersensitivity 
12 (30) 4 (12.5) 
0.33  0.09 – 1.15 
0.084 
Local Swelling 32 (80) 31 (96.9) 7.75  0.91 – 65.65 0.060 
Local Pain 34 (85) 31 (96.9%) 5.47  0.62 – 48.02 0.125 
Cellulitis 24 (60) 29 (90.63) 6.44  1.67 – 24.77 0.007* 
Necrotising 
Fasciitis  
4 (10) 6 (18.75) 
2.07  0.53 – 8.10 
0.293 
Local Bleeding 20 (50) 26 (81.25) 4.3  1.46 – 12.79 0.008* 
Systemic Bleed 8 (20) 17 (53.13) 4.53  1.6 – 12.53 0.004* 
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On analysis of various clinical characteristics associated with patients 
presenting with snake bite, the clinical predictors of severe envenomation were 
presence of cellulitis at admission (90.63% vs 60%, p value= 0.007), presence of local 
bleeding (81.25% vs 50%, p value=0.008),  presence of systemic bleeding (53.13% vs 
20%, 0.004), features of neurotoxicity at admission (81.25% vs 55%, p value=0.022), 
requirement of ventilation during the ward stay (34.38% vs 5%, p value=0.005), 
presence of renal failure (81.25% vs 27.5%, p value= <0.0001), requirement of blood 
or blood product transfusion during the course of the hospital stay (31.25% vs 5%, p 
value= 0.009).  
Haematuria 5 (12.5) 9 (28.13) 2.73  0.81 – 9.21 0.104 
Epistaxis  1 (2.5) 2 (6.25) 2.62  0.22 – 30.04 0.444 
Gum Bleed  1 (2.5) 5 (15.63) 7.22  0.79 – 65.33 0.078 
Compartment 
syndrome 
1 (2.5) 5 (15.63) 
4.42 0.49 – 40 
0.216 
Neurotoxicity 22 (55) 26 (81.25) 3.54  1.19 -10.48 0.022* 
Ptosis 19 (47.5) 20 (62.5) 1.84  0.71 – 4.75 0.206 
Diplopia 13 (32.5) 17 (53.13) 2.35  0.90 – 6.14 0.080 
Tachypnoea 25 (62.5) 25 (78.13) 2.14  0.74 – 6.15 0.157 
Paradoxical 
respiration 
5 (12.5) 8 (25) 
2.33  0.68 – 8.00 
0.178 
Ventilation 2 (5) 11 (34.38) 9.95  2.01 – 49.20 0.005* 
Renal Failure 11 (27.5) 26 (81.25) 11.42  3.70- 35.25 <0.001* 
Requiring blood 
transfusion 
2 (5) 10 (31.25) 
8.63  1.73 – 43.05 
0.009* 
Antibiotic Usage 32 (80) 31 (96.9) 7.75  0.91 – 65.65 0.060 
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Laboratory parameters: 
Table 10: Univariate analysis – Laboratory risk factors for the development of severe 
envenomation following snake bite.  
 
On analysis of various laboratory characteristics associated with patients 
presenting with snake bite, the predictors of severe envenomation were presence of 
anaemia (43.75% vs 10%, p value=0.002), thrombocytopenia (59.38% vs 17.95%, p 
value=0.001), jaundice (50% vs 10.53%, p value=0.001), hepatitis (50% vs 7.69%, p 
value = 0.004), haematuria on urinalysis (81.25% vs 40%, p value=0.001), prolonged 
Thromboelastography (72.73% vs 8%, p value= <0.0001). Other factors such as 
Variables Mild 
envenomation 
N=32  n(%) 
Severe 
envenomation 
N=40  n(%) 
Odds 
Ratio 
95 % 
Confidence 
Interval 
P-value 
Anaemia  4 (10) 14 (43.75) 6.99  2.01 – 24.35  0.002 
Leucocytosis 24 (61.54) 25 (78.13) 2.23 0.77 – 6.42 0.137 
Thrombocytopenia  7 (17.95) 19 (59.38) 6.68  2.26 – 19.67 0.001 
Icterus  4 (10.53) 16 (50) 8.5  2.44 – 29.56 0.001 
Hepatitis 2 (7.69) 10 (50) 12  2.21 – 64.89 0.004 
Rhabdomyolysis 21 (70) 26 (89.66) 3.71 0.89 – 15.4 0.072 
Hematuria on 
urinalysis  
16 (40) 26 (81.25) 6.5  2.18 – 19.33 0.001 
Low fibrinogen 1 (33.3) 4 (28.57) 0.80 0.05 – 11.5 0.870 
Prolonged WBCT 22 (56.41) 14 (43.75) 1.66 0.64 – 4.27 0.409 
Prolonged 
Prothrombin Time 
21 (52.50) 11 (34.38) 2.11  0.80 – 5.49 0.155 
Prolonged APTT 36 (90) 23 (71.88) 2.54  0.69 – 9.37 0.215 
Prolonged 
TEG/ROTEM 
2 (8) 16 (72.73) 30.66  5.5 – 171.7 <0.0001 
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leucocytosis, rhabdomyolysis, prolongation of whole blood clotting time, prothrombin 
time, activated partial Thromboplastin time were not significantly associated with 
severe envenomation.  
Multivariate analysis: 
Multivariate (adjusted) analysis using logistic regression methods was done 
for the fourteen variables (i.e. address, cellulitis, local bleeding, systemic bleeding, 
neurotoxicity, ventilation, renal failure, blood transfusion, anaemia, 
thrombocytopenia, jaundice, hepatitis, haematuria on urinalysis, prolonged 
Thromboelastography) were shown to be significant predictors of envenomation on 
univariate (unadjusted) analysis. None of the factors were found to be significant 
predictors of severe envenomation on multivariate analysis statistically. 
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Comparison of conventional coagulation tests with thromboelastography: 
 
A) With respect to severity of snake envenomation:  
Table 11: 2 x 2 contingency table showing the results of various tests of coagulation relative 
to severity of snake envenomation according to the snake bite severity score after snake bite. 
Test of 
Coagulation 
Number of patients with 
severe envenomation    
(severity score >= 8) (N=25) 
No of patients with mild/ 
moderate envenomation 
(severity score < 8)(N=22) 
Total number of 
patients (N=47) 
20 Minute WBCT  
Prolonged  
Normal  
 
14 
11 
 
8 
14 
 
22 
25 
Prothrombin Time 
Prolonged  
Normal 
 
16 
9 
 
7 
15 
 
23 
24 
APTT 
Prolonged  
Normal 
 
7 
18 
 
2 
20 
 
9 
38 
TEG/ROTEM 
Prolonged  
Normal 
 
23 
2 
 
6 
16 
 
29 
18 
 
 
Further statistical analysis was performed using the chi-square test with Yates correction 
where appropriate and the results are as follows: 
WBCT: Whole Blood Clotting Time, APTT: Activated Partial Thromboplastin Time, 
TEG: Thromboelastography, ROTEM: Rotational Thromboelastometry  
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Table 12: Table showing sensitivity, specificity, positive predictive value, negative predictive 
value, positive likelihood ratio, negative likelihood ration and odds ratio of various 
coagulation tests based on an abnormal test result being associated with severe envenomation 
after a snake bite. 
Tests of 
Coagulation 
Sensitivi
ty (%) 
Specifici
ty (%) 
PPV 
(%) 
NPV 
(%) 
PLR NLR OR 
20 Minute     
WBCT 
 
56 
 
63.6 
 
63.6 
 
56 
 
1.54 
 
0.69 
 
2.23 
Prothrombin 
Time 
 
64 
 
68.2 
 
69.6 
 
62.5 
 
2.01 
 
0.53 
 
3.81 
APTT 28 90.9 77.8 52.6 3.08 0.792 3.89 
TEG/ROTEM 92 72.7 79.3 88.9 3.37 0.11 30.7 
 
 
 
When used to predict a clinical course of severe envenomation, TEG/ROTEM had 
a sensitivity of 92% and specificity of 72.7%. The predictive value of an abnormal 
(prolonged) TEG/ROTEM for a severe clinical course was only 79.3% whereas the 
negative predictive value i.e. the predictive value for a mild course when TEG/ROTEM 
was normal was 88.9%. Whole blood clotting time, prothrombin time and activated 
partial Thromboplastin time had a sensitivity of 56%, 64%, 28% and a specificity of 
63.6%, 68.2%, 90.9% respectively. 
 
PPV: Positive Predictive Value, NPV: Negative Predictive Value, PLR: Positive likelihood ratio, 
NLR: Negative likelihood ratio, OR: Odds Ratio. 
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B) With respect to Clinical finding of features of coagulopathy:  
Table 13: 2 x 2 contingency table showing the results of various tests of coagulation relative 
to Clinical finding of features of coagulopathy after snake bite. 
Test of Coagulation Coagulopathy 
present clinically 
(N=32) 
Coagulopathy 
absent clinically 
(N=15) 
Total number 
of patients (N 
=47) 
20 Minute WBCT 
Prolonged  
Normal  
 
19 
13 
 
3 
12 
 
22 
25 
Prothrombin Time 
Prolonged  
Normal 
 
21 
11 
 
2 
13 
 
23 
24 
APTT 
Prolonged  
Normal 
 
7 
25 
 
2 
13 
 
9 
39 
TEG/ROTEM 
Prolonged  
Normal 
 
26 
6 
 
3 
12 
 
29 
18 
 
 
 
Further statistical analysis was performed using the chi-square test with Yates correction 
where appropriate and the results are as follows: 
WBCT: Whole Blood Clotting Time, APTT: Activated Partial Thromboplastin Time, 
TEG: Thromboelastography, ROTEM: Rotational Thromboelastometry  
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Table 14: Table showing sensitivity, specificity, positive predictive value, negative predictive 
value, positive likelihood ratio, negative likelihood ration and odds ratio of various 
coagulation tests based on an abnormal test result being associated with clinical manifestation 
of coagulopathy after a snake bite. 
Tests of 
Coagulation 
Sensitivi
ty (%) 
Specifici
ty (%) 
PPV 
(%) 
NPV 
(%) 
PLR NLR OR 
20 Minute     
WBCT 
59.4 80 86.4 48 2.97 0.508 5.85 
Prothrombin 
Time 
65.6 86.7 91.3 54.2 4.92 0.397 12.4 
APTT 21.9 86.7 77.8 34.2 1.64 0.901 1.82 
TEG/ROTEM 81.3 80 89.7 66.7 4.06 0.234 17.3 
 
 
 
When the tests of coagulation were compared with each other against 
clinically evident features of coagulopathy (either local or systemic bleeding), 
TEG/ROTEM had a sensitivity of 81.3% and specificity of 80%. The predictive value 
of an abnormal (prolonged) TEG/ROTEM was only 89.7% whereas the negative 
predictive value was only 66.7%. Other tests of coagulation such as 20 minute whole 
blood clotting time, prothrombin time and activated partial Thromboplastin time had a 
sensitivity of 59.4%, 65.6%, 21.9% and a specificity of 80%, 86.7%, 86.7% 
respectively. 
 
PPV: Positive Predictive Value, NPV: Negative Predictive Value, PLR: Positive likelihood ratio, 
NLR: Negative likelihood ratio, OR: Odds Ratio. 
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Correlation of Thromboelastography with thrombocytopenia: 
 
Table 15: 2 x 2 contingency table showing the results of TEG tracing suggestive of 
thrombocytopenia with laboratory finding of thrombocytopenia after snake bite 
(TEG tracing suggestive of platelet dysfunction is: r value normal, k value high, angle and 
MA are decreased) 
 Thrombocytopenia 
present 
Thrombocytopenia 
absent 
TEG tracing suggestive of 
thrombocytopenia 
18 11 
TEG tracing not suggestive of 
thrombocytopenia 
1 17 
 
Sensitivity: 94.74%     Odds Ratio: 27.81 
Specificity: 60.71%     Confidence interval: (3.23-239.24)  
Positive likelihood ratio: 2.41    p value: 0.0001 
Negative likelihood ratio: 0.09 
Positive predictive value: 62.07% 
Negative predictive value 94.44% 
 
When the TEG tracings suggestive of thrombocytopenia were compared to actual laboratory 
evidence of thrombocytopenia the sensitivity of the test picking up a low platelet count was 
94.74% and the negative predictive value i.e. a normal TEG ruling out a low platelet count 
was 94.44% (p value = 0.0001). 
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DISCUSSION: 
 
Demographic, Clinical and Laboratory Characteristics: 
 
Age and Sex: 
        The mean age of the study population was 40.78 years with a standard deviation 
of ±13.5 years. A significant proportion of the study population were males (53, 
74%). The male to female ratio was 2.78:1.   Snake bites were more common among 
males and a similar trend was present in all the age groups of <20, 21 – 40, 41 – 60, 
>60 years of age.  The maximum number of males with snake envenomation 
belonged to the age group of 41 – 60(n=23) closely followed by age group of 21 – 
40(n=22).  Equal numbers of females with snake envenomation were present in the 
age groups of 21 – 40 and 41 – 60 years which also had the highest number of bites. 
There was only one case below the age of 20 and no patients in this category above 
the age of 60 years. 
Similar observations were made in studies conducted by Kulkarni et al in 
Karnataka in 1994(8) and Ganneru B and Sasidhar RB in 2007 in Andhra 
Pradesh.(12)However one study conducted in Manipal by Montenerio et al found a 
female predominance with male to female ratio of 1:1.5.(83) 
The predominant age group being affected between 20-40 years was consistent 
with all the earlier studies conducted in India, however two studies by Hansdak et al 
(34.5%) in Nepal(84) and Rahman et al(85) in Bangladesh (46%) which could be due 
to problem of child labour or children being taken to the field. 
Occupation: In the present study majority of the patients were daily wage 
labourers working in the fields (34%), followed by farmers (29%). This was 
112 
 
consistent with the rural predominance and field related occupations like farmers and 
daily wage labourers being the most common group affected in various studies 
conducted for example Hansdak SG(84), Brunda and Sashidhar(12) and Bawaskar et 
al.(13) 
Time of occurrence:In our study we found that most of the snake bites 32% 
occurred during the morning period (6am to 12 am) and 30% occurred during the 
evening period (6pm to 12 pm). This was different to the findings in other studies 
conducted in Maharashtra by Bawaskar HS et al (2008)(13) and in Manipal by 
Monterio NP et al (2010).(83) 
Presence of fang mark and Site of Bite:  In our study fang mark was 
identified in 78% of the patients. Both the lower combined constituted about 80% of 
the bite sites with rest occurring over the upper limb. We had one patient with a bite 
over the anterior abdominal wall leading to extensive necrosis and death later. Our 
lower limb predominance is consistent with studies conducted by Kulkarni ML et al 
in Karnataka(8) and Bawaskar HS et al in rural Maharashtra(13).  
First Aid:Our study showed that 68% of the patients received some form of 
first aid prior to presentation to the hospital. Almost all of them received more than 
one form of first aid. Around 81% of the patients were administered this first aid by 
untrained personnel (either patient himself or the bystander). The predominant mode 
of first aid that was used was application of pressure tourniquet which was used by 
71% of the patients that received first aid. 19% of the population had received a local 
anaesthetic injection at the bite site by the local practitioner to relieve the pain. 
Around 10% of the patients had treatment with native medicine in the form of local 
application of crushed herbs or special powder.  
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Older methods of first aid that were reported in earlier studies such as 
application od stones at the bite site, multiple incision, manual squeezing of the 
venom were not reported by any patients in the study. This shows a probable increase 
in awareness among the general population about snake envenomation. However 
giving a local anaesthetic injection by the primary health care doctors at the local site 
which is not recommended by any guideline shows the poor level of training even 
among the doctors or paramedics working at the rural level.  
Type of Snake: Our study showed that around 42% of the patients were able 
to identify the snake and Russell’s viper was the most common cause in them (31%) 
which was similar to studies conducted by Kulkarni et al -38%(8) and Kalantri et al -
24%.(86) However studies done by Bawaskar et al in Maharashtra and showed krait 
being the most common, Sharma SK et al showed cobra being the most common 
suggestive of the regional difference in the distribution of snakes in India. 
Clinical manifestations: 
Local Signs: Of the 72 patients that were studied, fang marks were present in 
56 patients (78%). Local swelling was present in 87.50% of the patients. Features of 
cellulitis (such as local warmth with along with redness, swelling and tenderness) 
were present in 73.6% of the population. 64% of the patients had some amount of 
local bleed/ooze at the bite site. 14% went on develop necrotising fasciitis and 8.3% 
of the patients had compartment syndrome which required fasciotomy. The findings 
in our study were consistent with studies done by in Maharashtra by Bawaskar HS et 
al (2008)(13) and in Manipal by Monterio NP et al (2010).(83) 
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Systemic Features: 
The various syndromes of snake envenomation seen in our study were: 
1. Local Swelling only -10% 
2. Hemotoxicity with/without Local swelling – 18% 
3. Neurotoxicity only – 4% 
4. Neurotoxicity with local swelling – 8% 
5. Hemotoxicity + Neurotoxicity + Local swelling -18% 
6. Hemotoxicity + Neurotoxicity + Renal failure + Local swelling – 42% 
Hemotoxic features were noted in 35% of the patients with gross haematuria 
being the most common type seen in 40% and hematemesis seen in 20% of the 
patients. 1 patient has intra-abdominal bleed and 2 patients had intracranial bleeds 
resulting fatal outcome.  
Neurotoxic features were present in 67% of the patients with ophthalmic 
symptoms such as ptosis and diplopia together constituting about 84% of the 
manifestations.  
Renal failure was seen in 51.4% of the patient population with 19.5% of them 
requiring one or more episodes of dialysis. 
This was consistent with the studies conducted earlier by Kulkarni et al(8), 
Bawaskar et al(13) Hansdak et al(84) and Sharma et al (87). 
The syndrome of combined hemotoxicity, neurotoxicity, renal failure with 
local envenomation was highest which was in correlation with the high incidence of 
viper bite that were observed in the study sample. 
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Anti-Snake Venom: We found that 78% of the patients had received ASV 
prior to coming to our hospital. The remaining 22% of the patients were ASV naïve 
and received later in our hospital.  
The mean ASV received was 17.6 ± 7.7 vials on the whole. Among this the 
mean ASV received outside was 6.3 vials and the mean ASV received in the hospital 
was 11.25 ± 6 vials.  
Hypersensitivity to Anti-snake venom was noted in 22% (16 patients). Among 
this the incidence of mild hypersensitivity was 75% (overall 16.5%) and incidence of 
severe hypersensitivity reaction was 25% (overall 5.5%). The incidence of 
hypersensitivity was much higher compared to other studies like Kulkarni et al 
(1.2%)(8) and Sharma N et al (14%)(87). This could be explained by referral bias in 
view of the fact that many patients could have been referred to our hospital in view of 
developing hypersensitivity elsewhere, hence the high incidence.  
Mortality: The mortality in our study was only 4.1% which was also seen in 
study done by Hansdak SG et al in Nepal(3.8%)(84) and Kulkarni et al (5.4)% (8)  
However much higher rates of mortality have been reported in study by Kalantri et al 
(11%)(86). 
 
Risk factors for the development of severe snake envenomation: 
 
 The risk factors for the prediction of severe envenomation were 
divided into demographic, clinical and laboratory groups. 
Demographic factors: The demographic risk factor associated with 
development of severe envenomation was that if the patient was a resident from Tamil 
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Nadu. (OR=3.6, p=0.02) The possible explanation for this could be that as this was a 
referral centre more sick patients had come from the home state of Tamilnadu and 
only few people would have been referred from the neighbouring state. Most of the 
sick patients from Andhra Pradesh would have been referred to a higher centre in that 
state itself. However this factor was not found to have independent significance on 
multivariate analysis.    
Other risk factors that were associated with higher risk but did not have any 
statistical significance were not receiving first aid (OR=1.37, p = 0.137), usage of 
native treatment such as powders and herbs (OR=2.71, p =0.268), snake brought with 
the patient. (OR=2.52, p = 0.173). This would have probably delayed admission to 
hospital hence delayed ASV, thereby causing a severe clinical syndrome. 
Clinical factors: On analysis of various clinical characteristics associated 
with patients presenting with snake bite, the clinical predictors of severe 
envenomation were presence of cellulitis at admission (OR= 6.44, p value= 0.007), 
presence of local bleeding (OR=4.3, p value=0.008),  presence of systemic bleeding 
(OR=4.53, 0.004), features of neurotoxicity at admission (OR=3.54, p value=0.022), 
requirement of ventilation during the ward stay (OR=9.95, p value=0.005), presence 
of renal failure (OR=8.63, p value= <0.0001), requirement of blood or blood product 
transfusion during the course of the hospital stay (OR=8.63, p value= 0.009).  Again 
on unadjusted multivariate analysis none of these factors were found have 
independent statistical significance. 
Clinical features associated with higher risk but not statistically significant 
were administration of ASV at a local centre (OR=1.44, p value=0.527), local 
swelling (OR=7.75, p=0.06), local pain (OR=5.47, p value=0.125), necrotising 
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fasciitis (OR=2.07, p value=0.293). Though local and systemic bleeding were 
significant predictors, factors such as specific type of bleed like epistaxis (OR=2.62, 
p=0.44), gum bleed (OR=0.078), haematuria (OR=7.22, p= 0.07) were not 
statistically significant. Similarly specific manifestations of neurotoxicity like ptosis 
(OR=1.84, p=0.20), diplopia (OR=2.35, p =0.08) and paradoxical respiration 
(OR=2.33, p =0.178) were not statistically significant in spite of having higher odds 
ratio on analysis. 
Laboratory factors: On analysis of various laboratory characteristics 
associated with patients presenting with snake bite, the factors associated with 
statistical significance on univariate analysis were presence of anaemia (OR=6.99, p 
value=0.002), thrombocytopenia (OR=6.68, p value=0.001), jaundice (OR=8.5, p 
value=0.001), hepatitis (OR=12, p value = 0.004), haematuria on urinalysis (OR=6.5, 
p value=0.001), prolonged Thromboelastography (OR=30.66, p value= <0.0001). 
None of the factors were found to have statistical significance on multivariate 
analysis.    
Other factors such as leucocytosis (OR=2.23, p =0.137), rhabdomyolysis 
(OR=3.71, p=0.07), prolongation of whole blood clotting time (OR=1.66, p= 0.40), 
prothrombin time (OR= 2.11, p= 0.155), activated partial thromboplastin time 
(OR=2.54, p=0.215) though had higher odds ratio they were not statistically 
significant as shown by their p values. 
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Regional relevance - Comparison with Indian Data: 
 
 A study in department of Medicine in Kottayam Medical College, Kerala 
found that capillary leak syndrome, intracerebral bleed and respiratory paralysis as 
risk factors for mortality. Leucocytosis (OR=3.7), severe coagulopathy (OR=8) and 
late administration of ASV was associated with higher risk of complications. 
However none of these factors were significant on unadjusted analysis.(14) 
 A study conducted by Department of Medicine in the government hospital in 
Nagpur studied 262 patients with snake envenomation. The significant predictors of 
mortality on multivariate analysis were bleeding tendency (p= 0.013), mean PTTK 
(p= 0.047), respiratory failure (p= 0.045), shock (p= 0.013), mean ASV dose (p < 
0.001).(88) 
A study conducted by Mahatma Gandhi institute of Medical Sciences, Wardha 
collected patient data over a three year period. Of the 277 patients analysed, 11% was 
the mortality rate. Vomiting [OR 6.51 , P ≤ 0.002], neurotoxicity [OR 3.15,P = 0.004] 
and admission serum creatinine concentration [OR 1.35, P ≤ 0.001] were associated 
with higher risk of death in the adjusted analysis.(89) 
On comparing our study with the afore-mentioned studies the following points 
were evident: 
1) There have been very few prospective studies conducted on this topic. Most of the 
studies were retrospective studies with chart analysis. This may have led to 
observer bias and the data documentation is always not very reliable. 
2) Most of the studies have compared the risk factors in relation to mortality. The 
mortality rates in the studies have a wide range from 3%(14) to 20%.(84) 
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3) Like our study though multiple factors were found to be significant on adjusted 
univariate analysis, on the unadjusted multivariate analysis no particular risk 
factor was found to be significant for prediction of a severe clinical course or 
envenomation. 
Role of Thromboelastography (TEG/ROTEM) in snake envenomation:
  
 The physician attending a patient who had a snake bite is usually in a very 
undecided state and needs to be very vigilant for development of further complications. 
Very close and intensive monitoring is required. Multiple studies have already proved 
that detection of coagulopathy could be a very useful and specific indicator that 
envenomation has happened.(54,55,62,64,65) Therefore a very sensitive test such as 
TEG which assesses the dynamic coagulation status has a potentially useful role in this 
situation. 
Our study showed TEG having a sensitivity of 92% as compared to a sensitivity 
of 64% for prothrombin time and 56% for whole blood clotting time in predicting a 
higher disease severity. Also TEG had a negative predictive value of 88.9% compared 
to 56% for WBCT and 62.5% for prothrombin time, suggesting that a normal 
thromboelastogram can safely predict that severe envenomation may not have occurred 
and the patient is going to have a milder clinical course. However, all the three tests in 
comparison were not very good predictors (WBCT-63.6%, PT-69.6%, TEG-79.3%) of 
severe outcome (low specificity) in case of an abnormal test. The study done by 
Hadley et al also have similar outcomes with negative predictive value and sensitivity 
of TEG being 94%.(81) However the specificity for TEG was much lower in their study 
(45.5%) when compared to our results (72.7%).On searching PUBMED and INDMED 
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we could not find any earlier studies done on the role of Thromboelastography on snake 
bite done in India. 
On comparison of the coagulation tests to detect coagulopathy when patients 
had clinical evidence of bleeding present TEG had a higher level of sensitivity (81.3%) 
as compared to WBCT (59.4%) and prothrombin time (65.6%). TEG had a slightly 
better negative predictive value of 66.7% compared to WBCT(48%) and prothrombin 
time(54.2%). However the specificity of all three tests were almost similar (80% for 
TEG and WBCT, 86.7% for prothrombin time.  
It is well known that TEG can not only provide information regarding 
coagulation but also information regarding the components required such as platelets. 
When the TEG tracings suggestive of thrombocytopenia were compared to actual 
laboratory evidence of thrombocytopenia the sensitivity of the test picking up a low 
platelet count was 94.74% and the negative predictive value i.e. a normal TEG ruling 
out a low platelet count was 94.44% (p value = 0.0001).   
Hence we conclude that though Thromboelastography cannot replace the 
importance of clinical assessment in patients with snake envenomation or the need for 
continuous monitoring and reassessment, it can serve as an early warning signal in few 
patients where it is abnormal. As the predictive value of a prolonged TEG/ROTEM for 
a severe clinical course is high such patients may need more careful observation and 
more aggressive treatment. Similarly a normal TEG can reasonably assure that 
envenomation is not severe and the clinical course of the patient is going to be benign. 
The role of Thromboelastography needs to be further studied in areas of need such as 
snake bite and further assessment in comparison to the amount of ASV given and 
treatment outcome with a study involving a larger sample size. 
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CONFOUNDERS: 
Several studies have shown that conditions such as haematological or solid organ 
malignancies, chronic liver disease, anticoagulant or antiplatelet medications, 
immediate post-surgical period can interfere with the coagulation process and cause 
differences in the laboratory tests of haemostasis including TEG.  Hence patients with 
these factors were excluded at enrolment itself to prevent the confounding factor bias. 
 Other factor which could have influenced the outcome of TEG results is the 
probable effect of reperfusion injury on coagulation caused by the use of a tight 
tourniquet after it is released. The usage of tourniquet was in 40 out of the 47 (85%) 
patients that were assessed for comparison of TEG with other parameters. As most of 
the patients used tourniquet, it was unlikely that this reperfusion injury could have 
affected the results. 
LIMITATIONS: 
 
1. The recruitment of patients in the study was planned as a consecutive sampling. 
Due to practical constraints, there were small lapses, despite which, consecutive 
sampling was attempted to the best possible extent.  
2. The study protocol included coagulation testing at admission and 6 hours. 
However, repeat coagulation testing at more regular intervals, may have been 
ideal till the time of discharge; due to practical and financial feasibility 
constraints, this could not be done.   
3. This study was restricted to the patients presenting to CMC. There were other 
specialties like paediatrics and other CMC branches like CMC Community centre, 
Bagayam and Government Vellore Medical College locally, which also admitted 
patients with snake bite. They had not been considered for inclusion into the study 
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as per protocol. So CMC being a referral hospital would have led to us seeing the 
more morbid patients; hence a bias towards patients with higher severity of 
envenomation. The prevalence of risk factors may have been higher in those 
patients from the aforementioned areas. Exclusion of these patients creates a 
lacuna in our understanding of this problem. 
4. The number of patients with mild envenomation was considerably less than those 
with severe snake envenomation when coagulation tests were evaluated. As 
missing data for TEG was present in few patients, these patients had to be 
excluded from the final statistical analysis. Therefore, finally even though 47 (72 
totally) patients were enrolled into the study within the given time frame, the 
numbers within each category was not adequate to elucidate associations by 
statistical analysis. Hence the results of the primary objective of the study, aiming 
to look at the ability of TEG to detect the coagulation abnormalities in snake 
envenomation could not be accurately interpreted or extrapolated. 
5. Although the usual laboratory parameters like haemoglobin platelets were 
available for all patients, expensive tests such as fibrinogen could not be done as 
this was not included in the study protocol. Other tests results such as APTT 
waveform analysis, levels of fibrin degradation products, fibrinogen and thrombin 
antithrombin complex levels, level of snake venom in the plasma, ELISA to detect 
the snake type would have been helpful in analysing and better understanding of 
the coagulopathy process. 
6. There were only 4 patients admitted with pure neurotoxic envenomation and the 
results of coagulation testing were equivocal in them. Larger sample size of pure 
neurotoxic snake bites would be necessary to delineate the role of TEG in 
assessing envenomation in that subgroup.  
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7. Most of the patients had received ASV already prior to admission. This is an 
inherent problem in being a tertiary referral care centre and hence the results of 
coagulation testing could have been affected. 
8. Though TEG tracings showed good correlation with thrombocytopenia, TEG 
cannot accurately distinguish between platelet dysfunction or decrease in platelets. 
Platelet dysfunction studies were out of scope of this study as they are expensive. 
Hence this point needs to be kept in mind while interpreting the results of this 
study. 
MERITS 
 
Our study is one of the few prospective studies in the country to describe snake 
envenomation as most of the studies have been retrospective analysis by case records. It 
is the first study in India, to describe the role of Thromboelastography testing in the 
setting of snake bite envenomation. It is also the first in India to compare 
Thromboelastography with other coagulation testing in snake bite. The need for 
identification of a better and comprehensive test of assessment for a very common and 
significant problem of snake bite in the community in the absence of specific diagnostic 
kits was the driving force behind this study.  
A uniform protocol for management of snake bite is followed by all the doctors 
in the medical units and emergency department, as a result of which all the patients 
studied were on standard treatment. Therefore, the treatment bias of anti-snake venom 
affecting a particular coagulation test was reduced. Hence the results of all the 
coagulation tests would have been similarly affected. 
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CONCLUSIONS 
 
1. Thromboelastography is a more sensitive test of coagulopathy in snake 
envenomation than the tests used conventionally such as WBCT and prothrombin 
time. (92% vs 56%, 64%).  
2. Thromboelastography is a more sensitive test of identifying severe cases of snake 
envenomation than the tests used conventionally such as WBCT and prothrombin 
time. (81.3% vs 59.4%, 65.6%).  
3. A normal thromboelastogram has a better predictive value of a milder clinical 
course than a normal Whole blood clotting time or Prothrombin time 
(NPV=88.9%). 
4. Thromboelastography can significantly predict thrombocytopenia in cases of 
snake envenomation (OR=27.81, p value = 0.0001) 
5. Though we found multiple risk factors significant on univariate analysis to predict 
a severe clinical course, none of the variables were statistically significant on 
multivariate analysis.  
6. Socio-demographic variables, clinical findings, laboratory and treatment variables, 
ASV related data and mortality in our study were found to be consistent with 
studies done earlier. 
 Snake envenomation can be considered as one of the most neglected health 
problem in the country where prompt and appropriate therapy with adequate support 
can make a significant difference. Unfortunately not much research has gone into 
such an important public health problem and most of the studies conducted have been 
largely retrospective descriptive studies. Studies have shown that despite 
advancement of medical care in the rural areas and availability of ASV the mortality 
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related to snake envenomation has largely remained same. The main tests used for 
diagnosis and monitoring therapy still remain the traditional tests for coagulation 
namely WBCT and prothrombin time. Our study shows that Thromboelastography is 
a better sensitive test for identification of coagulation abnormalities and for prediction 
of severe envenomation than the routine tests of clotting. Our study also shows that a 
normal thromboelastogram has a higher prediction of a milder clinical course. Hence 
in areas of the world such as India where specific venom detection kits to detect 
envenomation are not available, newer tests such as TEG would provide a reasonable 
alternative to identify envenomation. 
Hence from this study we recommend that: 
1. Thromboelastography can be a useful adjunct to management of snake 
envenomation and in places where the testing is available it may be 
worthwhile consider doing it to make a better clinical decisions. 
2. Further studies comparing Thromboelastography must be done in patients 
with snake bite with larger sample size to prove the better sensitivity and 
specificity of TEG compared to conventional tests. 
3. Further studies are required to assess the role of TEG if it can play a role in 
determining the amount of ASV to be given or its use in determining the 
Transfusion requirements (platelet and FFPs) in patients with acquired 
DIC as a result of snake envenomation. 
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APPENDICES 
 
APPENDIX 1: INFORMED CONSENT 
 
                              INFORMED CONSENT FOR SNAKE ENVENOMATION STUDY 
Christian Medical College, Vellore 
Department of Medicine 
Title: An observational trial comparing Thromboelastography with conventional 
coagulation assays to assess disease severity in patients with snake bite. 
Information sheet 
You are being requested to participate in a study to see if a test called thromboelastography 
can help us predicting disease severity better than routine tests in patients with snake bite. 
There are no side effects expected as this is an observational study. We hope to include about 
100 people from this hospital in this study. 
What is thromboelastogram? 
Thromboelastogram is a blood test which is used to assess the clotting function of the blood.  
What is the reason for the study? Are the tests currently being used good enough? 
Traditionally snake envenomation is diagnosed and clotting ability of the blood is monitored 
by routine tests like whole blood clotting time and prothrombin time which also form the 
basis for administration of ASV to the patients. Therefore it is important to accurately know 
the coagulation status of the patients at admission for effective administration of ASV. 
Thromboelastography is a new test which also assesses the clotting profile. Hence we are 
comparing the older tests with a newer test. This may in future help us in better management 
of patients with snake bite. 
Does thromboelastogram have any side effects? 
No, thromboelastogram will not have any side effects. However, it has same chance of injury 
during the collection of blood sample for any other test. 
If you take part what will you have to do? 
If you agree to participate in this study, you will be asked to give two blood samples of 3 ml 
each at admission and after 6 hours along with the routine samples. All other treatments that 
you are already on will be continued and your regular treatment will not be changed during 
this study. You will also be administered a questionnaire at the time of admission.  
Can you withdraw from this study after it starts? 
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Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your usual 
treatment at this hospital in any way 
What will happen if you develop any study related injury? 
We do not expect any injury to happen as this is a observational study. We are unable to 
provide any monetary compensation, however.  
Will you have to pay for the study testing?  
No, thromboelastography will be done at free of cost. Any other treatment that you usually 
take will continue but the usual arrangements that you have with the hospital will decide how 
much you pay for this.  
What happens after the study is over? 
You may or may not benefit from the study test that you have given. Once the study is over, 
we wish to analyze the results and see if this test is better than the earlier tests. This would 
help us in managing patients with snake bite better in the future. 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be identified 
by name in any publication or presentation of results. However, your medical notes may be 
reviewed by people associated with the study, without your additional permission, should you 
decide to participate in this study.  
 
If you have any further questions, please ask  
Dr. HARSHA TEJA PERLA, 
PG REGISTRAR 
DEPARTMENT OF MEDICINE 
CHRISTIAN MEDICAL COLLEGE, VELLORE 
(tel: 0416 2282031) 
email: harsha.tej@gmail.com 
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                      CONSENT TO TAKE PART IN A CLINICAL TRIAL 
 
Study Title:An observational trial comparing Thromboelastography with conventinal 
coagulation assays to assess disease severity in patients with snake envenomation. 
Study Number: 
Participant’s name: 
Date of Birth / Age (in years): 
I_____________________________________________________________ 
___________, son/daughter of ___________________________________ 
 
(Please tick boxes) 
 Declare that I have read the information sheet provide to me regarding this study and 
have clarified any doubts that I had. [ ] 
 I also understand that my participation in this study is entirely voluntary and that I am 
free to withdraw permission to continue to participate at any time without affecting 
my usual treatment or my legal rights [ ] 
 I also understand that during the period of the study, the test will be provided free, but 
after this, if the same test is prescribed, I may have to pay for it [ ] 
 I understand that I will receive free treatment for any study related injury or adverse 
event but I will not receive and other financial compensation [ ] 
 I understand that the study staff and institutional ethics committee members will not 
need my permission to look at my health records even if I withdraw from the trial. I 
agree to this   access [ ]  
 I understand that my identity will not be revealed in any information released to third 
parties or published [ ]  
 I voluntarily agree to take part in this study [ ] 
 
Name:                                                              Name: 
Signature:                                                        Area for thumb impression:        
 
Name of witness:                                             Signature of the parent/guardian (if age < 18) 
Relation to participant:                                    Name: 
Date: 
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APPENDIX 2: CLINICAL RESEARCH FORM (DATA ABSTRACTION 
FORM) 
                      General information 
S.No:                                                          Patient Name / Label: 
Age:                                                            Sex:   male /female                             
Contact number:                                         Occupation:  
Address: 
Epidemiology: 
 Environmental setting:   field / house / if others mention where? 
 Season: February - June / July –September / October –January 
 Time of the day: 
 Type of snake: identified / not identified  
                            If identified name of the snake: 
Common names 
English name  Tamil name  Telugu name 
 Indian Cobra  Naagupambu Nagupaamu 
Russells viper  RethaaunaliKannadiviriyan Katukarekulapaamu or      
rakthapinjara/ pinjari 
Saw scaled viper Surattaipambu,viriyanpamboo, surutaivireyan Thrachupaamu 
Krait   Kattuviriyan, Pudayan Katlapaamu 
 
 Time of presentation (how many hours after the bite ): 
 Duration of hospital stay: 
 First aid measures prior to admission to the hospital 
o If yes, please specify: tourniquet/ multiple incisions /herbal or native 
medicines. 
 Whether ASV was administered before presentation to CMC:   yes/no 
o If yes, how many vials of ASV: 
 Bite to needle time :( time since the bite to time of first vial of ASV) 
Clinical features: 
1. Fang marks    Y/N                                 if Yes site of the bite? 
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2. Local features :      ( please tick ) 
                Inflammatory swelling / bleeding / ecchymosis / blister formation/ local necrosis                
3. Compartment syndrome: Y/N            if Yes did the patient require fasciotomy/other 
treatment? 
Systemic manifestations: 
i. Hemorrhagic manifestations :( internal bleeding or haemorrhage from other than local 
site)  including hematemesis, hematuria, epistaxis, bleeding per rectum and bleeding 
gums 
       Yes /no              if yes kindly mention the complication? 
ii. Neurological manifestations : 
a) Ptosis   Y/N 
b) Breathing difficulty requiring ventilator support   Y/N 
c) Severe muscular paralysis  Y/N 
d) Cranial nerve palsy  or aphasia  Y/N 
e) Other neurological manifestations  
Management: 
a) Total ASV vials given outside : 
b) Total number of ASV vials given in the hospital : 
c) Average total number of days requiring ventilation : 
d) Hypersensitivity to ASV: yes/ no 
e) If hypersensitivity present then    (tick one ) 
1. Mild reaction : (itching, tachycardia, palpitations, cough, nausea, vomiting ) 
2. Severe reaction : ( bronchospasm, hypotension, angioneurotic oedema ) 
f) Did the patient require haemodialysis:  Y/N       if Y how many sessions? 
g) Did the patient require blood transfusions : 
h) Final outcome of the patient :  completely recovered/ death/ residual sequelae 
i) If residual sequelae, present kindly mention the sequelae? 
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Co morbidities:  
 
Diabetes Yes / No Malignancy Yes / No 
Hypertension Yes / No Prior  antiplatelet therapy  Yes / No 
CKD Yes / No IHD/CAD  Yes / No 
CLD Yes / No History of bleeding disorder Yes / No 
 
Laboratory results: 
 At admission  After 6 hours 
20 min whole blood clotting time    
Prothrombin time with INR    
Activated partial thromboplastin time  (aPTT)   
TEG/ROTEM         Thromboelastography 
1) CT(Clotting Time): (in sec)  
2) CFT(Clot Formation Time) (in seconds)  
3) Alpha Angle : 50 – 68 (degree), 
4) MCF(Maximum Clot Firmness) : 55 – 66 
(mm) 
  
Fibrinogen  
 
  
CPK (creatine phosphokinase )    
Serum creatinine / electrolytes / urea   
LDH (lactate dehydrogenase)   
 
 
Liver function tests 
 
  
Haemoglobin    
Total counts   
Platelets 
 
  
Urinalysis   
Special tests : ultrasound/Doppler/CT Scan   
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Snake bite severity score:  
 
Total score at admission:  _____     (Mild - moderate 0-7, severe 8-20) 
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APPENDIX 3:  STANDARD OPERATING PROCEDURES 
3a. Rotational Thromboelastometry(ROTEM): 
 
1.1 PURPOSE: 
To check the coagulation state of a blood sample. 
 
1.2 PRINCIPLE: 
The ROTEM technology is based on a fixed cylindrical cup and a permanently 
oscillating vertical axis. The axis is supported by a high precision ball bearing and 
oscillates to the left and to the right through an angle of 4.75º. The rotation of the axis 
is driven by a motor that is connected to the axis via an elastic spring. For the 
measurement, a disposable plastic pin with 6 mm diameter is placed firmly on the axis 
and the blood sample is filled into a disposable 8 mm diameter cup and is then 
uplifted onto the measurement channel. Hence, the plastic pin is immersed into the 
blood sample. The rotation is detected optically via a mirror plate at the upper end of 
the axis, a diode as light source and a light sensitive sensor (CCD Chip). If no clotting 
takes place, the movement is not obstructed. When a clot is formed and attaches itself 
between pin and cup surfaces, the movement is obstructed. The result is a balance 
between the spring tension and the tension of the clot. As the clot becomes firmer, the 
rotational amplitude of the axis is reduced. 
 
1.3 PRIMARY SAMPLE: 
Citrated whole blood (platelet rich plasma can also be used) 
 
1.4 MATERIALS: 
1. Citrated whole blood 
2. Disposable cups and pins 
3. Pipettes (100-1000µl, 5-40µl) 
4. 0.2M calcium chloride 
5. Diluted thromboplastin (1/2000) 
6. Personnel Protective Equipment (PPE) 
 
1.5 SAMPLE PREPARATION: 
Blood Sample: 
Blood is preferably drawn via a 21G needle directly into vacuette Greiner tube 
containing 3.2% sodium citrate with minimal stasis. 
 
The temperature of the sample may influence the measurement results. 
Measure the blood sample directly after sampling. 
If this is not possible, preheat the blood sample for 5-10 min before 
measurement in the sample preheating station of the ROTEM delta. 
1.6 REAGENT PREPARATION: 
Preparation of Tissue factor: 
Dilute 10µl of recombiplastin into 490µl of Imidazole buffer in tube 1. 
Add 50 µl of the contents in tube 1 to 950 µl of Imidazole buffer in tube 2 and 
mix well. 
Add 500µl of the contents in tube 2 to 500 µl of imidazole buffer in tube 3 and 
mix well. 
This diluted recombiplastin is used for the processing of a sample on ROTEM. 
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1.7 PROCEDURE: 
Switching on the ROTEM system: 
Activate the ROTEM system with the main switch on the back of the device. 
Push the blue on/off button on the right hand side of the instrument. 
Log in to the system 
Touch the screen if the screen saver is active. 
Select user (admin) 
Enter password (admin) 
Measurement module screen will open 
Measuring Cell Preparation: 
Mounting Pins: 
Take the cup with the pin in it from the storage box. Push the pin in the cup 
onto the axis chosen for measurement. 
Note: The status line under the channel is grey by default. In case the axis has 
been moved heavily when attaching the pin, the channel becomes inactive and 
the status line turns blue during the time of initialization. Never touch the pin 
(not even with gloves) 
Placing Cups: 
Place the cup with its opening facing upwards into the appropriate 
preheated cup holder. Leave the cup holders always in the temperature 
controlled area. 
Fixing Cups: 
Push and fix the cup in the cup holder using the MC Rod. The cup must fit 
tightly. 
 
Enter Patient Data: 
Touch one of the four channels. 
In the upper part of the screen entry fields for patient data {Patient ID, Patient 
name (first name, last name, and comment} are displayed. 
Touch the respective entry field. 
Enter patient data. 
1.8 PROCEDURE: 
Add 20µl of 0.2M CaCl2 prewarmed cup. 
Add 30µl of diluted recombiplastin to a separate plastic vial. 
Mix 500µl of well mixed whole blood the tissue factor. 
Add 320µl of the mixture to the CaCl2 and mix well. 
Place the cup holder onto the measuring position using the guiding rods. 
The cup holder is kept in measuring position by magnets. 
Press the “Start manual” icon the screen. 
1.9 INTERPRETATION: 
During measurement, the large TEMogram is shown at the left upper side of 
the screen. In the upper right part of the screen, the current measurement 
results of the test parameters are shown. 
ROTEM Parameters: 
Clotting Time (CT): It is the time from the beginning of the test by adding the 
clot activator until the time when amplitude of 2 mm is achieved. 
 
Clot Formation Time (CFT): It is the time between 2 mm amplitude and 20 
mm amplitude of the clotting signal. 
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Alpha Angle (α): It is defined as the angle between the middle axis and the 
tangent to the clotting curve through the 2 mm amplitude point. It describes 
the kinetics of clotting. 
Maximum Clot Firmness (MCF): It is the measure for the firmness of the 
clot and therefore the clot quality. It is the maximum amplitude that is reached 
before the clot is dissolved by fibrinolysis and the clot firmness falls again. 
Maximum Lysis (ML): It is the degree of fibrinolysis relative to maximum 
clot firmness achieved during the measurement. 
1.10 Possible Interference: 
Clotted sample. 
1.11 Safety protocols: 
Always use the necessary PPE for all procedures done in the laboratory. 
Consider every biological sample as potential bio hazard. 
 
 
 
 
3b. Prothrombin Time (PT) 
 
2.1 Purpose 
To look for the overall efficiency of extrinsic pathway of coagulation and 
monitoring of oral anticoagulant therapy. 
 
2.2 Principle 
Clot based assay. 
 
2.3 Performance specifications 
Limits of detection - 5 to >120 Sec 
 
2.4 Primary sample 
Citrated blood. 
 
2.5 Type of container 
1. Light blue top vacutainer. 
2. 1ml mini collect Greiner Vacutte (For pediatric purposes) 
 
2.6 Reagents and Materials 
1. Innovin: product needs to be reconstituted as per product insert/instruction 
sheet, and prewarmed to 37oC. This reagent already contains CaCl2. 
2. Patient plasma, control plasmas as required. (NB: test normal plus abnormal 
QC plasma whenever a fresh vial of recombiplastin is reconstituted). 
3. Waterbath, 12 x 75 test tubes, stop watches, yellow tips, and 100 and 200ul 
automatic pipettes and light source. 
 
2.7 Procedure 
1. Add 0.1ml plasma into duplicate small glass tubes placed in a 37oC water bath, 
and leave 3 min to equilibrate to 37oC. Add 0.2ml prewarmed innovin, and 
simultaneously start stop watches. 
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2. Mix and tilt tubes to nearly horizontal position at one second intervals, 
otherwise maintaining in 37oC water bath. 
3. Depress stop watch mechanism on first appearance of a clot. The time taken for 
the clot to form (i.e. between addition of Innovin and the appearance of the 
clot) is the 'prothrombin time' (PT). 
4. Take the mean of the duplicate readings (providing that they don't differ by 
more than two seconds; otherwise repeat the procedure and check the reagent; 
replace if necessary). 
 
2.8 QC protocol 
1. A normal control (e.g. pooled normal plasma [PNP]) and an abnormal control 
plasma (eg Coag-path from Stago) should also be included with every batch of 
patient plasma tested, or every few hours if testing a large number of plasmas 
throughout the day. 
2. Run normal control and abnormal control plasma for 10 days and calculate the 
mean and +/-2SD. The control values should fall within +/-2SD. 
 
2.9 Possible interference 
1. Improper centrifugation. 
2. Plasmafrom badly haemolysed blood. Badly haemolysed blood may give an 
artifactual coagulation results that do not accurately represent the coagulation 
status of the patient under investigation. Haemolysed blood may suggest a 
traumatic blood collection and you may need to request a repeat sample 
collection. 
3. Highly lipemic sample 
4. Blood not tested within four hours of collection. 
 
2.10 Alert values 
All the abnormal values. 
 
2.11 Result interpretation 
1. The results are expressed as a mean of the duplicate reading in seconds, both 
mean of the patient time and mean of the normal control time; the results are 
always interpreted with INR (International Normalized Ratio). 
2. Normal Range. 10 – 12Secs. 
3. (Normal values varies depending on the Thromboplastin used the exact 
technique under visual or automated end point reading is used) 
INR= Prothrombin Time (PT) of test plasma (sec)/ Mean Normal Prothrombin 
Time (sec) 
ISI = International Sensitivity Index. 
INR= International normalized ratio. 
4. Ideally, laboratory should establish its own Mean Normal Prothrombin Time 
(MNPT). Classically, for the MNPT: this is obtained by testing at least 20 
normal plasmas in that laboratory’s PT assay, and taking the mean PT. 
Selected instrument specific ISI values are usually provided for each batch of 
Innovin. 
 
2.12 Safety protocols 
1. Always use the necessary PPE for all procedures done in the laboratory. 
2. Consider every biological sample as a potential bio hazard. 
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3. Ensure that all laboratory work benches are mopped with 70% ethanol before 
and after work. 
4. In case of any needle stick injury, take a patient sample & hospital number, 
wash the wound with soap and water, inform the any department staff/ DSA 
and rush to the SSHS. 
 
2.1 Potential sources of variation/environmental impact on procedure 
All samples must be processed within four hours of collection. 
 
 
 
  
3c. Activated Partial Thromboplastin Time (APTT) 
 
3.1 Purpose 
To rule out overall efficiency of intrinsic and common pathway of coagulation 
and monitoring of heparin therapy. 
 
3.2 Principle 
Clot based assay 
 
3.3 Performance specifications 
Limits of detection – 20 to >180 Sec 
 
3.4 Primary sample 
Citrated blood. 
 
3.5 Type of container 
1. Light blue top vacutainer. 
2. 1ml mini collect Greiner Vacutte (For pediatric purposes) 
 
3.6 Reagents and Materials 
1. SynthAsil (IL) 
2. CaCl2 0.025M pre-warmed to 37oC 
3. Patient plasma and control plasma 
4. 12 x 75 glass tubes and stopwatches. 
5. Water bath 
6. Automated Pipettes/glass pipettes and tips. 
 
3.7 Procedure 
1. Add 0.1ml of plasma and 0.1ml APTT reagent in a glass tube (12 x 75) and 
place it in a 37oCwater bath. 
2. Mix, and leave for 5 minutes to equilibrate to 37 deg C and to provide suitable 
activation of plasma with contact factor. 
3. Add 0.1ml of warmed 0.025M cacl2, and simultaneously start stopwatch. 
4. Mix and tilt tubes to nearly horizontal position at one-second intervals, 
otherwise maintaining in 37 deg C water bath. 
144 
 
5. Depress stopwatch mechanism on first appearance of a clot. The time taken for 
the clot to form (i.e., between addition of CaCl2 and the appearance of the 
clot) is the APTT. 
6. Always do in duplicates. 
7. Take the mean of the duplicate reading (provided that they don’t differ by more 
than 2 seconds otherwise repeat procedure and check reagents. 
 
3.8 QC protocol 
1. A normal control (e.g. pooled normal plasma [PNP]) and an abnormal control 
plasma (e.g. Coag-path from Stago) should also be included with every batch 
of patient plasma tested, or every few hours if testing a large number of 
plasmas throughout the day. 
2. Run normal control and abnormal control plasma for 10 days and calculate the 
mean and +/-2SD. The control values should fall within +/-2SD. 
 
3.9 Possible interference 
1. Improper centrifugation of patient sample 
2. Badly haemolysed bloodmay give an artifactual coagulation results that do not 
accurately represent the coagulation status of the patient under investigation. 
Haemolysed blood may suggest a traumatic blood collection and you may 
need to request a repeat sample collection. 
3. Blood not tested within four hours of collection. 
 
3.10 Alert values 
All the abnormal values. 
 
3.11 Result interpretation 
1. Report APTT results in seconds for example control 30 sec, patient 36 sec. 
2. Each lab has to establish their own range. 
3. As a rough guide the APTT of normal plasma should be 25 to 35 sec. 
4. In our lab a difference of more than 6 sec between the control and patient is 
considered as abnormal and needs further evaluation. 
 
3.12 Safety protocols 
1.  Always use the necessary PPE for all procedures done in the laboratory. 
2. Consider every biological sample as a potential bio hazard. 
3. Ensure that all laboratory work benches are mopped with 70% ethanol before 
and after work. 
4. In case of any needle stick injury, take a patient sample & hospital number, 
wash the wound with soap and water, inform the any department staff/ DSA 
and rush to the SSHS. 
 
3.13 Potential sources of variation/environmental impact on procedure 
All samples must be processed within four hours of collection. 
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DATA TABLES 
 
patien
t 
Se
x 
Ag
e 
agecod
e 
Occ
u 
Adr
s 
TO
B 
TES
B 
Modtran
s 
Snideny
n 
Sntyp
e 
Snbrin
g 
EnvSe
t 
Durhos
p 
1 1 43 3 1 2 3 3 4 1 1 2 1 3 
2 1 50 3 2 1 3 2 3 2 5 2 1 4 
3 1 60 3 1 1 4 2 4 2 5 2 2 4 
4 1 37 2 1 2 1 2 2 1 4 2 1 7 
5 1 25 2 2 1 3 1 4 2 5 2 1 2 
6 1 45 3 4 1 1 1 2 2 5 2 1 2 
7 2 23 2 3 1 3 1 5 2 5 2 1 12 
8 1 65 4 1 1 4 1 2 1 1 2 1 7 
9 1 56 3 2 1 3 3 4 2 5 2 1 7 
10 2 53 3 3 1 1 1 4 1 1 2 1 5 
11 1 38 2 1 1 1 1 5 1 1 2 1 16 
12 1 43 3 1 2 3 1 4 1 1 2 1 3 
13 2 56 3 3 1 1 3 5 2 5 2 1 6 
14 2 53 3 2 1 1 2 4 2 5 2 1 3 
15 1 59 3 2 1 1 3 2 2 5 2 1 1 
16 1 18 1 6 1 4 1 2 2 5 2 2 1 
17 2 41 3 2 1 3 1 3 1 1 1 1 12 
18 1 39 2 2 1 4 2 3 1 1 1 1 11 
19 1 81 4 1 1 4 1 3 1 2 1 2 6 
20 2 31 2 2 1 2 1 4 2 5 2 1 5 
21 1 36 2 2 1 3 3 5 2 5 2 1 10 
22 1 46 3 4 2 3 1 5 2 5 2 1 14 
23 2 31 2 3 1 4 1 2 1 4 1 1 3 
24 1 18 1 6 1 3 3 5 2 5 2 1 5 
25 1 41 3 2 1 4 2 3 2 5 2 2 6 
26 1 56 3 2 2 1 1 3 1 1 2 1 2 
27 1 46 3 3 1 1 2 3 1 1 2 1 7 
28 1 36 2 2 1 2 1 5 1 1 1 1 11 
29 1 45 3 2 1 1 3 3 2 5 2 1 1 
30 1 51 3 1 1 2 1 3 2 5 2 2 13 
31 2 24 2 3 2 3 1 3 2 5 2 1 13 
32 2 18 1 6 1 1 2 3 2 5 2 1 8 
33 1 42 3 1 1 4 2 5 2 5 2 2 5 
34 1 35 2 1 2 1 2 3 2 5 2 1 3 
35 1 35 2 2 1 1 1 3 1 1 1 1 6 
36 1 22 2 1 1 4 3 5 1 1 2 1 10 
37 2 31 2 3 1 1 1 4 1 1 2 1 8 
38 2 55 3 3 2 1 1 3 1 3 2 1 13 
39 1 55 3 2 2 3 1 5 2 5 2 1 5 
40 1 16 1 6 1 2 1 1 2 5 2 1 6 
41 1 50 3 1 1 2 1 3 1 1 2 1 7 
42 1 47 3 2 1 2 4 5 1 1 1 1 4 
43 1 37 2 1 1 2 1 5 1 1 1 1 1 
44 1 22 2 6 1 4 3 5 1 4 1 2 4 
 
45 1 36 2 2 1 2 1 1 1 1 2 1 4 
46 2 41 3 3 1 1 3 5 2 5 2 1 3 
47 1 23 2 2 2 2 3 4 1 1 2 1 6 
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48 1 39 2 1 1 1 3 4 1 1 2 1 9 
49 1 23 2 1 2 3 1 5 2 5 2 1 1 
50 1 48 3 1 1 3 1 5 2 5 2 1 5 
51 2 31 2 3 1 4 1 4 2 5 2 2 5 
52 2 32 2 3 1 4 1 5 2 5 2 1 6 
53 2 62 4 3 2 4 1 1 2 5 2 2 2 
54 1 34 2 4 2 4 1 2 2 5 2 2 2 
55 1 62 4 1 2 1 1 5 1 1 2 1 5 
56 1 42 3 1 1 4 3 3 2 5 2 1 4 
57 2 47 3 3 1 3 3 4 2 5 2 1 3 
58 1 24 2 6 1 2 3 5 1 1 1 1 10 
59 1 24 2 6 2 3 1 4 2 5 2 2 5 
60 1 62 4 1 1 4 2 3 2 5 2 1 6 
61 1 33 2 2 1 1 1 1 1 4 2 1 4 
62 2 37 2 3 1 1 1 3 2 5 2 2 9 
63 1 51 3 2 2 4 1 4 1 1 2 2 4 
64 2 37 2 3 2 3 1 3 2 5 2 1 8 
65 1 45 3 1 1 3 1 3 1 3 2 1 6 
66 1 35 2 2 2 3 1 2 2 5 2 1 5 
67 1 55 3 1 2 3 3 4 2 5 2 1 24 
68 1 31 2 2 1 3 3 5 2 5 2 1 19 
69 2 50 3 3 2 1 2 2 2 5 2 2 4 
70 1 45 3 2 1 3 1 1 1 2 1 1 5 
71 1 55 3 2 1 1 1 2 2 5 2 1 3 
72 1 21 2 6 2 1 4 5 2 5 2 1 21 
 
 
 
FirstAid tornquet herbnati locanaes TT PriorASV ASVout ASVin ASVtot ASVHS tyasvhs BTNtime 
1 1 2 2 1 1 4 12 16 2   6 
1 1 2 1 1 1 2 10 12 2   2 
1 2 1 2 1 1 10 8 18 2   9 
2 2 2 2 1 1 2 18 20 2   8 
2 2 2 2 1 1 8 10 18 2   5 
1 1 2 2 1 1 8 4 12 1 1 3 
1 1 2 2 1 1 17 22 37 2   4 
2 2 2 2 1 2 0 16 16 2   2 
1 1 2 2 1 1 12 4 16 2   1 
1 1 2 2 1 1 8 6 14 2   2 
2 2 2 2 1 1 8 14 22 2   1 
2 2 2 2 1 1 4 12 16 1 2 2 
1 2 2 2 1 1 24 4 28 2   4 
2 2 2 2 1 1 8 14 22 1 1 2 
2 2 2 2 1 2 0 0 0 2   2 
2 2 2 2 1 2 0 10 10 2   1 
1 1 2 2 1 2 0 24 24 1 1 2 
1 1 1 2 1 1 2 12 14 2   3 
1 1 2 2 1 2 0 18 18 2   1 
2 2 2 2 1 2 0 16 16 2   2 
1 1 2 2 1 1 18 4 22 2   5 
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1 1 2 1 1 2 0 14 14 2   4 
1 1 2 2 1 1 8 12 20 2   1 
1 1 2 1 1 1 2 10 12 1 1 4 
2 2 2 2 1 2 0 20 20 2   8 
1 1 2 2 1 1 1 4 5 2   1 
1 1 2 2 1 1 6 10 16 2   8 
2 2 2 2 1 1 4 6 10 2   3 
2 2 2 2 1 2 0 2 2 2   1 
1 1 1 2 1 2 0 18 18 2   2 
1 2 2 2 1 1 1 14 15 2   1 
1 1 2 1 1 1 4 10 14 2   6 
1 1 2 2 1 1 15 10 25 2   3 
1 1 2 1 1 1 6 9 15 1 2 1 
1 1 2 2 1 1 8 9 17 2   4 
1 2 2 1 1 1 20 24 44 2   2 
2 2 2 2 1 2 0 27 27 2   1 
1 1 2 2 1 1 7 7 14 2   2 
1 1 2 2 1 1 2 12 14 2   1 
1 1 2 2 1 1 8 24 32 2   7 
1 1 2 2 1 1 8 10 18 1 1 2 
1 1 1 1 1 1 10 10 20 2   6 
1 1 2 2 1 1 10 0 10 2   1 
1 1 2 1 1 1 30 2 32 2   2 
1 1 2 1 1 1 8 8 16 2   2 
2 2 2 2 1 1 11 4 15 2   4 
2 2 2 2 1 2 0 8 8 1 1 2 
2 2 2 2 1 1 6 6 12 2   3 
1 1 2 2 1 1 4 6 10 1 1 2 
1 1 1 2 1 1 4 10 14 1 1 1 
1 1 2 2 1 1 8 6 14 2   0.25 
1 1 2 2 1 2 0 15 15 2   2.5 
2 2 2 2 1 2 0 6 6 2   2 
2 2 2 2 1 2 0 10 10 2   1.5 
1 1 2 2 1 1 4 14 18 1 2 1 
1 1 2 1 1 1 8 10 18 1 1 2 
2 2 2 2 1 1 14 18 32 2   3 
1 1 2 2 1 1 20 4 24 2   4 
1 1 2 2 1 1 6 10 16 2   1 
1 2 1 2 1 1 8 18 26 2   2 
1 1 2 1 1 1 8 12 20 1 1 3 
1 1 2 2 1 1 8 10 18 2   1 
2 2 2 2 1 1 6 10 16 1 2 1 
1 1 2 2 1 1 4 18 22 1 1 1 
1 1 2 2 1 1 8 12 20 1 1 1 
2 2 2 2 1 1 2 12 14 2   1 
2 2 2 2 1 1 2 12 14 2   0.5 
1 1 2 2 1 1 10 25 35 2   3 
1 1 2 1 1 1 17 11 28 2   1 
1 1 2 2 1 1 4 13 17 2   1 
2 2 2 2 1 2 0 10 10 2   1 
1 1 2 2 1 1 5 10 15 2   2 
 
 
148 
 
CoMorb Fangmark Bitesite vomit Locswell Pain Cellu Necfas coag Locbleed Sysbleed bleedtyp hemturia 
0 1 4 2 1 1 1 2 1 1 2   2 
9,10 1 4 2 1 1 1 2 1 1 2   2 
0 2 3 2 1 1 1 2 1 1 1   1 
0 1 3 2 2 2 2 2 2 2 2   2 
0 2 4 2 1 1 2 2 2 2 2   2 
0 2 3 2 1 1 2 2 2 2 2   2 
0 1 3 2 1 1 1 2 1 2 1   1 
0 1 4 1 1 1 1 2 1 1 2   2 
0 2 3 1 1 1 1 2 2 2 2   2 
0 1 1 2 1 1 1 2 1 1 1 4 2 
0 2 3 2 1 1 1 2 1 1 1   2 
0 1 4 1 1 1 1 2 1 1 2   2 
0 2 4 1 1 1 1 1 1 1 2   2 
1 1 4 2 1 1 1 2 1 1 1   2 
1,2 1 2 2 1 1 2 2 2 2 2   2 
0 1 4 2 1 1 2 2 1 1 1   1 
0 1 4 2 1 1 1 2 1 1 1 7 1 
0 1 3 1 1 1 1 2 1 1 1 6 1 
1,2,3 1 1 2 1 1 1 1 1 1 2   2 
0 2 4 1 1 1 2 2 1 1 2   2 
0 1 3 2 1 1 1 2 1 1 2   2 
0 2 3 2 1 1 1 2 1 2 1 7 2 
0 2 3 2 1 1 2 2 2 2 2   2 
0 2 3 2 1 1 1 2 1 1 2   2 
0 2 7 2 2 2 2 2 2 2 2   2 
0 1 4 1 2 1 2 2 2 2 2   2 
0 1 4 2 1 1 1 2 1 1 2   2 
0 1 3 2 1 1 1 2 1 1 2   2 
0 1 4 2 2 2 2 2 2 2 2   2 
2 1 3 1 1 1 1 2 1 1 1 4 2 
0 1 3 1 1 1 1 1 2 2 2   2 
0 2 7 2 2 2 2 2 2 2 2   2 
1 1 1 1 1 1 2 2 1 1 1   2 
0 1 2 1 1 1 1 2 2 2 2   2 
0 1 4 1 1 1 1 2 1 1 1   1 
0 1 5 1 1 1 1 1 1 1 1 7 2 
0 1 3 1 1 1 1 1 1 1 2   2 
0 1 1 1 1 1 1 1 1 1 2   2 
1 1 3 2 1 1 1 2 1 1 1   1 
0 1 3 1 1 1 1 2 1 1 2   2 
1 1 3 1 1 1 1 2 1 1 2   2 
2 1 3 2 1 1 1 1 1 1 1 4 1 
0 1 4 2 1 1 1 2 1 1 2   2 
0 1 6 1 2 2 2 2 2 2 2   2 
0 1 4 2 1 1 2 2 2 2 2   2 
0 2 4 2 1 1 1 2 2 2 2   2 
0 1 2 2 1 1 1 1 1 1 2   2 
0 1 2 2 1 1 1 2 1 1 2   2 
0 1 4 2 2 1 2 2 1 2 1   1 
0 1 4 2 1 1 1 2 1 1 2   2 
0 1 2 1 1 1 1 2 1 1 1 4 1 
0 1 4 1 1 1 2 2 2 2 2   2 
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0 2 3 2 2 2 2 2 2 2 2   2 
0 1 3 1 1 1 2 2 2 2 2   2 
0 1 3 2 1 1 1 2 1 1 2   2 
0 1 4 1 2 2 2 2 2 2 2   2 
0 1 4 1 1 1 1 2 1 1 2   2 
0 1 3 1 1 1 1 2 1 1 2   2 
0 1 4 1 1 1 1 1 1 1 2   2 
0 2 3 1 1 1 1 1 1 1 2   2 
0 1 1 2 1 1 1 2 2 2 2   2 
0 1 3 1 1 1 1 2 1 2 1   2 
0 1 1 1 1 1 1 2 1 1 1 4 2 
0 1 1 1 1 1 1 2 1 1 1 4 2 
0 1 3 1 1 1 1 2 2 2 2   2 
0 1 4 1 1 1 1 2 1 1 1 4 2 
0 1 4 1 1 1 1 2 1 1 1 6 1 
0 2 4 1 1 1 1 2 1 1 1   1 
0 1 4 2 1 1 1 2 1 1 1   1 
0 1 4 2 1 1 1 2 2 2 2   2 
0 1 4 1 1 1 1 2 1 1 2   2 
0 1 3 1 1 1 1 2 1 1 1   1 
 
 
epista
x 
gumblee
d 
Compsy
n 
Neuroto
x 
ptosi
s 
diplopi
a 
pdxres
p 
Vent
i 
Ventday
s 
Renfai
l 
dialysi
s 
blodtra
n 
2 2 2 1 1 2 2 2   2 2 2 
2 2 2 1 1 2 2 2   1 2 2 
2 2 2 2 2 2 2 2   1 2 2 
2 2 2 1 2 1 2 2   1 2 2 
2 2 2 1 1 1 2 2   2 2 2 
2 2 2 2 2 2 2 2   2 2 2 
2 1 2 1 1 1 2 2   1 1 1 
2 2 2 1 1 1 2 2   1 1 2 
2 2 2 1 1 2 1 1 5 1 1 2 
2 2 2 1 1 2 2 2   1 2 2 
2 1 2 1 1 1 2 2   1 1 1 
2 2 2 1 1 2 2 2   2 2 2 
2 2 1 2 2 2 2 1 5 1 1 1 
2 1 2 2 2 2 2 2   1 2 2 
2 2 2 2 2 2 2 2   2 2 2 
2 2 2 2 2 2 2 2   1 2 2 
2 1 2 1 1 2 2 2   1 2 1 
2 1 2 1 1 1 2 1 2 1 1 1 
2 2 2 2 2 2 2 2   1 2 2 
2 2 2 1 1 1 2 2   2 2 2 
2 2 2 1 1 1 1 1 3 1 2 2 
2 2 2 1 1 1 2 2   1 2 1 
2 2 2 1 1 1 2 2   2 2 2 
2 2 2 2 2 2 2 2   2 2 2 
2 2 2 1 2 1 1 1 3 2 2 2 
2 2 2 2 2 2 2 2   2 2 2 
2 2 2 1 1 2 2 2   1 1 2 
2 2 2 1 1 2 2 1 4 1 1 1 
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2 2 2 2 2 2 2 2   2 2 2 
2 1 2 2 2 2 2 2   1 1 1 
2 2 1 1 1 2 1 2   2 2 2 
2 2 2 1 1 2 1 1 2 2 2 2 
1 2 2 1 1 1 2 2   1 2 2 
2 2 2 2 2 1 2 2   2 2 2 
2 2 2 1 1 1 1 1 2 1 2 2 
2 2 1,abdo 2 2 2 2 1 10 1 1 1 
2 2 2 1 2 2 1 1 2 1 2 2 
2 2 1 2 2 2 2 2   2 2 2 
2 2 2 1 2 1 2 2   2 2 2 
2 2 2 1 1 1 2 2   1 2 2 
2 2 2 2 2 2 2 2   2 2 2 
2 2 2 1 2 2 1 2   1 2 2 
2 2 2 1 2 2 1 1 1 2 2 2 
2 2 2 1 1 1 2 2   2 2 2 
2 2 2 1 1 2 2 2   2 2 2 
2 2 2 1 2 1 2 2   2 2 2 
2 2 1 2 2 2 2 2   2 2 2 
2 2 2 2 2 2 2 2   1 1 2 
1 2 2 2 2 2 2 2   2 2 2 
2 2 2 1 1 1 2 2   1 2 2 
2 2 2 1 1 2 1 2   2 2 2 
2 2 2 2 2 2 2 2   2 2 2 
2 2 2 2 2 2 2 2   2 2 2 
2 2 2 2 2 2 2 2   2 2 2 
2 2 2 1 1 1 2 2   2 2 2 
2 2 2 1 2 2 1 2   1 2 2 
2 2 2 1 1 1 2 2   2 2 2 
2 2 2 1 1 1 2 2   1 2 2 
2 2 1 1 1 2 2 2   1 2 1 
2 2 2 1 2 2 1 1 2 1 1 1 
2 2 2 2 2 2 2 2   2 2 2 
1 2 2 1 1 1 2 2   2 2 2 
2 2 2 1 1 1 2 2   2 2 2 
2 2 2 1 1 1 2 2   1 2 2 
2 2 2 1 1 1 2 2 2 2 2 2 
2 2 2 2 1 2 2 2 2 2 2 2 
2 2 2 1 2 1 2 2   1 2 2 
2 2 2 1 1 1 2 2   1 1 2 
2 2 2 1 1 2 2 2   1 2 2 
2 2 2 1 1 1 2 2   1 2 2 
2 2 2 2 2 2 2 2   2 2 2 
2 2 2 1 1 1 1 1 7 1 1 1 
 
No of units 
transfused 
envtyp
e 
Outcom
e 
Antbi
o 
tyantbi
o 
GC
S 
SPO
2 
HR SBP DBP 
Tachy
p  
GRB
S 
CO2RETE
N 
AB
G 
  6 1 1 1 15 95 115 110 70 1 130 2 1 
  6 1 1 1 15 90 64 110 60 1 112 2 1 
  3 1 1 1 15 95 90 110 60 1 244 2 2 
  7 1 1 1 15 98 110 110 70 1 145 2 2 
  5 1 1 1 15 98 66 110 70 2 130 2 1 
  2 1 1 3 15 96 68 110 70 1 92 2 1 
3ffps and 5 7 1 1 1 15 98 110 110 70 1   2 2 
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cryos 
  7 1 1 1 15 93 74 110 80 1 127 2 2 
  7 1 1 4 3 98 160 170 110 1 249 2 2 
  7 1 1 1 15 99 78 140 90 1 168 2 1 
3ffps and 5 
cryos 
7 1 1 1 15 100 106 110 70 1 445 2 2 
  5 1 1 1 15 90 102 92 66 1 180 2 2 
3ffps and 6 
cryos  8 plts 
3 2 1 4 15 98 116 110 80 1 230 2 2 
  3 1 1 1 15 98 166 170 100 1 523 2 2 
  2 1 1 1 15 100 120 120 80 1 300 2 1 
  3 1 2   15 100 84 120 80 2   2 1 
4 ffps and 6 
cryos 
7 1 1 4 15 97 66 94 60 1 190 2 2 
6 ffps 8 
cryos 2 prcs 
7 1 1 4 15 72 108 150 100 1 153 1 1 
  7 1 1 1 15 98 72 140 90 1 281 2 1 
  6 1 1 1 15 100 82 130 90 2 167 2 1 
  7 1 1 1 15 97 108 90 50 2 160 1 5 
6ffps 4plts 7 1 1 4 8 100 86 140 90 1 260 2 2 
  5 1 1 1 15 100 82 140 80 2 140 2 1 
  3 1 1 1 15 99 72 100 60 2 110 2 1 
  4 1 2   9 80 80 170 90 1 207 1 3 
  2 1 2   15 100 82 90 70 2 100 2 1 
  7 1 1 1 15 86 122 120 70 1 81 2 2 
4 plts 7 1 1 4 12 45 118 100 60 1 146 1 5 
  1 1 2   15 100 64 110 70 2 120 2 1 
 4FFPS 
2PRCS 
7 1 1 1 15 70 142 150 90 1 167 2 1 
  5 1 1 1 15 99 98 110 60 1 147 2 1 
  4 1 1 1 9t 90 112 100 60 2 103 2 1 
  6 1 1 1 15 100 142 100 60 1 108 2 1 
  2 1 1 1 15 94 90 110 90 1 94 2 1 
  7 1 1 1 8 90 60 140 80 1 122 2 2 
8plts 7ffp 
2prc 
7 2 1 4 8 75 160 80 40 1 38 1 5 
  7 1 1 4 15 98 84 100 60 1 100 2 2 
  2 1 1 1 15 96 106 140 80 1 107 2 1 
  6 1 1 1 15 95 98 120 60 2 162 2 1 
  7 1 1 1 12 90 128 100 60 1 107 2 1 
  3 1 1 3 15 92 144 80 60 1 390 2 1 
  7 2 1 5 15 90 112 120 70 1 148 2 2 
  6 1 1 1 15 98 78 120 70 2 83 2 2 
  4 1 2   15 95 92 110 60 2 136 2 1 
  6 1 2   15 96 90 110 80 1 140 2 1 
  5 1 1 1 15 98 120 120 76 1 140 2 1 
  2 1 1 2 15 98 106 120 70 1 78 2 2 
  3 1 1 1 15 98 98 120 80 2 97 2 2 
  3 3 1 1 15 94 112 80 50 1 182 2 1 
  7 1 1 1 15 93 112 90 70 1 241 2 1 
  6 1 1 1 15 96 130 110 70 1 137 2 4 
  3 1 1 1 15 100 96 110 60 1 130 2 1 
  1 1 2   15 98 78 140 90 2 153 2 1 
  2 1 2   15 96 84 130 90 2   2 1 
  6 1 2   15 94 82 90 60 1 166 2 2 
  7 1 1 1 15 95 96 130 90 1 222 2 2 
  5 1 1 1 15 96 96 90 60 2 263 2 1 
  7 1 1 3 15 98 82 120 80 2 123 2 2 
4 ffps 7 1 1 4 15 97 86 110 80 1   2 2 
  7 1 1 1 15 92 122 170 80 1 422 2 1 
  3 1 1 1 15 98 118 90 60 1 169 2 1 
152 
 
  6 1 1 1 15 92 100 100 70 1 88 2 2 
  6 1 1 3 15 98 74 100 70 2 165 2 1 
  7 1 1 1 15 96 110 100 70 2 146 2 2 
  6 1 1 1 15 95 112 90 60 1 125 2 1 
  6 1 1 1 15 96 84 90 60 2 194 2 1 
  7 1 1 1 15 96 66 120 90 1 143 2 1 
  7 1 1 1 15 99 100 180 100 2 143 2 2 
  7 1 1 2 15 91 74 150 100 1 195 2 1 
  7 1 1 1 15 98 92 90 60 2 171 2 2 
  3 1 1 1 15 96 90 120 80 1 126 2 1 
  7 1 1 5 15 86 142 90 60 1   1 5 
 
 
Hb 
Anemi
a 
TC 
highT
C 
Plts 
lowpl
ts  
HU
S 
CX
R 
EC
G 
Icter
us 
TB 
Al
b 
SGO
T 
SGP
T 
heptit
is 
Rhabd
o 
CPK 
15.
8 
2 9000 2 
25300
0 
2 2 1 2 2 1 
4.
5 
36 10 2 1 275 
16.
4 
2 2500 2 
14400
0 
2 1 1 1 1 
3.
6 
3.
6 
89 19 2 1 315 
12.
5 
2 
1850
0 
1 
15200
0 
2 2 1 1 2           2   
15.
4 
2 
2060
0 
1 
19000
0 
2 1 1 2 2           1 681 
15.
3 
2 
1350
0 
1 
17800
0 
2 2 1 1 2               
12.
7 
2 7800 2 23900 1 2 1 1 2           2 85 
10.
7 
1 
2490
0 
1 
10800
0 
2 1 1 1 1 
4.
2 
4.
2 
134 29 1 1 913 
6.6 1 7400 2 
15100
0 
2 1 1 1 2 
0.
5 
2.
7 
52 12 2 1 1404 
12.
9 
2 
3490
0 
1 25000 1 1 1 2 2 
0.
7 
1.
6 
29 28 2 1 
1137
4 
13.
8 
2 
1050
0 
2 
29400
0 
2 2 1 1 2           1 2923 
14.
4 
2 
2560
0 
1 66000 1 1 1 2 2 
1.
9 
3.
6 
142 36 1 1 2089 
15.
8 
2 9000 2 
25300
0 
2 2 1 2 2 1 
4.
5 
36 10 2 1 275 
8.1 1 
2170
0 
1 50000 1 1 1 2 2           1 7498 
14 2 
2040
0 
1 
25100
0 
2 2 1 2 2 
1.
6 
3.
9 
58 20 2 2 95 
13.
9 
2 7300 2 
25600
0 
2 2 1 2 2 
0.
4 
4.
5 
15 8 2 2   
12.
9 
2 
1490
0 
1 
17700
0 
2 2 1 1 2 
0.
5 
4.
5 
17 9 2 2 155 
8.1 1 
1670
0 
2 50000 1 1 1 2 2 
0.
7 
4.
3 
35 13 2 1 434 
12.
4 
2 
2140
0 
1 44000 1 1 2 2 1 11 
3.
6 
238 37 2 1 431 
13.
3 
2 
1000
0 
2 61000 1 1 1 1 2           2 116 
13.
4 
2 
1200
0 
1 
17500
0 
2 2 1 1 2           1 2214 
13.
7 
2 
5350
0 
1 
26300
0 
2 1 2 2 1 
2.
2 
3 229 53 1 1 6448 
7.9 1 
3720
0 
1 11000 1 1 1 2 1 
3.
8 
4.
3 
960 89 1 1 
1011
4 
11.
6 
2 
2200
0 
1 
29100
0 
2 2 1 2 2           1 1817 
15. 2 2600 1 10200 1 2 1 1 2           1 2108 
153 
 
7 0 0 
12.
1 
1 
1770
0 
1 
33300
0 
2 2 1 1 2               
14.
1 
2 6900 2 
17800
0 
2 2 1 1 2 
0.
9 
3.
5 
34 15 2     
10 1 
1970
0 
1 74000 1 1 1 2 1 
2.
1 
3 108 22 1 1 853 
10 1 
1340
0 
1 15000 1 1 2 2 1 
3.
6 
3.
3 
244 71 1 1 7761 
14.
7 
2 5900 2 
24100
0 
2 2 1 1 2 
0.
5 
4.
2 
26 16 2     
11.
5 
1 
4190
0 
1 
51600
0 
2 1 1 2 1 
2.
8 
3.
8 
137 35 2 1 2169 
9.1 1 
2470
0 
1 
37500
0 
2 2 1 1 2 
0.
4 
4.
1 
22 10 2 2 146 
13 2 
1012
0 
2 
28400
0 
2 2 1 2 2 
0.
4 
3.
4 
41 23 2 2 138 
12.
7 
2 8830 2 75000 1 1 1 1 2 
1.
2 
3.
6 
38 16 2 1 220 
13.
7 
2 8500 2 
20800
0 
2 2 1 1 2 
0.
5 
4.
2 
20 12 2 1 245 
10 1 
4115
0 
1 32000 1 1 1 1 1 
7.
7 
2.
8 
250 29 1 1 
1138
0 
6.1 1 
2160
0 
1 11000 1 1 1 2 1 14 
2.
4 
103 69 1 1 5142 
14.
7 
2 
3880
0 
1 32000 1 1 1 1 2 
1.
4 
3.
1 
112
0 
186 1 1 
4034
0 
12.
9 
2 
1600
0 
1 
26900
0 
2 2 1 1 2           1 380 
14.
2 
2 
1660
0 
1 
19600
0 
2 2 1 1 2           1 257 
16 2 
2120
0 
1 
14500
0 
1 1 1 1 1 3 
2.
8 
118 40 1 1 5502 
16.
1 
2 4100 2 
14300
0 
1 2 1 1 2 
1.
8 
3.
7 
23 10 2 1 2189 
11.
1 
1 
1210
0 
1 93000 1 1 1 1 1 
7.
9 
3.
7 
215 99 1 1 
1150
6 
10.
6 
2                               
13.
3 
2 
1380
0 
1 
26200
0 
2 2 1 1 2 
0.
3 
4.
7 
15 6 2     
14.
1 
2 7200 2 
21300
0 
2 2 1 2 2     53 14 2 1 1433 
11.
5 
2 
2100
0 
1 
29100
0 
2 2 1 2 2 
0.
4 
3.
4 
38 19 1 1 269 
15 2 8700 2 
15500
0 
2 2 1 2 2           1 880 
11.
6 
2 
1330
0 
1 68000 1 1 1 2 2 
1.
3 
3.
1 
63 34 2 1 1498 
15.
2 
2 
1990
0 
1 
26000
0 
2 2 1 1 2               
13.
7 
2 
2630
0 
1 
22300
0 
2 2 1 2 2 
1.
1 
4.
1 
23 11 2 2 162 
13 2 
2206
0 
1 
25100
0 
2 2 1 2 2 
0.
4 
3.
7 
27 12 2 2 129 
9.4 1 
1520
0 
1 23700 2 2 1 1 2 
0.
5 
3.
6 
10 10 2 1 550 
12 2 9200 2 
28000
0 
2 2 1 1 2         2     
15.
6 
2 5900 2 
1,61,0
00 
2 2 1 1 2 
0.
7 
4.
5 
23 16 2     
15.
6 
2 
1170
0 
2 77000 1 1 1 1 2 
1.
7 
3.
5 
55 14 2 2 178 
13.
3 
2 
2010
0 
1 
12900
0 
2 1 1 1 2           1 541 
11 1 
2720
0 
1 
38600
0 
2 2 1 2 2           1 704 
14.
5 
2 
1830
0 
1 60000 1 1 1 1 1           1 674 
154 
 
14.
2 
2 
1410
0 
1 
18800
0 
2 1 1 1 2           1 2224 
13.
8 
2 
2270
0 
1 
18900
0 
2 1 1 1 1 
4.
9 
3.
1 
222 36 2 1 5753 
17.
7 
2 
1750
0 
1 
33600
0 
2 2 1 1 2           2 186 
11.
5 
2 6700 2 
16800
0 
2 2 1 1 1 
2.
6 
3.
1 
61 24 2     
12.
9 
2 
2100
0 
1 
24100
0 
2 2 1 1 2 
1.
7 
4.
1 
63 38 2     
15.
9 
2 
2310
0 
1 99000 1 1 1 1 1 
3.
5 
3.
2 
110 9   1 3427 
17 2 
1370
0 
1 
26300
0 
2 2 1 1             1 9495 
14.
3 
2 
1760
0 
1 
17700
0 
2 2 1 1 1 
2.
7 
4.
6 
80 35 2     
6.7 1 
2150
0 
1 
10000
0 
1 1 2 1 1           1 688 
9.1 1 
2080
0 
1 
18900
0 
2 1 2 1 1 14 
3.
7 
75 28 2 1 3985 
11.
1 
2 
2690
0 
1 
25700
0 
2 2 1 1 2           1 2791 
14.
6 
2 
1530
0 
1 67000 1 1 1 1 2           1 1600 
13 2 
1170
0 
2 99000 1 2 1 1 2 
1.
4 
3.
9 
40 12 2     
7.2 1 
3260
0 
1 30000 1 1 2 2 1 
8.
6 
3 470 55 2 1 7327 
 
 
LDH 
Crea
t 
Neosti
g 
MRCGra
de 
Urinco
lr 
Ure
a 
Na K⁺ 
Urinal
ys 
Fibv
al 
lowfi
b 
Timenor
m 
SSscor
e 
Severity  
sevcod
e 
  1.24 2 5 2 31 
14
2 
4.5 4     2 4 
moderat
e 
1 
  1.25 2 5 2 31 
13
4 
4.3 4     2 9 high 2 
  1.73 2 5 2 51 
14
1 
3.8 4     2 8 high 2 
931 2.8 1 4 2 69 
13
9 
2.8 2     2 4 
moderat
e 
1 
  1.2 1 5 1 33 
13
9 
3.6 1     2 8 high 2 
  0.96 2 5 1 43 
13
8 
2.9 1     1 3 mild 1 
245
9 
9.43 2 5 2 92 
13
9 
3.9 4 22.6 1 2 8 high 2 
  7.47 2 5 2 88 
14
1 
4 4     1 8 high 2 
235
6 
8.2 1 5 2 155 
14
6 
5 4     1 9 high 2 
  3.33 2 5 2 60 
14
6 
3.2 4     2 11 high 2 
368
0 
9.5 2 5 2 82 
13
4 
4.9       1 9 high 2 
  1.24 2 5 2 31 
14
2 
4.5 4     2 5 
moderat
e 
1 
309
8 
6.74 2 5 2   
11
7 
5.5   235 2 1 8 high 2 
182
2 
2.17 2 5 2 41 
12
9 
5.3 4     2 9 high 2 
  1.05 2 5 1 19 
13
7 
4.1       1 3 mild 1 
  1.49 2 5 2 28     2     2 6 
moderat
e 
1 
155 
 
763 1.9 2 5 2 52 
13
8 
4.2 4 118 1 4 9 high 2 
514 3.9 2 5 2 90 
13
2 
4.3 4 127 1 1 10 high 2 
233 2.3 2 5 1 25 
14
2 
3.5 3 0 1 4 9 high 2 
  0.72 2 5 2 23 
13
8 
3.1 4     2 5 
moderat
e 
1 
875 2.75 2 5 2 117 
13
1 
3.6 4     3 9 high 2 
230
0 
2.11 2 5 2 100 
13
9 
5.4 4 265 2 3 9 high 2 
  0.5 1 5 2 24 
13
7 
4 4     2 3 mild 1 
712 1.32 2 5 1 51 
14
6 
4 3     3 10 high 2 
  1.01 1 0 1 31 
13
3 
3.7 1     1 9 high 2 
  0.73 2 5 1 32 
13
6 
3.9 1     1 3 mild 1 
126
3 
4.58 2 5 2 111 
14
0 
4.4 4 406 2 2 9 high 2 
139
4 
7.08 2 4 2 129 
12
9 
3.4 4 560 2 2 9 high 2 
  0.97 2 5 1 21 
13
9 
3.6 1     1 3 mild 1 
  4.78 2 5 2 88 
14
3 
5 4     3 5 
moderat
e 
1 
  0.53 2 5 1 30 
13
2 
3.1 4     1 6 
moderat
e 
1 
  0.5 2 0 1 10 
13
3 
3.6 1     1 6 
moderat
e 
1 
  1.87 2 1 2 39 
13
9 
3 4 480 2 2 8 high 2 
  0.73 2 5 1 38 
13
3 
5 1     1 2 mild 1 
  1.4 1 3 2 85 
14
7 
3.7 4 320 2 3 8 high 2 
216
6 
5.7 1 5 2 205 
13
9 
4.5 4 354 2 3 9 high 2 
324
8 
0.74 1 3 2 57 
13
3 
4.3 4 630 2 3 10 high 2 
  0.73 2 5 1 23 
14
3 
3.4 1     1 4 
moderat
e 
1 
  1.17 2 5 1 35 
13
8 
3.5 2     2 9 high 2 
185
3 
1,14 1 3 2 23 
14
5 
3.5 4 53 1 3 5 
moderat
e 
1 
  0.9 2 5 2 30 
13
7 
3.3 4     2 6 
moderat
e 
1 
524
8 
6.34 2 0 2 260 
14
2 
5 4 471 2 4 8 high 2 
  0.91 2 5 1 19 
13
9 
4.2 1     2 3 mild 1 
  0.71 1 4 1 23 
14
2 
3.5 2     1 5 
moderat
e 
1 
  0.89 1 4 2 34 
13
9 
3.2 4     2 5 
moderat
e 
1 
  0.72 2 4 1 24 
13
4 
3.3 4     1 3 mild 1 
  0.99 2 5 1 23 
13
7 
4.2 1     1 4 
moderat
e 
1 
756 10.2 2 5 2 141 
13
6 
4.2 4     1 6 
moderat
e 
1 
  1.24 2 5 1 37 
13
6 
3.7 1     1 3 mild 1 
  1.3 2 5 1 26 
14
0 
3.7 1     2 2 mild 1 
459 0.5 2 5 1 15 13 3.6 4     1 5 moderat 1 
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4 e 
  0.8 2 5 1   
13
3 
4 1 371 2 2 5 
moderat
e 
1 
  0.99 2 5 1 20     2     1 2 mild 1 
  0.91 2 5 1 17 
14
0 
3.2 1     1 3 mild 1 
  1.5 2 5 1 44 
13
9 
3.4 2     2 4 
moderat
e 
1 
824 1.89 2 5 1 41 
14
2 
4.1       3 4 
moderat
e 
1 
  0.81 2 5 1   
14
1 
3.7 1     1 8 high 2 
637 12.1 2 5 2 208 
14
3 
4.5 4     1 10 high 2 
263
4 
1.27 2 5 2   
13
5 
4,2 4     2 7 
moderat
e 
1 
449
9 
3.55 2 5 2 119 
12
8 
4.3 4     2 8 high 2 
  1.45 2 5 1 36 
13
6 
3.7 1     2 6 
moderat
e 
1 
  0.8 1 5 2 17 
14
1 
3.3 4     3 10 high 2 
  1.13 2 5 1 36 
14
0 
4 1     3 7 
moderat
e 
1 
152
4 
3.7 2 5 2 35 
13
7 
3.5 4     3 8 high 2 
  1.22 2 5 1 36 
13
2 
3.3 4     1 3 mild 1 
  1.39 2 5 2 31 
14
4 
4.3 4     2 6 
moderat
e 
1 
115
2 
8.56 2 5 2 113 
14
0 
4.7 4     1 9 high 2 
224 7.36 2 5 2 153 
14
1 
4.4 4 225 2 3 7 
moderat
e 
1 
  0.91 2 5 1   
13
6 
3.5 1     1 5 
moderat
e 
1 
  1.76 2 5 2 39 
13
3 
3.6 4     1 4 
moderat
e 
1 
  1.28 2 5 2 29 
13
6 
3.9 2     2 5 
moderat
e 
1 
349
3 
11.1 2 3 2 230 
14
0 
4.5 4 447 2 2 11 high 2 
 
WBCT PT Ptvalue INR aptt Apttval TEG/Rotem 
CT(324-
565) 
CFT(112-
224) 
α(50-
68) 
MCF(55-
66) 
ML(0-
15) 
2 2 20.8 1.87 1 23.7 1 293 157 61 49 4 
2 2 67.8 6.28 1 35.2 2 981 0 7 15   
2 2 21.8 1.96 1 28.6 2 391 780 28 30 1 
2 2 19.3 1.74 1 25.1 2 410 647 38 34 2 
2 2 28.5 2.54 2 40.1 2 272 199 54 50 7 
1 1 12 1.1 1 25 1 305 103 70 59 19 
2 2 21.8 1.96 1 31.4 2 2530     5 1 
1 1 10.9 1 1 25 2 860 441 33 39 10 
1 1 11.8 1.08 1 35.1 2 550 411 37 49 10 
2 2 41.4 3.65 1 34.8 2 349 444 38 41 0 
1 1 11.9 1.09 1 25 2 365 295 43 45   
1 2 20.8 1.87 1 23.7 2 171 298 44 48 12 
1 1 13.7 1.14 1 35.4 2 470 232 49 43 1 
2 2 25.3 2.26 1 30 2 2357         
1 1 10.9 1 1 24.6 1 217 88 72 64 6 
2 1 11.8 1 1 24.2 1 315 129 65 52 11 
2 2 130 10 2 200 2 5395         
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1 1 12.4 1.1 1 24.7 2 401 494 30 37 1 
1 1 11.4 1.04 1 27.9 2 2305 0 0 4 N\A 
2 2 16.5 1.51 1 23 1 235 267 54 57 15 
1 2 15.1 1.38 1 28 1 283 119 67 59 2 
2 2 42.7 3.58 1 28.3 2 389 115 67 48 7 
1 1 13 1.2 1 24 1 304 122 66 57 9 
2 2 31.4 2.68 1 35.5 2 652 1424 22 25 1 
1 1 11.6 1.06 1 26.3 1 256 102 71 71 6 
1 1 11.1 1.02 1 31 1 223 80 74 59 10 
2 1 12.4 1.2 1 31 2 753 343 41 41 7 
2 2 15.6 1.42 1 36.4 2 849 632 25 34 5 
1 1 11.9 1.08 1 25 1 283 204 58 64 3 
2 2 47.2 4.35 2 70 1 280 81 74 70 6 
1 1 12.5 1.14 1 27 1 191 102 72 75 7 
1 1 12.5 1.14 1 26.9 1 230 104 69 59 12 
1 2 18.8 1.72 2 43.7 2 738 388 35 41 9 
1 1 10.8 1 1 25 1 184     9   
2 2 19.8 1.81 2 114.4 2 2284   11 8 40 
1 2 27.3 2.5 2 44.1 2 582 356 37 35   
2 2 28 2.57 2 36.8 2 1244 556 28 35   
1 1 11 1 1 24 2 979 2518 7 35   
1 1 13 1.18 2 68 2 1209 1431   40   
2 2 31.9 2.93 1 34.4 2 1324 1864 57 10 14 
1 1 13.5 1.23 1 25.4 2 768 2900 9 31   
2 2 18.9 1.73 1 37 2 397 404 39 52 3 
2 2 23 2.14 1 25 2 1192     17   
1 1 11.1 1.01 1 25 1 296 91 72 63 8 
2 1 12 1.1 2 180 1 199 96 71 60   
1 1 12.5 1.14 1 26.2 1 418 142 63 53   
1 1 10.9 1 1 24 1   not done        
 
2 1 11.6 1.06 1 24.8 
1 1 12.5 1.1 1 34 
2 2 14.4 1.41 1 30.6 
2 1 11.4 1.04 1 24 
1 1 9.7 0.88 1 27 
1 1 10.2 0.94 1 28.9 
1 1 11.3 1.04 1 31 
2 2 26.4 2.36 2 107.3 
1 2 18.5 1.67 1 24 
1 1 12.5 1.14 1 24 
1 2 14.2 1.29 1 29.1 
2 2 49.2 4.31 2 120 
2 2 17.9 1.59 1 28.1 
2 2 28.7 2.56 1 31.1 
2 2 120 10 2 180 
  2 38.1 3.37 1 36.4 
2 2 18.3 1.65 1 25.1 
1 2 24 2.15 1 25.3 
2 2 18.9 1.71 1 28.2 
1 1 13 1.19 1 26.3 
1 2 14.4 1.31 1 27.7 
1 2 14.4 1.31 1 32.8 
2 2 21.3 1.92 1 29.5 
2 2 57 4.98 1 24.1 
2 2 22.9 2.05 2 46.7 
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R(3-8) 
K(1-
3) 
Angle(55-
78) 
MA(51-
69) 
Ly30(0-
8) 
4.3 2.3 56.3 52.9 0.1 
32.8 N\A 2.3 9.7 0 
5.3 8 36.8 34.8 0 
5.8 7.3 35 38.3 0 
7.1 8.3 25.1 41.9 0 
7.5 2.5 55.6 60.1 0 
33.8 N\A 1.6 2.4 0 
11.5 8.9 23.6 43.4 0 
12.9 6.8 26.9 50.8 0 
6 9.3 18.7 41.7 0 
6.9 4 39 41.8 0 
3.6 2.3 62.7 52.9 0 
11.8 5.3 33.6 44.7 0 
26.9 N\A 1.7 2.2 0 
3.1 1.2 74.6 61.7 0.3 
4.8 2.2 58.8 56.3 0 
                              NOT 
DONE 
        
                              NOT 
DONE 
        
195.5 0 0 0 0 
7 1.9 59.5 62.3 0.6 
3.8 1.7 53.4 64.5 0 
7.9 18 28.5 21.2 0 
                              NOT 
DONE 
        
                              NOT 
DONE 
        
13.5 5.1 31.6 62.9 0 
                              NOT 
DONE 
        
                              NOT 
DONE 
        
17.9 10.6 20.2 34.3 0 
                              NOT 
DONE 
        
                              NOT 
DONE 
        
                              NOT 
DONE 
        
                              NOT 
DONE 
        
                              NOT 
DONE 
        
                              NOT 
DONE 
        
                              NOT 
DONE 
        
                              NOT 
DONE 
        
                              NOT 
DONE 
        
                              NOT 
DONE 
        
                              NOT 
DONE 
        
                              NOT 
DONE 
        
                              NOT 
DONE 
        
                              NOT         
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DONE 
                              NOT 
DONE 
        
                              NOT 
DONE 
        
3.8 2.5 58.3 54.1 0 
7.1 2.7 53.4 59.4 0 
6.6 4.7 44.1 56.1 0 
 
 
  
SEX 
 
  
1. MALE 
 
  
2. FEMALE 
 
  
Occupation( OCCU ) 
 
  
1. Agriculture 
 
  
2.Coolie / Casual Labour/service 
 age  
 
3. Housewife 
 1.<20 
 
4. Office Work / business / Doctor 
 2.21-40 
 
5. Retired Staff 
 3.41-60 
 
6. Students 
 4.>60 
 
7. Unemployed 
 
  
ADDRESS ( adrs ) 
  
1. TN 
 
  
2. AP  
 
  
3. Others 
 
  
TIME OF BITE ( TOB ) 
 
  
1. Morning 
 
  
2. Afternoon 
 
  
3. evening 
 
  
4. Night 
 
  
TIME ELAPSED SINCE BITE ( TESC )  
 
  
1. < 6 hours 
 
  
2. 6-12 hours 
 
  
3.12-24 hours 
 
  
4. > 24 hours 
 
  
MODE OF TRANSPORT ( modtrans ) 
 
  
1. Foot 
 
  
2. Motorcycle 
 
  
3. Rickshaw/auto 
 
  
4. Four wheeler 
 
  
5. Ambulance 
 
  
SNAKE IDENTIFIED ( snidenyn ) 
 
  
1. YES 
 
  
2. NO 
 
  
SNAKE TYPE ( sntype ) 
 
  
1. Russel's viper 
 
  
2. Saw scaled viper 
 
  
3. Indian cobra 
 
  
4. Krait 
 
  
5. not identified 
 
  
SNAKE BROUGHT WITH PATIENT - snbring 
 
  
1. yes 
 
  
2. no  
 
  
ENVIRONMENT SETTING ( envsetng ) 
 
  
1. outdoor/fields 
 
  
2. house/indoor 
 
  
3. water bodies 
 
  
4. others 
 
  
FIRST AID/LOCAL MEASURES GIVEN ? - FIRSTAID 
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1. Yes 
 
  
2. No 
 
  
TYPE OF FIRST AID/ LOCAL MEASURES - AIDTYPE 
 
  
1. Tourniquet 
 
  
2. multiple incisions 
 
  
3. herbal/native medicine 
 
  
4. none 
 
  
5. local anaesthetic 
 
  
TETANUS TOXOID - TETTOX 
 
  
1. yes 
 
  
2. no 
 
  
PRIOR ASV 
 
  
1. Yes 
 
  
2. No 
 
  
ASV Hypersensitivity ? - ASVhyper 
 
  
1. Yes 
 
  
2. No 
 
  
Type of ASV hypersensitivity ? - tyasvhs 
 
  
1. Mild 
 
  
2. Severe 
 
  
CO MORBIDITIES - comorb 
 
  
1. DM 
 
  
2. HTN  
 
  
3. IHD/CAD 
 
  
4. CKD 
 
  
5. CLD 
 
  
6. Prior antiplatelet / anticoagulant therapy 
 
  
7. Known bleeding disorder 
 
  
8. Malignancy 
 
  
9. smoking 
 
  
10.alchohol consumption  
 
  
11. others 
 
  
FANG MARKS 
 
  
1. Yes 
 
  
2. No 
 
  
SITE OF BITE - BITESITE 
 
  
1. Right upper limb 
 
  
2. Left upper limb 
 
  
3. Right lower limb 
 
  
4. Left lower limb 
 
  
5. Trunk 
 
  
6. Face 
 
  
7. Other areas 
 
  
Local edema/swelling - Locswell 
 
  
1. Yes 
 
  
2. No 
 
  
PAIN 
 
  
1. Yes 
 
  
2. No 
 
  
CELLULITIS - cellu 
 
  
1. Yes 
 
  
2. No 
 
  
GANGRENE 
 
  
1. Yes 
 
  
2. No 
 
  
LOCAL BLEEDING - locbleed 
 
  
1. Yes 
 
  
2. No 
 
  
Systemic bleeding/ Compartment syndrome 
 
  
1. Yes 
 
  
2. No 
 
  
TYPE OF SYSTEMIC BLEED - bleedtyp 
 
161 
 
  
1. Bleeding Gums 
 
  
2. Epistaxis/Hemoptysis 
 
  
3. Hematuria 
 
  
4. Hemetemesis 
 
  
5. Bleed PR/ Malena 
 
  
6. IV site ooze 
 
  
7. Internal bleed eg. Intra cranial / Intra abdominal 
 
  
8. Others 
 
  
Neurotoxicity - neurotox 
 
  
1. yes 
 
  
2.no 
 
  
What neurologic manifestation ? - nutoxTyp 
 
  
1. Ptosis/drooping eyelids 
 
  
2. Opthalmoplegia / Diplopia 
 
  
3. Breathing difficulty/ paradoxical resp 
 
  
4. Severe muscular weakness 
 
  
5. Other Cranial  nerve palsies 
 
  
6. Other manifestations ? 
 
  
VENTILATION  - VENTI////// RENAL FAILURE - renfail 
 
  
DIALYSIS/////// BLOOD TRANSFUSION - blodtran 
 
  
1. yes 
 
  
2. no 
 
  
NO OF VENTILATION DAYS - VENTDAYS 
 
  
TYPE OF SNAKE ENVENOMATION - envtype 
 
  
1.No envenomation 
 
  
2.Local swelling  only 
 
  
3.Haemotoxicity with / without local swelling  
 
  
4.Neurotoxicity only  
 
  
5. Neurotoxicity with Local swelling 
 
  
6.Haemotoxicity + Neurotoxicity  with / without local swelling 
 
  
7.Haemotoxicity + Neurotoxicity +renal failure  with local 
swelling 
 
  
8.Neurotoxicity + myoglobinuria    
 
  
OUTCOME 
 
  
1. completely recovered 
 
  
2. Died 
 
  
3. Discharged against medical advice 
 
  
4. Referred to higher/other centres 
 
  
type of Antibiotic - TYANTBIO 
 
  
1. Augmentin 
 
  
2. Benzyl penicillin 
 
  
3.cloxacillin 
 
  
4. piptaz 
 
  
5.meropenem 
 
  
6.colistin 
 
  
20 MIN WBCT 
 
  
1. Normal 
 
  
2. Prolonged 
 
  
URINE COLOUR - urincolr 
 
  
1. Clear 
 
  
2. Brown/red 
 
  
ABG 
 
  
1. Normal 
 
  
2. Metabolic acidosis 
  
3. Respiratory acidosis 
  
4. Respiratory alkalosis 
  
5. Metabolic Acidosis + Respiratory Acidosis 
  
URINE ROUTINE 
 
  
1. normal 
 
  
2. hematuria  
  
3. proteinuria 
  
4. hematuria + proteinuria 
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SNAKE BITE SEVERITY 
 
  
1. Mild to Moderate severity 
  
2. Severe envenomation 
  
TIMENORM- time to normal bleeding tests 
 
  
1. <12 hours 
 
  
2. 12-24 hours 
  
3. 24- 48 hours 
  
4. 48 - 72 hours 
  
5. >72 hours 
 
    
    
     
